<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Androgens for the anaemia of chronic kidney disease in adults - Yang, Q - 2014 | Cochrane Library</title> <meta content="Androgens for the anaemia of chronic kidney disease in adults - Yang, Q - 2014 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006881.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Androgens for the anaemia of chronic kidney disease in adults - Yang, Q - 2014 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006881.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD006881.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Androgens for the anaemia of chronic kidney disease in adults" name="citation_title"/> <meta content="Qianchun Yang" name="citation_author"/> <meta content="Ewha Woman's University" name="citation_author_institution"/> <meta content="Minawaer Abudou" name="citation_author"/> <meta content="Xinjiang Medical University" name="citation_author_institution"/> <meta content="Xi Sheng Xie" name="citation_author"/> <meta content="Second Clinical Hospital of North Sichuan Medical College (Nanchong Central Hospital)" name="citation_author_institution"/> <meta content="Taixiang Wu" name="citation_author"/> <meta content="West China Hospital, Sichuan University" name="citation_author_institution"/> <meta content="txwutx@hotmail.com" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="10" name="citation_issue"/> <meta content="10.1002/14651858.CD006881.pub2" name="citation_doi"/> <meta content="2014" name="citation_date"/> <meta content="2014/10/09" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006881.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006881.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006881.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Androgens [*therapeutic use]; Anemia [blood, *drug therapy, etiology]; Cholesterol [blood]; Erythropoietin [therapeutic use]; Hematocrit; Nandrolone [analogs &amp; derivatives, therapeutic use]; Nandrolone Decanoate; Oxymetholone [therapeutic use]; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic [*complications]; Triglycerides [blood]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006881.pub2&amp;doi=10.1002/14651858.CD006881.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006881.pub2&amp;doi=10.1002/14651858.CD006881.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006881.pub2&amp;doi=10.1002/14651858.CD006881.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006881.pub2&amp;doi=10.1002/14651858.CD006881.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006881.pub2&amp;doi=10.1002/14651858.CD006881.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006881.pub2&amp;doi=10.1002/14651858.CD006881.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006881.pub2&amp;doi=10.1002/14651858.CD006881.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006881.pub2&amp;doi=10.1002/14651858.CD006881.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006881.pub2&amp;doi=10.1002/14651858.CD006881.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006881.pub2&amp;doi=10.1002/14651858.CD006881.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006881.pub2&amp;doi=10.1002/14651858.CD006881.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006881.pub2&amp;doi=10.1002/14651858.CD006881.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006881.pub2&amp;doi=10.1002/14651858.CD006881.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006881.pub2&amp;doi=10.1002/14651858.CD006881.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006881.pub2&amp;doi=10.1002/14651858.CD006881.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006881.pub2&amp;doi=10.1002/14651858.CD006881.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006881.pub2&amp;doi=10.1002/14651858.CD006881.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006881.pub2&amp;doi=10.1002/14651858.CD006881.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006881.pub2&amp;doi=10.1002/14651858.CD006881.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006881.pub2&amp;doi=10.1002/14651858.CD006881.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006881.pub2&amp;doi=10.1002/14651858.CD006881.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006881.pub2&amp;doi=10.1002/14651858.CD006881.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006881.pub2&amp;doi=10.1002/14651858.CD006881.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="xNbeAU8n";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD006881\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD006881\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006881\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006881\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","hr","fr","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD006881.pub2",title:"Androgens for the anaemia of chronic kidney disease in adults",firstPublishedDate:"Oct 9, 2014 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Kidney and Transplant Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=xNbeAU8n&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006881.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD006881.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD006881.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD006881.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006881.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD006881.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD006881.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD006881.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD006881.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD006881.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD006881.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD006881.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD006881.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD006881.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>1399 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD006881.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006881.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006881.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006881.pub2/full#CD006881-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006881.pub2/full#CD006881-sec-0087"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006881.pub2/full#CD006881-sec-0022"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006881.pub2/full#CD006881-sec-0023"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006881.pub2/full#CD006881-sec-0028"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006881.pub2/full#CD006881-sec-0029"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006881.pub2/full#CD006881-sec-0053"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006881.pub2/full#CD006881-sec-0081"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD006881.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006881.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006881.pub2/appendices#CD006881-sec-0092"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006881.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006881.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD006881.pub2/media/CDSR/CD006881/table_n/CD006881StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD006881.pub2/media/CDSR/CD006881/table_n/CD006881StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006881.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006881.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006881.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD006881.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD006881.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD006881.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2014 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD006881.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Androgens for the anaemia of chronic kidney disease in adults</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006881.pub2/information#CD006881-cr-0002">Qianchun Yang</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006881.pub2/information#CD006881-cr-0003">Minawaer Abudou</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006881.pub2/information#CD006881-cr-0004">Xi Sheng Xie</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006881.pub2/information#CD006881-cr-0005"><i class="icon corresponding-author fa fa-envelope"></i>Taixiang Wu</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD006881.pub2/information/en#CD006881-sec-0097">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 09 October 2014 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD006881.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD006881.pub2">https://doi.org/10.1002/14651858.CD006881.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD006881-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD006881-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD006881-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD006881-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD006881-abs-0002">Français</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD006881-abs-0001" lang="en"> <section id="CD006881-sec-0001"> <h3 class="title" id="CD006881-sec-0001">Background</h3> <p>Anaemia occurs when blood contains fewer red blood cells and lower haemoglobin levels than normal, and is a common complication among adults with chronic kidney disease (CKD). Although a number of approaches are applied to correct anaemia in adults with CKD, the use of androgen therapy is controversial. </p> </section> <section id="CD006881-sec-0002"> <h3 class="title" id="CD006881-sec-0002">Objectives</h3> <p>The aim of this review was to determine the benefits and harms of androgens for the treatment of anaemia in adult patients with CKD. </p> </section> <section id="CD006881-sec-0003"> <h3 class="title" id="CD006881-sec-0003">Search methods</h3> <p>We searched CENTRAL, the Cochrane Renal Group's Specialised Register, the Chinese Biomedicine Database (CBM), CNKI, VIP and reference lists of articles without language restriction. The most recent search was conducted in August 2014. </p> </section> <section id="CD006881-sec-0004"> <h3 class="title" id="CD006881-sec-0004">Selection criteria</h3> <p>All randomised controlled trials (RCTs) that assessed the use of androgens for treating anaemia of CKD in adults were eligible for inclusion. </p> </section> <section id="CD006881-sec-0005"> <h3 class="title" id="CD006881-sec-0005">Data collection and analysis</h3> <p>Two authors independently extracted data and assessed risk of bias in the included studies. Meta‐analyses were performed using relative risk (RR) for dichotomous outcomes and mean differences (MD) for continuous outcomes, with 95% confidence intervals (CI). </p> </section> <section id="CD006881-sec-0006"> <h3 class="title" id="CD006881-sec-0006">Main results</h3> <p>We included eight studies that reported data from 181 participants. Study quality was assessed as moderate in six studies, one was low quality, and one was high quality. The small number of included studies, and low participant numbers adversely influenced evidence quality overall. </p> <p>We found limited evidence (1 study, 24 participants) to indicate that oxymetholone can increase haemoglobin (Hb) (MD 1.90 g/dL, 95% CI 1.66 to 2.14), haematocrit (HCT) (MD 27.10%, 95% CI 26.49 to 27.71), change in albumin (MD 4.91 g/L, 95% CI 3.69 to 6.13), alanine aminotransferase (ALT) (MD 54.50 U/L, 95% CI 43.94 to 65.06), and aspartate aminotransferase (AST) (MD 47.33 U/L, 95% CI 37.69 to 56.97); and decrease high‐density lipoprotein (HDL) (MD ‐15.66 mg/dL, 95% CI ‐24.84 to ‐6.48). We also found that compared with erythropoietin alone, nandrolone decanoate plus erythropoietin may increase HCT (3 studies, 73 participants: MD 2.54%, 95% Cl 0.96 to 4.12). Compared with erythropoietin (1 study, 27 participants), limited evidence was found to suggest that nandrolone decanoate can increase plasma total protein (MD 0.40 g/L, 95% CI 0.13 to 0.67), albumin (MD 0.20 g/L, 95% CI 0.01 to 0.39), and transferrin (MD 45.00 mg/dL, 95% CI 12.61 to 77.39) levels. Compared with no therapy (remnant kidney), evidence was found to suggest that nandrolone decanoate can increase Hb (2 studies, 33 participants: MD 1.04 g/dL, 95% Cl 0.66 to 1.41) and HCT (1 study, 24 participants: MD 3.70%, 95% Cl 0.68 to 6.72). Compared with no therapy (anephric), evidence was found (1 study, 5 participants) to suggest that nandrolone decanoate can increase Hb (MD 1.30 g/dL, 95% Cl 0.57 to 2.03), but nandrolone decanoate did not increase HCT (MD 2.00%, 95% Cl ‐0.85 to 4.85). </p> <p>However, oxymetholone was not found to reduce blood urea nitrogen (BUN), serum creatinine (SCr), cholesterol, or triglycerides; or increase plasma total protein, prealbumin, or transferrin. No evidence was found to indicate that nandrolone decanoate increased prealbumin or decreased BUN, SCr, AST, ALT, cholesterol, triglycerides, HDL or low‐density lipoprotein (LDL). Adverse events associated with androgen therapy were reported infrequently. </p> </section> <section id="CD006881-sec-0007"> <h3 class="title" id="CD006881-sec-0007">Authors' conclusions</h3> <p>We found insufficient evidence to confirm that use of androgens for adults with CKD‐related anaemia is beneficial. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD006881-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD006881-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD006881-abs-0007">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD006881-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD006881-abs-0006">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD006881-abs-0005">Hrvatski</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD006881-abs-0004" lang="en"> <h3>Androgens for the anaemia of chronic kidney disease in adults</h3> <p>Anaemia, which occurs when red blood cell and haemoglobin levels fall below normal, is a common problem among adults with chronic kidney disease (CKD). Anaemia can cause breathlessness, dizziness and chest pain (angina); reduce ability to think clearly; limits ability to exercise; and contributes to sexual problems, poor appetite and reduced quality of life. Anaemia may also cause longer hospital stays, and sometimes death. </p> <p>There are several approaches to correct anaemia in people with CKD, including drugs to stimulate red blood cell production, dialysis to remove waste and excess water from the blood, blood transfusions, dietary management, and supplementary iron and folate agents. </p> <p>Other drugs, such as androgens ‐ which are male steroid hormones ‐ may be given in some settings to help reduce undesirable effects of treatments. Another possible benefit of androgen therapy for people with CKD, especially in regions with limited health resources, is that these drugs have lower costs than some other treatments. </p> <p>We assessed eight small studies that presented data from 181 adults with CKD‐related anaemia that investigated use of androgen therapy. Limitations and flaws in the evidence lead to our conclusion that androgen therapy for adults with CKD‐related anaemia was not associated with substantial benefits. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD006881-sec-0087" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD006881-sec-0087"></div> <h3 class="title" id="CD006881-sec-0088">Implications for practice</h3> <section id="CD006881-sec-0088"> <p>Oxymetholone may help to correct anaemia and increase albumin among adults with CKD‐related anaemia by increasing ALT and AST, and decreasing HDL levels. However, evidence quality was poor, and we were unable to confirm if oxymetholone could reduce BUN, SCr, cholesterol, or TG. Furthermore, it could not be established if oxymetholone increased plasma total protein, prealbumin, or transferrin. Limited evidence suggested that nandrolone decanoate may increase HCT, plasma total protein, plasma albumin, and transferrin. </p> <p>There was no compelling evidence to indicate if nandrolone decanoate increased Hb or prealbumin, or decreased BUN, SCr, AST, ALT, cholesterol, TG, HDL, adverse events, or LDL. </p> <p>Suboptimal study quality meant that evidence to support the use of androgens in adults with anaemia of CKD was not identified. </p> </section> <h3 class="title" id="CD006881-sec-0089">Implications for research</h3> <section id="CD006881-sec-0089"> <p>Large, multicentre RCTs investigating androgens for anaemia of CKD in adults are required. Future investigators should ensure that people at all CKD stages are recruited, and assessment of a comprehensive range of targeted androgen therapies is undertaken. Triallists should plan measure changes in symptom relief, quality of life, and rate of CKD progression to end‐stage kidney disease. </p> <p>Reporting of mortality, quality of life and adverse events outcomes is required. Future studies should explore if occurrence of relative EPO insufficiency is a possible rationale for using androgens for adults with CKD‐related anaemia, and whether prolonged or short courses of androgen therapy is of greater benefit. The most suitable dosages of androgens should also be explored for adults living with CKD‐related anaemia. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD006881-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD006881-sec-0022"></div> <div class="table" id="CD006881-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span><span class="table-title"></span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Nandrolone decanoate plus erythropoietin (rHuEPO) versus erythropoietin (rHuEPO) for the anaemia of chronic kidney disease in adults</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with the anaemia of chronic kidney disease </p> <p><b>Intervention:</b> nandrolone decanoate plus rHuEPO versus rHuEPO </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>rHuEPO</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Nandrolone decanoate plus rHuEPO</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Haematocrit (%)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean haematocrit in the intervention group was <b>2.4 higher</b> (1.04 to 3.77 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b>¹ </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Haemoglobin (g/dL)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean haemoglobin in the intervention group was <b>0.44 higher</b> (0.17 lower to 1.05 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b>² </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serum albumin (g/L)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Mean serum albumin in the intervention group was <b>0.09 lower</b> (0.24 lower to 0.06 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b>² </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 7.72</b> <br/> (1.45 to 41.12) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>83 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>very low</b>³ </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate </p> <p><b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate </p> <p><b>Very low quality:</b> We are very uncertain about the estimate </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Reduce the evidence quality factors:</b> methodology defect, included in the research results of the inconsistency, indirect evidence, inexactness, publication bias.   </p> <p><b>Increase the level of evidence factor:</b> large effect quantity, confounding factors cannot change effect quantity, or the existing concentration–response relationship. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>¹ Few studies included<br/> ² One study included<br/> ³ High risk of performance bias<br/> Two studies included </p> </td> </tr> </tbody> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD006881-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD006881-sec-0023"></div> <section id="CD006881-sec-0024"> <h3 class="title" id="CD006881-sec-0024">Description of the condition</h3> <p>Chronic kidney disease (CKD) is a major public health challenge. In the USA, 20 million adults have CKD, and another 20 million are at risk of developing the disease (<a href="./references#CD006881-bbs2-0055" title="National Kidney Foundation. About chronic kidney disease. http://www.kidney.org/kidneydisease/aboutckd.cfm (accessed 23 August 2014). ">NKF 2007</a>). Data from NHANES III (1988 to 1994) and USRDS (1998) indicated that prevalence of CKD ranged from 64.3% for stage 1 to 0.2% for stage 5 (<a href="./references#CD006881-bbs2-0053" title="National Kidney Foundation. K/DOQI Clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. American Journal of Kidney Diseases2002;39(2 Suppl 1):S1‐266. [MEDLINE: 11904577] ">NKF 2002</a>). </p> <p>Anaemia occurs when levels of red blood cells and haemoglobin are reduced. Anaemia is a common complication among people with CKD, and contributes to the burden of disease, causing breathlessness, dizziness, angina, decreased exercise capacity, cognitive and dysfunctions, poor appetite, reduced quality of life, longer hospital stays, and death. Given that numbers of people with CKD are increasing, the public health impact of CKD‐associated anaemia is substantial. Anaemia prevalence increases as kidney function decreases. <a href="./references#CD006881-bbs2-0049" title="McClellanW , AronoffSL , BoltonWK , HoodS , LorberDL , TangKL , et al. The prevalence of anemia in patients with chronic kidney disease. Current Medical Research &amp; Opinion2004;20(9):1501‐10. [MEDLINE: 15383200] ">McClellan 2004</a> reported that anaemia was present in 47.7% of predialysis patients, and <a href="./references#CD006881-bbs2-0045" title="HsuCY , McCullochCE , CurhanGC . Epidemiology of anemia associated with chronic renal insufficiency among adults in the United States: results from the Third National Health and Nutrition Examination Survey. Journal of the American Society of Nephrology2002;13(2):504‐10. [MEDLINE: 11805181] ">Hsu 2002</a> estimated that the overall burden of CKD‐associated anaemia (haemoglobin (Hb) ≤ 11 g/dL) was 610,000 women and 230,000 men in the US population. In 2000, five European countries participating in the Dialysis Outcomes and Practice Patterns Study (DOPPS, <a href="./references#CD006881-bbs2-0036" title="CombeC , PisoniRL , PortFK , YoungEW , CanaudB , MapesDL , et al. Dialysis Outcomes and Practice Patterns Study: data on the use of central venous catheters in chronic hemodialysis [Dialysis Outcomes and Practice Patterns Study: donnees sur l'utilisation des catheters veineux centraux en hemodialyse chronique]. Nephrologie2001;22(8):379‐84. [MEDLINE: 11810992] ">Combe 2001</a>) reported that 49% of haemodialysis patients had Hb concentrations below the level recommended by the European Best Practice Guidelines (<a href="./references#CD006881-bbs2-0041" title="GeddesCC , WooYM . The European Best Practice Guidelines (EBPG) for peritoneal dialysis recommendation for minimum Kt/Vurea is not supported by current evidence. Nephrology Dialysis Transplantation2006;21(9):2674. [MEDLINE: 16554321] ">Geddes 2006</a>). Patients with Hb &lt; 10 g/dL were 29% more likely to be hospitalised than those with Hb levels between 11 and 12 g/dL. The risk of hospitalisation was 4% lower for every 1 g/dL increase in Hb concentration, and mortality risk in these patients was 5% lower for each 1 g/dL increase (<a href="./references#CD006881-bbs2-0048" title="LocatelliF , PisoniRL , CombeC , BommerJ , AndreucciVE , PieraL , et al. Anaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrology Dialysis Transplantation2004;19(1):121‐32. [MEDLINE: 14671047] ">Locatelli 2004b</a>). </p> </section> <section id="CD006881-sec-0025"> <h3 class="title" id="CD006881-sec-0025">Description of the intervention</h3> <p>Several approaches are commonly applied to correct anaemia in adults with CKD, including erythropoiesis‐stimulating agents (ESAs), dialysis, blood transfusions, nutritional management, iron and folate supplements. ESAs augment erythropoiesis through direct or indirect actions on the erythropoietin receptor, and dialysis can improve anaemia by eliminating some toxins. In the past, iron and folate supplements were mainstay treatments. Although a direct and effective method of treating CKD‐related anaemia, blood transfusion carries risk of infection and inducing histocompatibility leukocyte antigens, which may jeopardise future kidney transplant in eligible patients (<a href="./references#CD006881-bbs2-0040" title="EschbachJW . The anemia of chronic renal failure: pathophysiology and the effects of recombinant erythropoietin. Kidney International1989;35(1):134‐48. [MEDLINE: 2651751] ">Eschbach 1989</a>; <a href="./references#CD006881-bbs2-0063" title="WardHJ . Implications of recombinant erythropoietin therapy for renal transplantation. American Journal of Nephrology1990;10 Suppl 2:44‐52. [MEDLINE: 2260618] ">Ward 1990</a>). </p> <p>The human erythropoietin (EPO) gene was characterised in 1983 (<a href="./references#CD006881-bbs2-0046" title="LinFK , SuggsS , LinCH , BrowneJK , SmallingR , EgrieJC , et al. Cloning and expression of the human erythropoietin gene. Proceedings of the National Academy of Sciences of the United States of America1985;82(22):7580‐4. [MEDLINE: 3865178] ">Lin 1985</a>), and recombinant human EPO (rHuEPO) treatment efficacy was first demonstrated in dialysis patients in 1986 (<a href="./references#CD006881-bbs2-0064" title="WinearlsCG , OliverDO , PippardMJ , ReidC , DowningMR , CotesPM . Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet1986;2(8517):1175‐8. [MEDLINE: 2877323] ">Winearls 1986</a>). The advent of rHuEPO revolutionised management for people with CKD‐associated anaemia and contributed to reducing risks associated with blood transfusion (<a href="./references#CD006881-bbs2-0035" title="CodyJ , DalyC , CampbellM , DonaldsonC , KhanI , RabindranathK , et al. Recombinant human erythropoietin for chronic renal failure in pre‐dialysis patients. Cochrane Database of Systematic Reviews2005, Issue 3. [DOI: 10.1002/14651858.CD003266.pub2] ">Cody 2005</a>), sensitisation, and preventing iron overload, and enhancing exercise tolerance, cognitive capacity, sexual function, and quality of life. However, three key issues have been associated with rHuEPO use: </p> <p> <ol id="CD006881-list-0001"> <li> <p>Cost: Medicare spending on EPO reached US$1.8 billion in 2004, an increase of 17% from 2003 (<a href="./references#CD006881-bbs2-0062" title="United States Renal DataSystem . Atlas of end‐stage renal disease in the United States. hthttp://www.usrds.org/atlas06.aspx (accessed 23 August 2014). ">USRDS 2006</a>). </p> </li> <li> <p>Risk of pure red cell aplasia (PRCA): a severe, non‐regenerative form of anaemia, with selective erythroid aplasia of the bone marrow. </p> </li> <li> <p>Predictable side effects: hypertension, clotting of arteriovenous fistulas, and seizures (<a href="./references#CD006881-bbs2-0052" title="NavarroJF . In the erythropoietin era, can we forget alternative or adjunctive therapies for renal anaemia management? The androgen example. Nephrology Dialysis Transplantation2003;18(11):2222‐6. [MEDLINE: 14551346] ">Navarro 2003</a>). </p> </li> </ol> </p> <p>Furthermore, rHuEPO may increase cancer mortality risk by stimulating tumour growth (<a href="./references#CD006881-bbs2-0034" title="Leyland‐JonesB , SemiglazovV , PawlickiM , PienkowskiT , TjulandinS , ManikhasG , et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first‐line chemotherapy: a survival study. Journal of Clinical Oncology2005;23(25):5960‐72. [MEDLINE: 16087945] ">Brian 2005</a>; <a href="./references#CD006881-bbs2-0042" title="HenkeM , LaszigR , RubeC , SchaferU , HaaseKD , SchilcherB , et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double‐blind, placebo‐controlled trial. Lancet2003;362(9392):1255‐60. [MEDLINE: 14575968] ">Henke 2003</a>). </p> </section> <section id="CD006881-sec-0026"> <h3 class="title" id="CD006881-sec-0026">How the intervention might work</h3> <p>Androgens are a class of male steroid hormones that play a major role in the development and maintenance of masculine secondary sexual characters, and which also affect nitrogen metabolism (<a href="./references#CD006881-bbs2-0033" title="Britannica OnlineEncyclopaedia . Androgens. http://www.britannica.com/eb/article‐292/androgen (accessed 23 August 2014). ">BOE 2007</a>; <a href="./references#CD006881-bbs2-0056" title="OmwanchaJ , BrownTR . Selective androgen receptor modulators: in pursuit of tissue‐selective androgens. Current Opinion in Investigational Drugs2006;7(10):873‐81. [MEDLINE: 17086931] ">Omwancha 2006</a>; <a href="./references#CD006881-bbs2-0057" title="PieleckaJ , QuaynorSD , MoenterSM . Androgens increase gonadotropin‐releasing hormone neuron firing activity in females and interfere with progesterone negative feedback. Endocrinology2006;147(3):1474‐9. [MEDLINE: 16339200] ">Pielecka 2006</a>). Androgens mechanism of action is thought to be due to an increase in EPO synthesis and secretion (<a href="./references#CD006881-bbs2-0059" title="ShahaniS , Braga‐BasariaM , MaggioM , BasariaS . Androgens and erythropoiesis: past and present. Journal of Endocrinological Investigation2009;32(8):704‐16. [MEDLINE: 19494706] ">Shahani 2009</a>). A positive correlation has been shown between increased Hb and HCT in people treated with androgens (<a href="./references#CD006881-bbs2-0050" title="NavarroJF , MoraC . Androgen therapy for anemia in elderly uremic patients. International Urology &amp; Nephrology2001;32(4):549‐57. [MEDLINE: 11989543] ">Navarro 2001a</a>; <a href="./references#CD006881-bbs2-0051" title="NavarroJF , MoraC . Effect of androgens on anemia and malnutrition in renal failure: implications for patients on peritoneal dialysis. Peritoneal Dialysis International2001;21(1):14‐24. [MEDLINE: 11280492] ">Navarro 2001b</a>; <a href="./references#CD006881-bbs2-0006" title="NavarroJF , MoraC , MaciaM , ChahinJ , GallegoE , MendezML , et al. Effects of androgen therapy on hematologic and nutritional parameters in elderly peritoneal dialysis patients [abstract]. International Urology &amp; Nephrology2001;33(4):715‐6. [CENTRAL: CN‐00615848] NavarroJF , MoraC , MaciaML , GallegoE , ChahinJ , MendezML , et al. Prospective comparison between rHuEPO and androgens in CAPD patients: impact on hematologic and nutritional parameters [abstract]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):436A. [CENTRAL: CN‐00644231] NavarroJF , MoraF , MaciaM , GarciaJ . Randomized prospective comparison between erythropoietin and androgens in CAPD patients. Kidney International2002;61(4):1537‐44. [MEDLINE: 11918762] ">Navarro 2002</a>; <a href="./references#CD006881-bbs2-0065" title="YaredK , GagnonRF , BroxAG . Mechanisms of action of androgen treatment on the anemia of experimental chronic renal failure [abstract]. Journal of the American Society of Nephrology1997;Program &amp; Abstracts(8):633A. ">Yared 1997</a>). </p> <p>Adjuvant therapy is often required to help optimise therapeutic response among people with CKD‐associated anaemia who are either unresponsive to erythropoiesis‐stimulating agents (ESA) or require large doses of ESAs (<a href="./references#CD006881-bbs2-0050" title="NavarroJF , MoraC . Androgen therapy for anemia in elderly uremic patients. International Urology &amp; Nephrology2001;32(4):549‐57. [MEDLINE: 11989543] ">Navarro 2001a</a>). In some settings, androgens may be administered as adjuvant therapies for people with CKD‐related anaemia. Androgens have been reported to increase erythropoiesis, raise plasma EPO concentration in dialysed patients with CKD‐anaemia (<a href="./references#CD006881-bbs2-0060" title="TeruelJL , MarcenR , Navarro‐AntolinJ , AguileraA , Fernandez‐JuarezG , OrtunoJ . Androgen versuserythropoietin for the treatment of anemia in hemodialyzed patients: a prospective study. Journal of the American Society of Nephrology1996;7(1):140‐4. [MEDLINE: 8808121] ">Teruel 1996a</a>), and elevate Hb concentration in people with CKD (<a href="./references#CD006881-bbs2-0061" title="TeruelJL , AguileraA , MarcenR , AntolinJN , OteroGG , OrtunoJ . Androgen therapy for anaemia of chronic renal failure. Scandinavian Journal of Urology &amp; Nephrology1996;30(5):403‐8. [MEDLINE: 8936631] ">Teruel 1996b</a>). Androgens have also achieved satisfactory results for treating PRCA (<a href="./references#CD006881-bbs2-0058" title="Sanchez de la NietaMD , Caparros G. RiveraF . Epoetin‐induced pure red cell aplasia successfully treated with androgens. Journal of Nephrology2006;19(2):220‐1. [MEDLINE: 16736425] ">Sanchez 2006</a>). Economic cost benefits have been identified for androgen therapy in resource‐limited settings (<a href="./references#CD006881-bbs2-0047" title="LocatelliF , AljamaP , BaranyP , CanaudB , CarreraF , EckardtKU , et al. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrology Dialysis Transplantation2004;19 Suppl 2:ii1‐47. [MEDLINE: 15206425] ">Locatelli 2004a</a>). </p> </section> <section id="CD006881-sec-0027"> <h3 class="title" id="CD006881-sec-0027">Why it is important to do this review</h3> <p>Controversy exists about the use of androgens to treat anaemia in people with CKD. The KDOQI guidelines strongly recommend against androgens as adjuvant therapy to ESA treatment in people with CKD‐related anaemia. The rationale is that androgens have been associated with adverse effects including acne, virilisation, priapism, hyperglycaemia, liver dysfunction, injection site pain, risk of peliosis hepatis, hepatocellular carcinoma, risk of prostate cancer, and cancer risk in women. Three small, short‐term RCTs (<a href="./references#CD006881-bbs2-0012" title="BernsJS , RudnickMR , CohenRM . A controlled trial of recombinant human erythropoietin and nandrolone decanoate in the treatment of anemia in patients on chronic hemodialysis. Clinical Nephrology1992;37(5):264‐7. [MEDLINE: 1606777] ">Berns 1992</a>; <a href="./references#CD006881-bbs2-0003" title="GaughanWJ , LissKA , DunnSR , MangoldAM , BuhsmerJP , MichaelB , et al. A 6‐month study of low‐dose recombinant human erythropoietin alone and in combination with androgens for the treatment of anemia in chronic hemodialysis patients. American Journal of Kidney Diseases1997;30(4):495‐500. [MEDLINE: 9328363] LissKA , GaughanWJ , DunnSR , MichaelB , GoldmanJM , ArmentiVT , et al. A six month study of low‐dose recombinant human erythropoietin alone and in combination with androgen for the treatment of anemia in chronic hemodialysis patients [abstract no: A1206]. Journal of the American Society of Nephrology1996;7(9):1490. [CENTRAL: CN‐00626123] ">Gaughan 1997</a>; <a href="./references#CD006881-bbs2-0007" title="SheashaaH , Abdel‐RazekW , El‐HusseiniA , SelimA , HassanN , AbbasT , et al. Use of nandrolone decanoate as an adjuvant for erythropoietin dose reduction in treating anemia in patients on hemodialysis. Nephron2005;99(4):c102–6. [MEDLINE: 15703460] ">Sheashaa 2005a</a>) explored the possible role of adjuvant androgen therapy with ESA for people undergoing haemodialysis. Recommended Hb levels were not achieved; however, these studies did not enrol participants with ESA hyporesponsiveness (<a href="./references#CD006881-bbs2-0054" title="National Kidney Foundation. Clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. http://www.kidney.org/Professionals/kdoqi/guidelines_anemia/index.htm (accessed 23 August 2014). ">NKF 2006</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD006881-sec-0028" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD006881-sec-0028"></div> <p>The aim of this review was to determine the benefits and harms of androgens for the treatment of anaemia in adult patients with CKD. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD006881-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD006881-sec-0029"></div> <section id="CD006881-sec-0030"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD006881-sec-0031"> <h4 class="title">Types of studies</h4> <p>All randomised controlled trials (RCTs) assessing the use of androgens for the treatment of CKD‐related anaemia in adults were eligible for inclusion. There was no restriction on language or publication type. The first phases of cross‐over RCTs were also eligible for inclusion. </p> </section> <section id="CD006881-sec-0032"> <h4 class="title">Types of participants</h4> <section id="CD006881-sec-0033"> <h5 class="title">Inclusion criteria</h5> <p> <ul id="CD006881-list-0002"> <li> <p>Adults (aged 18 years or over) with CKD‐related anaemia. All CKD stages were included (predialysis, dialysis, and transplant patients). Anaemia and CKD definitions applied by each study were accepted. </p> </li> <li> <p>CKD‐related anaemia participants with controlled hypertension and cardiac disorders, left ventricular hypertrophy, hypogonadism, kidney‐related bone disease, or neurological disorders were included. </p> </li> </ul> </p> </section> <section id="CD006881-sec-0034"> <h5 class="title">Exclusion criteria</h5> <p> <ul id="CD006881-list-0003"> <li> <p>Pregnancy</p> </li> <li> <p>Androgen therapy in the six months before study entry</p> </li> <li> <p>Anaemia related to causes other than kidney disease, such as folate or B deficiency, sickle cell disease, primary haemolytic anaemia, or multiple myeloma </p> </li> <li> <p>Haematological disorders known to cause anaemia</p> </li> <li> <p>Iron deficiency (ferritin &lt; 100 ng/mL or transferrin saturation &lt; 20% or both)</p> </li> <li> <p>Bleeding</p> </li> <li> <p>Known malignancy such as prostate cancer</p> </li> <li> <p>Presence of infection or inflammation</p> </li> <li> <p>Active ischaemic heart disease</p> </li> <li> <p>Uncontrolled hypertension (systolic blood pressure &gt; 190 mm Hg, diastolic &gt; 105 mm Hg) </p> </li> <li> <p>Abnormal liver function (positive albumin, bilirubin, alkaline phosphatase (ALP), gamma glutamic transpeptidase (gamma GT), aspartate aminotransferase (AST), alanine aminotransferase (ALT), or prothrombin findings) </p> </li> <li> <p>Active hepatitis</p> </li> <li> <p>HIV infection</p> </li> <li> <p>Study duration less than six months</p> </li> <li> <p>Studies in which only one arm received dialysis or transplantation.</p> </li> </ul> </p> </section> </section> <section id="CD006881-sec-0035"> <h4 class="title">Types of interventions</h4> <p> <ul id="CD006881-list-0004"> <li> <p>Any androgen versus no drug or placebo alone</p> </li> <li> <p>Any androgen versus routine therapy (e.g<i>.</i> androgens versus EPO) </p> </li> <li> <p>Any androgen plus routine therapy versus routine therapy (androgens plus EPO versus EPO) </p> </li> <li> <p>Any androgen plus routine therapy versus placebo plus routine therapy (e.g. androgen plus EPO versus placebo plus EPO). </p> </li> </ul> </p> </section> <section id="CD006881-sec-0036"> <h4 class="title">Types of outcome measures</h4> <p> <ul id="CD006881-list-0005"> <li> <p>Mortality</p> </li> <li> <p>Measures of anaemia correction (e.g. haemoglobin (Hb) and haematocrit (HCT) values)</p> </li> <li> <p>Participant‐based quality of life assessment using an internationally validated minimum standard checklist (<a href="./references#CD006881-bbs2-0037" title="EfficaceF , BottomleyA , OsobaD , GotayC , FlechtnerH , D'haeseS , et al. Beyond the development of health‐related quality‐of‐life (HRQOL) measures: a checklist for evaluating HRQOL outcomes in cancer clinical trials‐‐does HRQOL evaluation in prostate cancer research inform clinical decision making?. Journal of Clinical Oncology2003;21(18):3502‐11. [MEDLINE: 12972527] ">Efficace 2003</a>; <a href="./references#CD006881-bbs2-0038" title="EfficaceF , HorneberM , LejeuneS , VanDamF , LeeringS , RottmannM , et al. Methodological quality of patient‐reported outcome research was low in complementary and alternative medicine in oncology. Journal of Clinical Epidemiology2006;59(12):1257‐65. [MEDLINE: 17098568] ">Efficace 2006</a>; <a href="./references#CD006881-bbs2-0039" title="EfficaceF , OsobaD , GotayC , SprangersM , CoensC , BottomleyA . Has the quality of health‐related quality of life reporting in cancer clinical trials improved over time? Towards bridging the gap with clinical decision making. Annals of Oncology2007;18(4):775‐81. [MEDLINE: 17259641] ">Efficace 2007</a>) </p> </li> <li> <p>Liver function (e.g<i>.</i> alanine aminotransferase (ALT) and aspartate aminotransferase (AST) values) </p> </li> <li> <p>Kidney function (e.g. blood urea nitrogen (BUN) and serum creatinine (SCr) values)</p> </li> <li> <p>Lipid profile (e.g. cholesterol, triglyceride (TG), high‐density lipoprotein (HDL), and low‐density lipoprotein (LDL) values) </p> </li> <li> <p>Total protein, albumin, prealbumin, and transferrin values</p> </li> <li> <p>Adverse events: acne, virilisation, priapism, hyperglycaemia, liver dysfunction, prostate cancer, prostate hypertrophy, peliosis hepatis, hepatocellular carcinoma, rash, amenorrhoea, menstrual disorders, enlarged clitoris, excess body hair, increased appetite, increased sexual desire, depression, mania, delirium, acute schizophrenia, cardiovascular adverse events, and other adverse effects including gastrointestinal bleeding, episodes of peritonitis and hydrothorax. </p> </li> </ul> </p> <section id="CD006881-sec-0037"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD006881-list-0006"> <li> <p>Mortality</p> </li> <li> <p>Measures of anaemia correction, such as Hb and HCT values.</p> </li> </ul> </p> </section> <section id="CD006881-sec-0038"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD006881-list-0007"> <li> <p>Quality of life assessment using an internationally validated minimum standard checklist (<a href="./references#CD006881-bbs2-0037" title="EfficaceF , BottomleyA , OsobaD , GotayC , FlechtnerH , D'haeseS , et al. Beyond the development of health‐related quality‐of‐life (HRQOL) measures: a checklist for evaluating HRQOL outcomes in cancer clinical trials‐‐does HRQOL evaluation in prostate cancer research inform clinical decision making?. Journal of Clinical Oncology2003;21(18):3502‐11. [MEDLINE: 12972527] ">Efficace 2003</a>; <a href="./references#CD006881-bbs2-0038" title="EfficaceF , HorneberM , LejeuneS , VanDamF , LeeringS , RottmannM , et al. Methodological quality of patient‐reported outcome research was low in complementary and alternative medicine in oncology. Journal of Clinical Epidemiology2006;59(12):1257‐65. [MEDLINE: 17098568] ">Efficace 2006</a>; <a href="./references#CD006881-bbs2-0039" title="EfficaceF , OsobaD , GotayC , SprangersM , CoensC , BottomleyA . Has the quality of health‐related quality of life reporting in cancer clinical trials improved over time? Towards bridging the gap with clinical decision making. Annals of Oncology2007;18(4):775‐81. [MEDLINE: 17259641] ">Efficace 2007</a>) </p> </li> <li> <p>Liver function (ALT and AST values)</p> </li> <li> <p>Kidney functions (BUN and SCr values)</p> </li> <li> <p>Lipid profile (cholesterol, TG, HDL, and LDL values)</p> </li> <li> <p>Total protein, albumin, prealbumin, and transferrin values</p> </li> <li> <p>Adverse events: acne, virilisation, priapism, hyperglycaemia, liver dysfunction, prostate cancer, prostate hypertrophy, peliosis hepatis, hepatocellular carcinoma, rash, amenorrhoea, menstrual disorders, enlarged clitoris, excess body hair, increased appetite, increased sexual desire, depression, mania, delirium, acute schizophrenia, cardiovascular adverse events, and other adverse effects including gastrointestinal bleeding, episodes of peritonitis and hydrothorax. </p> </li> </ul> </p> </section> </section> </section> <section id="CD006881-sec-0039"> <h3 class="title">Search methods for identification of studies</h3> <p>We searched electronic databases and where necessary corresponded with study authors to obtain additional information. </p> <section id="CD006881-sec-0040"> <h4 class="title">Electronic searches</h4> <p>We searched the Cochrane Renal Group's Specialised Register (to August 2014) through contact with the Trials' Search Co‐ordinator using search terms relevant to this review. The Cochrane Renal Group’s Specialised Register contains studies identified from the following sources. </p> <p> <ol id="CD006881-list-0008"> <li> <p>Monthly searches of the Cochrane Central Register of Controlled Trials CENTRAL</p> </li> <li> <p>Weekly searches of MEDLINE OVID SP</p> </li> <li> <p>Handsearching of renal‐related journals and the proceedings of major renal conferences</p> </li> <li> <p>Searching of the current year of EMBASE OVID SP</p> </li> <li> <p>Weekly current awareness alerts for selected renal journals</p> </li> <li> <p>Searches of the International Clinical Trials Register (ICTRP) Search Portal and ClinicalTrials.gov.</p> </li> </ol> </p> <p>Studies contained in the Specialised Register are identified through search strategies for CENTRAL, MEDLINE, and EMBASE based on the scope of the Cochrane Renal Group. Details of these strategies as well as a list of handsearched journals, conference proceedings and current awareness alerts are available in the Specialised Register section of information about the <a href="http://onlinelibrary.wiley.com/o/cochrane/clabout/articles/RENAL/frame.html" target="_blank">Cochrane Renal Group</a>. </p> <p>We also searched the Chinese Biomedicine Database (CBM), VIP and China National Knowledge Infrastructure (CNKI) (to August 2012). </p> <p>See <a href="./appendices#CD006881-sec-0093">Appendix 1</a> for search terms used in strategies for this review. </p> </section> <section id="CD006881-sec-0041"> <h4 class="title">Searching other resources</h4> <p>We searched reference lists of identified study reports and the ISI Citation Index database, Science and Social Science Citation Index/Web of Science Services. </p> <p>We were unable to contact primary investigators of identified studies for details of additional studies and companies or pharmaceutical firms that produce immunosuppressants used for unpublished data they may possess. </p> </section> </section> <section id="CD006881-sec-0042"> <h3 class="title" id="CD006881-sec-0042">Data collection and analysis</h3> <section id="CD006881-sec-0043"> <h4 class="title">Selection of studies</h4> <p>The search strategy described was used to obtain titles and abstracts of studies that may be relevant to the review. Titles and abstracts were screened independently by two authors who discarded studies that were not applicable; however, studies and reviews that might include relevant data or information on studies were retained initially. Two authors independently assessed retrieved abstracts, and if necessary, the full text of these studies to determine which satisfied the inclusion criteria. </p> </section> <section id="CD006881-sec-0044"> <h4 class="title">Data extraction and management</h4> <p>Data extraction was carried out independently by two authors using a pre‐tested data extraction form. Where more than one publication of one study existed, reports were grouped together and only the publication with the most complete data was used. Where relevant outcomes were only published in earlier versions, these data were used. Any discrepancies between published versions were to be highlighted. Any further information required from the original author was requested by written correspondence. Disagreements were resolved by consensus and with a third author. </p> </section> <section id="CD006881-sec-0045"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>The following items were independently assessed by two authors using the risk of bias assessment tool (<a href="./references#CD006881-bbs2-0044" title="HigginsJP , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>) (see <a href="./appendices#CD006881-sec-0094">Appendix 2</a>). </p> <p> <ul id="CD006881-list-0009"> <li> <p>Was there adequate sequence generation (selection bias)?</p> </li> <li> <p>Was allocation adequately concealed (selection bias)?</p> </li> <li> <p>Was knowledge of the allocated interventions adequately prevented during the study (detection bias)? </p> <ul id="CD006881-list-0010"> <li> <p>Participants and personnel</p> </li> <li> <p>Outcome assessors</p> </li> </ul> </li> <li> <p>Were incomplete outcome data adequately addressed (attrition bias)?</p> </li> <li> <p>Are reports of the study free of suggestion of selective outcome reporting (reporting bias)? </p> </li> <li> <p>Was the study apparently free of other problems that could put it at a risk of bias?</p> </li> </ul> </p> </section> <section id="CD006881-sec-0046"> <h4 class="title">Measures of treatment effect</h4> <p>We analysed data both dichotomous and continuous data in this review. Results for dichotomous data are expressed as relative risk (RR) with 95% confidence intervals (CI). We showed continuous data as mean differences (MD) with 95% CI. </p> </section> <section id="CD006881-sec-0047"> <h4 class="title">Dealing with missing data</h4> <p>Where necessary, further information required from the original author was requested by written correspondence or telephone. Evaluation of important numerical data such as screened, randomised patients as well as intention‐to‐treat, as‐treated and per‐protocol population was carefully performed. Attrition rates, such as drop‐outs, losses to follow‐up and withdrawals, were investigated. Issues of missing data and imputation methods were critically appraised (<a href="./references#CD006881-bbs2-0044" title="HigginsJP , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). </p> </section> <section id="CD006881-sec-0048"> <h4 class="title">Assessment of heterogeneity</h4> <p>Heterogeneity was analysed using a Chi² test on N‐1 degrees of freedom, with an alpha of 0.05 used for statistical significance and with the I² test (<a href="./references#CD006881-bbs2-0043" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analysis. BMJ2003;327(7174):227‐60. [MEDLINE: 12958120] ">Higgins 2003</a>). I² values of 25%, 50% and 75% correspond to low, medium and high levels of heterogeneity. </p> </section> <section id="CD006881-sec-0049"> <h4 class="title">Assessment of reporting biases</h4> <p>We planned to assess for reporting bias by plotting data in a funnel plot.</p> </section> <section id="CD006881-sec-0050"> <h4 class="title">Data synthesis</h4> <p>Data were pooled using the random‐effects model under the assumption that the effects being estimated were not identical throughout, but followed certain distribution patterns. The fixed‐effect model was also analysed to ensure robustness of the model chosen and susceptibility to outliers (<a href="./references#CD006881-bbs2-0044" title="HigginsJP , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). </p> </section> <section id="CD006881-sec-0051"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned to conduct subgroup analyses based on androgen type, comparators and outcomes, however there were insufficient studies to do this. </p> </section> <section id="CD006881-sec-0052"> <h4 class="title">Sensitivity analysis</h4> <p>We planned to perform sensitivity analyses to evaluate evidence stability, however there were insufficient studies to do this. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD006881-sec-0053" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD006881-sec-0053"></div> <section id="CD006881-sec-0054"> <h3 class="title">Description of studies</h3> <p>See: <a href="./references#CD006881-sec-0103" title="">Characteristics of included studies</a>; <a href="./references#CD006881-sec-0104" title="">Characteristics of excluded studies</a>; <a href="./references#CD006881-sec-0105" title="">Characteristics of studies awaiting classification</a>. </p> <section id="CD006881-sec-0055"> <h4 class="title">Results of the search</h4> <p>The search strategy described identified 269 records. After removing 148 duplicates, 121 titles and abstracts were assessed, and 77 records were excluded. After further assessment, 20 studies (23 records) were excluded, and three studies (7 records) could not be obtained and are awaiting assessment (<a href="./references#CD006881-bbs2-0029" title="GanguliA , SinghNP , AhujaN . A comparative study of nandrolone decanoate and erythropoietin on albumin levels, quality of life, and progression of renal disease in Indian predialysis CKD patients [abstract no: W455]. Nephrology Dialysis Transplantation2003;18(Suppl 4):692. [CENTRAL: CN‐00653811] GanguliA , SinghNP , SinghT , AgarwalSK , NeerajA . Nandrolone decanoate is equiefacious to erythropoietin in correcting anemia and quality of life in predialysis chronic kidney disease patients [abstract no: 137]. Journal of the Association of Physicians of India2003;51(Dec):1188. [CENTRAL: CN‐00765715] SinghNP , AnirbanG , SinghT , AgarwalSK , NeeraA . Long term effects of anemia correction on progression of renal disease and cognitive function using erythropoietin and androgenic steroids [abstract no: 136]. Journal of the Association of Physicians of India2003;51(Dec):1188. [CENTRAL: CN‐00783567] SinghNP , GanguliA , SinghT . A comparative study of nandrolone decanoate versus recombinant human erythropoietin on anemia in Indian predialysis chronic kidney disease patients [abstract no: W456]. Nephrology Dialysis Transplantation2003;18(Suppl 4):692‐3. [CENTRAL: CN‐00447760] ">Ganguli 2003</a>; <a href="./references#CD006881-bbs2-0030" title="OtaK , KoshikawaS , MimuraN , MizoguchiH , KatataokaK , KonT , et al. Effects of Org DD‐100 (Nandrolone decanoate) on renal anemia: a multi‐center double‐blind study. Rinsho Hyoka1986;14:827‐57. [CENTRAL: CN‐00320731] OtaK , MimuraN , KoshikawaS , MizoguchiH . High dose nandrolone decanoate therapy on the anemia of haemodialysis patients [abstract]. Kidney International1985;28(2):349. ">Ota 1986</a>; <a href="./references#CD006881-bbs2-0031" title="SuzukiT . Therapeutic efficacy of nandrolone decanoate for anemia in hemodialysis patients: a multicenter randomized dose‐finding study comparing 3 dose regimens. Kiso to Rinsho1986;20(4):2473‐87. [CENTRAL: CN‐00636146] ">Suzuki 1986</a>). We included eight studies (14 records) in our review (<a href="./references#CD006881-bbs2-0001" title="AramwitP , PalapinyoS , WiwatniwongS , SupasyndhO . The efficacy of oxymetholone in combination with erythropoietin on hematologic parameters and muscle mass in CAPD patients. International Journal of Clinical Pharmacology &amp; Therapeutics2010;48(12):803‐13. [MEDLINE: 21084036] SupasyndhO , WiwatniwongS , AramwitP , RuangkanchanasetrP , ChoovichianP . Short course oral androgenic steroid improved lean body mass in continuous ambulatory peritoneal dialysis patients [abstract no: F‐PO580]. Journal of the American Society of Nephrology2005;16:461A. WiwatniwongS , SupasyndhO , AramwitP , RuangkanchanasetrP , LuesuthiviboonL . Oral androgenic steroid therapy for anemia in continuous ambulatory peritoneal dialysis patients [abstract no: F‐PO599]. Journal of the American Society of Nephrology2005;16:465A. ">Aramwit 2010</a>; <a href="./references#CD006881-bbs2-0002" title="CattranDC , FentonSS , WilsonDR , OreopoulosD , ShimizuA , RichardsonRM . A controlled trial of nandrolone decanoate in the treatment of uremic anemia. Kidney International1977;12(6):430‐7. [MEDLINE: 609193] ">Cattran 1977</a>; <a href="./references#CD006881-bbs2-0003" title="GaughanWJ , LissKA , DunnSR , MangoldAM , BuhsmerJP , MichaelB , et al. A 6‐month study of low‐dose recombinant human erythropoietin alone and in combination with androgens for the treatment of anemia in chronic hemodialysis patients. American Journal of Kidney Diseases1997;30(4):495‐500. [MEDLINE: 9328363] LissKA , GaughanWJ , DunnSR , MichaelB , GoldmanJM , ArmentiVT , et al. A six month study of low‐dose recombinant human erythropoietin alone and in combination with androgen for the treatment of anemia in chronic hemodialysis patients [abstract no: A1206]. Journal of the American Society of Nephrology1996;7(9):1490. [CENTRAL: CN‐00626123] ">Gaughan 1997</a>; <a href="./references#CD006881-bbs2-0004" title="KimHY , EarmJH , SeoJC . Effects of low‐dose nandrolone decanoate on anemia and nutritional parameters in chronic hemodialysis patients with low‐dose subcutaneous erythropoietin [abstract no: A1452]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):287A. ">Kim 1999a</a>; <a href="./references#CD006881-bbs2-0005" title="KoronisC , MakrisF , StavroulakiE , LambropoulouA , OrthopoulosV . Combination of low‐dose recombinant human erythropoietin with androgens for the treatment of anaemia in hemodialysis patients [abstract]. 37th Congress European Renal Association. European Dialysis and Transplantation Association; 2000 Sept 17‐20; Nice, France. 2000:235. [CENTRAL: CN‐00461096] ">Koronis 2000</a>; <a href="./references#CD006881-bbs2-0006" title="NavarroJF , MoraC , MaciaM , ChahinJ , GallegoE , MendezML , et al. Effects of androgen therapy on hematologic and nutritional parameters in elderly peritoneal dialysis patients [abstract]. International Urology &amp; Nephrology2001;33(4):715‐6. [CENTRAL: CN‐00615848] NavarroJF , MoraC , MaciaML , GallegoE , ChahinJ , MendezML , et al. Prospective comparison between rHuEPO and androgens in CAPD patients: impact on hematologic and nutritional parameters [abstract]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):436A. [CENTRAL: CN‐00644231] NavarroJF , MoraF , MaciaM , GarciaJ . Randomized prospective comparison between erythropoietin and androgens in CAPD patients. Kidney International2002;61(4):1537‐44. [MEDLINE: 11918762] ">Navarro 2002</a>; <a href="./references#CD006881-bbs2-0007" title="SheashaaH , Abdel‐RazekW , El‐HusseiniA , SelimA , HassanN , AbbasT , et al. Use of nandrolone decanoate as an adjuvant for erythropoietin dose reduction in treating anemia in patients on hemodialysis. Nephron2005;99(4):c102–6. [MEDLINE: 15703460] ">Sheashaa 2005a</a>; <a href="./references#CD006881-bbs2-0008" title="HendlerED , SolomonLR . Prospective controlled study of androgen effects on red cell oxygen transport and work capacity in chronic hemodialysis patients. Acta Haematologica1990;83(1):1‐8. [MEDLINE: 2105563] SolomonLR , HendlerED . Prospective controlled study of androgen therapy in the anemia of chronic renal disease: effects on iron kinetics. Acta Haematologica1988;79(1):12‐9. [MEDLINE: 3124456] ">Solomon 1988b</a>) (<a href="#CD006881-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD006881-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Flow diagram showing study selection" data-id="CD006881-fig-0001" src="/cdsr/doi/10.1002/14651858.CD006881.pub2/media/CDSR/CD006881/image_n/nCD006881-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Flow diagram showing study selection</p> </div> </div> </div> </section> <section id="CD006881-sec-0056"> <h4 class="title">Included studies</h4> <p>We included eight studies that enrolled 194 adults with CKD‐associated anaemia, of whom 181 completed the studies. Study populations were small, ranging from 9 to 37 participants (average = 24.25 participants). Studies were conducted in Thailand, USA, Egypt, Canada, Spain, Korea and Greece. </p> <p>We found a substantial bias favouring inclusion of males (M/F: 107/24) in the five studies that reported gender (<a href="./references#CD006881-bbs2-0001" title="AramwitP , PalapinyoS , WiwatniwongS , SupasyndhO . The efficacy of oxymetholone in combination with erythropoietin on hematologic parameters and muscle mass in CAPD patients. International Journal of Clinical Pharmacology &amp; Therapeutics2010;48(12):803‐13. [MEDLINE: 21084036] SupasyndhO , WiwatniwongS , AramwitP , RuangkanchanasetrP , ChoovichianP . Short course oral androgenic steroid improved lean body mass in continuous ambulatory peritoneal dialysis patients [abstract no: F‐PO580]. Journal of the American Society of Nephrology2005;16:461A. WiwatniwongS , SupasyndhO , AramwitP , RuangkanchanasetrP , LuesuthiviboonL . Oral androgenic steroid therapy for anemia in continuous ambulatory peritoneal dialysis patients [abstract no: F‐PO599]. Journal of the American Society of Nephrology2005;16:465A. ">Aramwit 2010</a>; <a href="./references#CD006881-bbs2-0002" title="CattranDC , FentonSS , WilsonDR , OreopoulosD , ShimizuA , RichardsonRM . A controlled trial of nandrolone decanoate in the treatment of uremic anemia. Kidney International1977;12(6):430‐7. [MEDLINE: 609193] ">Cattran 1977</a>; <a href="./references#CD006881-bbs2-0003" title="GaughanWJ , LissKA , DunnSR , MangoldAM , BuhsmerJP , MichaelB , et al. A 6‐month study of low‐dose recombinant human erythropoietin alone and in combination with androgens for the treatment of anemia in chronic hemodialysis patients. American Journal of Kidney Diseases1997;30(4):495‐500. [MEDLINE: 9328363] LissKA , GaughanWJ , DunnSR , MichaelB , GoldmanJM , ArmentiVT , et al. A six month study of low‐dose recombinant human erythropoietin alone and in combination with androgen for the treatment of anemia in chronic hemodialysis patients [abstract no: A1206]. Journal of the American Society of Nephrology1996;7(9):1490. [CENTRAL: CN‐00626123] ">Gaughan 1997</a>; <a href="./references#CD006881-bbs2-0006" title="NavarroJF , MoraC , MaciaM , ChahinJ , GallegoE , MendezML , et al. Effects of androgen therapy on hematologic and nutritional parameters in elderly peritoneal dialysis patients [abstract]. International Urology &amp; Nephrology2001;33(4):715‐6. [CENTRAL: CN‐00615848] NavarroJF , MoraC , MaciaML , GallegoE , ChahinJ , MendezML , et al. Prospective comparison between rHuEPO and androgens in CAPD patients: impact on hematologic and nutritional parameters [abstract]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):436A. [CENTRAL: CN‐00644231] NavarroJF , MoraF , MaciaM , GarciaJ . Randomized prospective comparison between erythropoietin and androgens in CAPD patients. Kidney International2002;61(4):1537‐44. [MEDLINE: 11918762] ">Navarro 2002</a>; <a href="./references#CD006881-bbs2-0007" title="SheashaaH , Abdel‐RazekW , El‐HusseiniA , SelimA , HassanN , AbbasT , et al. Use of nandrolone decanoate as an adjuvant for erythropoietin dose reduction in treating anemia in patients on hemodialysis. Nephron2005;99(4):c102–6. [MEDLINE: 15703460] ">Sheashaa 2005a</a>). Participants' sex was not reported in three studies (<a href="./references#CD006881-bbs2-0004" title="KimHY , EarmJH , SeoJC . Effects of low‐dose nandrolone decanoate on anemia and nutritional parameters in chronic hemodialysis patients with low‐dose subcutaneous erythropoietin [abstract no: A1452]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):287A. ">Kim 1999a</a>; <a href="./references#CD006881-bbs2-0005" title="KoronisC , MakrisF , StavroulakiE , LambropoulouA , OrthopoulosV . Combination of low‐dose recombinant human erythropoietin with androgens for the treatment of anaemia in hemodialysis patients [abstract]. 37th Congress European Renal Association. European Dialysis and Transplantation Association; 2000 Sept 17‐20; Nice, France. 2000:235. [CENTRAL: CN‐00461096] ">Koronis 2000</a>; <a href="./references#CD006881-bbs2-0008" title="HendlerED , SolomonLR . Prospective controlled study of androgen effects on red cell oxygen transport and work capacity in chronic hemodialysis patients. Acta Haematologica1990;83(1):1‐8. [MEDLINE: 2105563] SolomonLR , HendlerED . Prospective controlled study of androgen therapy in the anemia of chronic renal disease: effects on iron kinetics. Acta Haematologica1988;79(1):12‐9. [MEDLINE: 3124456] ">Solomon 1988b</a>). </p> <p>Participants' ages ranged from 25 to 78 years. Mean participant age was not reported in three studies (<a href="./references#CD006881-bbs2-0004" title="KimHY , EarmJH , SeoJC . Effects of low‐dose nandrolone decanoate on anemia and nutritional parameters in chronic hemodialysis patients with low‐dose subcutaneous erythropoietin [abstract no: A1452]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):287A. ">Kim 1999a</a>; <a href="./references#CD006881-bbs2-0005" title="KoronisC , MakrisF , StavroulakiE , LambropoulouA , OrthopoulosV . Combination of low‐dose recombinant human erythropoietin with androgens for the treatment of anaemia in hemodialysis patients [abstract]. 37th Congress European Renal Association. European Dialysis and Transplantation Association; 2000 Sept 17‐20; Nice, France. 2000:235. [CENTRAL: CN‐00461096] ">Koronis 2000</a>; <a href="./references#CD006881-bbs2-0008" title="HendlerED , SolomonLR . Prospective controlled study of androgen effects on red cell oxygen transport and work capacity in chronic hemodialysis patients. Acta Haematologica1990;83(1):1‐8. [MEDLINE: 2105563] SolomonLR , HendlerED . Prospective controlled study of androgen therapy in the anemia of chronic renal disease: effects on iron kinetics. Acta Haematologica1988;79(1):12‐9. [MEDLINE: 3124456] ">Solomon 1988b</a>) </p> <p>All studies recruited participants with CKD‐related anaemia (<a href="./references#CD006881-bbs2-0001" title="AramwitP , PalapinyoS , WiwatniwongS , SupasyndhO . The efficacy of oxymetholone in combination with erythropoietin on hematologic parameters and muscle mass in CAPD patients. International Journal of Clinical Pharmacology &amp; Therapeutics2010;48(12):803‐13. [MEDLINE: 21084036] SupasyndhO , WiwatniwongS , AramwitP , RuangkanchanasetrP , ChoovichianP . Short course oral androgenic steroid improved lean body mass in continuous ambulatory peritoneal dialysis patients [abstract no: F‐PO580]. Journal of the American Society of Nephrology2005;16:461A. WiwatniwongS , SupasyndhO , AramwitP , RuangkanchanasetrP , LuesuthiviboonL . Oral androgenic steroid therapy for anemia in continuous ambulatory peritoneal dialysis patients [abstract no: F‐PO599]. Journal of the American Society of Nephrology2005;16:465A. ">Aramwit 2010</a>; <a href="./references#CD006881-bbs2-0002" title="CattranDC , FentonSS , WilsonDR , OreopoulosD , ShimizuA , RichardsonRM . A controlled trial of nandrolone decanoate in the treatment of uremic anemia. Kidney International1977;12(6):430‐7. [MEDLINE: 609193] ">Cattran 1977</a>; <a href="./references#CD006881-bbs2-0003" title="GaughanWJ , LissKA , DunnSR , MangoldAM , BuhsmerJP , MichaelB , et al. A 6‐month study of low‐dose recombinant human erythropoietin alone and in combination with androgens for the treatment of anemia in chronic hemodialysis patients. American Journal of Kidney Diseases1997;30(4):495‐500. [MEDLINE: 9328363] LissKA , GaughanWJ , DunnSR , MichaelB , GoldmanJM , ArmentiVT , et al. A six month study of low‐dose recombinant human erythropoietin alone and in combination with androgen for the treatment of anemia in chronic hemodialysis patients [abstract no: A1206]. Journal of the American Society of Nephrology1996;7(9):1490. [CENTRAL: CN‐00626123] ">Gaughan 1997</a>; <a href="./references#CD006881-bbs2-0004" title="KimHY , EarmJH , SeoJC . Effects of low‐dose nandrolone decanoate on anemia and nutritional parameters in chronic hemodialysis patients with low‐dose subcutaneous erythropoietin [abstract no: A1452]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):287A. ">Kim 1999a</a>; <a href="./references#CD006881-bbs2-0005" title="KoronisC , MakrisF , StavroulakiE , LambropoulouA , OrthopoulosV . Combination of low‐dose recombinant human erythropoietin with androgens for the treatment of anaemia in hemodialysis patients [abstract]. 37th Congress European Renal Association. European Dialysis and Transplantation Association; 2000 Sept 17‐20; Nice, France. 2000:235. [CENTRAL: CN‐00461096] ">Koronis 2000</a>; <a href="./references#CD006881-bbs2-0006" title="NavarroJF , MoraC , MaciaM , ChahinJ , GallegoE , MendezML , et al. Effects of androgen therapy on hematologic and nutritional parameters in elderly peritoneal dialysis patients [abstract]. International Urology &amp; Nephrology2001;33(4):715‐6. [CENTRAL: CN‐00615848] NavarroJF , MoraC , MaciaML , GallegoE , ChahinJ , MendezML , et al. Prospective comparison between rHuEPO and androgens in CAPD patients: impact on hematologic and nutritional parameters [abstract]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):436A. [CENTRAL: CN‐00644231] NavarroJF , MoraF , MaciaM , GarciaJ . Randomized prospective comparison between erythropoietin and androgens in CAPD patients. Kidney International2002;61(4):1537‐44. [MEDLINE: 11918762] ">Navarro 2002</a>; <a href="./references#CD006881-bbs2-0007" title="SheashaaH , Abdel‐RazekW , El‐HusseiniA , SelimA , HassanN , AbbasT , et al. Use of nandrolone decanoate as an adjuvant for erythropoietin dose reduction in treating anemia in patients on hemodialysis. Nephron2005;99(4):c102–6. [MEDLINE: 15703460] ">Sheashaa 2005a</a>; <a href="./references#CD006881-bbs2-0008" title="HendlerED , SolomonLR . Prospective controlled study of androgen effects on red cell oxygen transport and work capacity in chronic hemodialysis patients. Acta Haematologica1990;83(1):1‐8. [MEDLINE: 2105563] SolomonLR , HendlerED . Prospective controlled study of androgen therapy in the anemia of chronic renal disease: effects on iron kinetics. Acta Haematologica1988;79(1):12‐9. [MEDLINE: 3124456] ">Solomon 1988b</a>). Dialysis interventions included peritoneal dialysis for at least three months (<a href="./references#CD006881-bbs2-0001" title="AramwitP , PalapinyoS , WiwatniwongS , SupasyndhO . The efficacy of oxymetholone in combination with erythropoietin on hematologic parameters and muscle mass in CAPD patients. International Journal of Clinical Pharmacology &amp; Therapeutics2010;48(12):803‐13. [MEDLINE: 21084036] SupasyndhO , WiwatniwongS , AramwitP , RuangkanchanasetrP , ChoovichianP . Short course oral androgenic steroid improved lean body mass in continuous ambulatory peritoneal dialysis patients [abstract no: F‐PO580]. Journal of the American Society of Nephrology2005;16:461A. WiwatniwongS , SupasyndhO , AramwitP , RuangkanchanasetrP , LuesuthiviboonL . Oral androgenic steroid therapy for anemia in continuous ambulatory peritoneal dialysis patients [abstract no: F‐PO599]. Journal of the American Society of Nephrology2005;16:465A. ">Aramwit 2010</a>); continuous peritoneal dialysis for at least six months (<a href="./references#CD006881-bbs2-0006" title="NavarroJF , MoraC , MaciaM , ChahinJ , GallegoE , MendezML , et al. Effects of androgen therapy on hematologic and nutritional parameters in elderly peritoneal dialysis patients [abstract]. International Urology &amp; Nephrology2001;33(4):715‐6. [CENTRAL: CN‐00615848] NavarroJF , MoraC , MaciaML , GallegoE , ChahinJ , MendezML , et al. Prospective comparison between rHuEPO and androgens in CAPD patients: impact on hematologic and nutritional parameters [abstract]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):436A. [CENTRAL: CN‐00644231] NavarroJF , MoraF , MaciaM , GarciaJ . Randomized prospective comparison between erythropoietin and androgens in CAPD patients. Kidney International2002;61(4):1537‐44. [MEDLINE: 11918762] ">Navarro 2002</a>); haemodialysis (<a href="./references#CD006881-bbs2-0003" title="GaughanWJ , LissKA , DunnSR , MangoldAM , BuhsmerJP , MichaelB , et al. A 6‐month study of low‐dose recombinant human erythropoietin alone and in combination with androgens for the treatment of anemia in chronic hemodialysis patients. American Journal of Kidney Diseases1997;30(4):495‐500. [MEDLINE: 9328363] LissKA , GaughanWJ , DunnSR , MichaelB , GoldmanJM , ArmentiVT , et al. A six month study of low‐dose recombinant human erythropoietin alone and in combination with androgen for the treatment of anemia in chronic hemodialysis patients [abstract no: A1206]. Journal of the American Society of Nephrology1996;7(9):1490. [CENTRAL: CN‐00626123] ">Gaughan 1997</a>; <a href="./references#CD006881-bbs2-0004" title="KimHY , EarmJH , SeoJC . Effects of low‐dose nandrolone decanoate on anemia and nutritional parameters in chronic hemodialysis patients with low‐dose subcutaneous erythropoietin [abstract no: A1452]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):287A. ">Kim 1999a</a>; <a href="./references#CD006881-bbs2-0005" title="KoronisC , MakrisF , StavroulakiE , LambropoulouA , OrthopoulosV . Combination of low‐dose recombinant human erythropoietin with androgens for the treatment of anaemia in hemodialysis patients [abstract]. 37th Congress European Renal Association. European Dialysis and Transplantation Association; 2000 Sept 17‐20; Nice, France. 2000:235. [CENTRAL: CN‐00461096] ">Koronis 2000</a>; <a href="./references#CD006881-bbs2-0007" title="SheashaaH , Abdel‐RazekW , El‐HusseiniA , SelimA , HassanN , AbbasT , et al. Use of nandrolone decanoate as an adjuvant for erythropoietin dose reduction in treating anemia in patients on hemodialysis. Nephron2005;99(4):c102–6. [MEDLINE: 15703460] ">Sheashaa 2005a</a>; <a href="./references#CD006881-bbs2-0008" title="HendlerED , SolomonLR . Prospective controlled study of androgen effects on red cell oxygen transport and work capacity in chronic hemodialysis patients. Acta Haematologica1990;83(1):1‐8. [MEDLINE: 2105563] SolomonLR , HendlerED . Prospective controlled study of androgen therapy in the anemia of chronic renal disease: effects on iron kinetics. Acta Haematologica1988;79(1):12‐9. [MEDLINE: 3124456] ">Solomon 1988b</a>); or chronic dialysis (<a href="./references#CD006881-bbs2-0002" title="CattranDC , FentonSS , WilsonDR , OreopoulosD , ShimizuA , RichardsonRM . A controlled trial of nandrolone decanoate in the treatment of uremic anemia. Kidney International1977;12(6):430‐7. [MEDLINE: 609193] ">Cattran 1977</a>). Blood chemistry requirements varied, but included Hb concentration &lt; 11 g/dL; serum ferritin concentrations of at least 100 ng/mL; serum transferrin saturations of at least 20%. Iron parameters also varied, as did Hb and HCT levels. </p> <p>All studies were of six months duration. Intervention arm participants received androgens administered as subcutaneous (SC) or intramuscular (IM) injections (nandrolone decanoate), or oral tablets (oxymetholone). Study drug doses and frequencies were: 50 mg tablet twice daily (<a href="./references#CD006881-bbs2-0001" title="AramwitP , PalapinyoS , WiwatniwongS , SupasyndhO . The efficacy of oxymetholone in combination with erythropoietin on hematologic parameters and muscle mass in CAPD patients. International Journal of Clinical Pharmacology &amp; Therapeutics2010;48(12):803‐13. [MEDLINE: 21084036] SupasyndhO , WiwatniwongS , AramwitP , RuangkanchanasetrP , ChoovichianP . Short course oral androgenic steroid improved lean body mass in continuous ambulatory peritoneal dialysis patients [abstract no: F‐PO580]. Journal of the American Society of Nephrology2005;16:461A. WiwatniwongS , SupasyndhO , AramwitP , RuangkanchanasetrP , LuesuthiviboonL . Oral androgenic steroid therapy for anemia in continuous ambulatory peritoneal dialysis patients [abstract no: F‐PO599]. Journal of the American Society of Nephrology2005;16:465A. ">Aramwit 2010</a>); nandrolone decanoate 200 mg IM once weekly (<a href="./references#CD006881-bbs2-0002" title="CattranDC , FentonSS , WilsonDR , OreopoulosD , ShimizuA , RichardsonRM . A controlled trial of nandrolone decanoate in the treatment of uremic anemia. Kidney International1977;12(6):430‐7. [MEDLINE: 609193] ">Cattran 1977</a>; <a href="./references#CD006881-bbs2-0006" title="NavarroJF , MoraC , MaciaM , ChahinJ , GallegoE , MendezML , et al. Effects of androgen therapy on hematologic and nutritional parameters in elderly peritoneal dialysis patients [abstract]. International Urology &amp; Nephrology2001;33(4):715‐6. [CENTRAL: CN‐00615848] NavarroJF , MoraC , MaciaML , GallegoE , ChahinJ , MendezML , et al. Prospective comparison between rHuEPO and androgens in CAPD patients: impact on hematologic and nutritional parameters [abstract]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):436A. [CENTRAL: CN‐00644231] NavarroJF , MoraF , MaciaM , GarciaJ . Randomized prospective comparison between erythropoietin and androgens in CAPD patients. Kidney International2002;61(4):1537‐44. [MEDLINE: 11918762] ">Navarro 2002</a>); nandrolone decanoate 100 mg IM once weekly (<a href="./references#CD006881-bbs2-0008" title="HendlerED , SolomonLR . Prospective controlled study of androgen effects on red cell oxygen transport and work capacity in chronic hemodialysis patients. Acta Haematologica1990;83(1):1‐8. [MEDLINE: 2105563] SolomonLR , HendlerED . Prospective controlled study of androgen therapy in the anemia of chronic renal disease: effects on iron kinetics. Acta Haematologica1988;79(1):12‐9. [MEDLINE: 3124456] ">Solomon 1988b</a>); nandrolone decanoate 100 mg IM plus rHuEPO 1500 U intravenously (IV) once weekly (<a href="./references#CD006881-bbs2-0003" title="GaughanWJ , LissKA , DunnSR , MangoldAM , BuhsmerJP , MichaelB , et al. A 6‐month study of low‐dose recombinant human erythropoietin alone and in combination with androgens for the treatment of anemia in chronic hemodialysis patients. American Journal of Kidney Diseases1997;30(4):495‐500. [MEDLINE: 9328363] LissKA , GaughanWJ , DunnSR , MichaelB , GoldmanJM , ArmentiVT , et al. A six month study of low‐dose recombinant human erythropoietin alone and in combination with androgen for the treatment of anemia in chronic hemodialysis patients [abstract no: A1206]. Journal of the American Society of Nephrology1996;7(9):1490. [CENTRAL: CN‐00626123] ">Gaughan 1997</a>); nandrolone decanoate 100 mg IM plus rHuEPO 2000 U SC (<a href="./references#CD006881-bbs2-0004" title="KimHY , EarmJH , SeoJC . Effects of low‐dose nandrolone decanoate on anemia and nutritional parameters in chronic hemodialysis patients with low‐dose subcutaneous erythropoietin [abstract no: A1452]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):287A. ">Kim 1999a</a>); nandrolone decanoate 100 mg IM plus rHuEPO 1000 U SC every 15 days (<a href="./references#CD006881-bbs2-0005" title="KoronisC , MakrisF , StavroulakiE , LambropoulouA , OrthopoulosV . Combination of low‐dose recombinant human erythropoietin with androgens for the treatment of anaemia in hemodialysis patients [abstract]. 37th Congress European Renal Association. European Dialysis and Transplantation Association; 2000 Sept 17‐20; Nice, France. 2000:235. [CENTRAL: CN‐00461096] ">Koronis 2000</a>); and nandrolone decanoate 50 mg IM plus rHuEPO 1000 U SC twice weekly (<a href="./references#CD006881-bbs2-0007" title="SheashaaH , Abdel‐RazekW , El‐HusseiniA , SelimA , HassanN , AbbasT , et al. Use of nandrolone decanoate as an adjuvant for erythropoietin dose reduction in treating anemia in patients on hemodialysis. Nephron2005;99(4):c102–6. [MEDLINE: 15703460] ">Sheashaa 2005a</a>). Only <a href="./references#CD006881-bbs2-0001" title="AramwitP , PalapinyoS , WiwatniwongS , SupasyndhO . The efficacy of oxymetholone in combination with erythropoietin on hematologic parameters and muscle mass in CAPD patients. International Journal of Clinical Pharmacology &amp; Therapeutics2010;48(12):803‐13. [MEDLINE: 21084036] SupasyndhO , WiwatniwongS , AramwitP , RuangkanchanasetrP , ChoovichianP . Short course oral androgenic steroid improved lean body mass in continuous ambulatory peritoneal dialysis patients [abstract no: F‐PO580]. Journal of the American Society of Nephrology2005;16:461A. WiwatniwongS , SupasyndhO , AramwitP , RuangkanchanasetrP , LuesuthiviboonL . Oral androgenic steroid therapy for anemia in continuous ambulatory peritoneal dialysis patients [abstract no: F‐PO599]. Journal of the American Society of Nephrology2005;16:465A. ">Aramwit 2010</a> reported three month follow‐up. Four studies investigated nandrolone decanoate plus rHuEPO versus rHuEPO alone as the control (<a href="./references#CD006881-bbs2-0003" title="GaughanWJ , LissKA , DunnSR , MangoldAM , BuhsmerJP , MichaelB , et al. A 6‐month study of low‐dose recombinant human erythropoietin alone and in combination with androgens for the treatment of anemia in chronic hemodialysis patients. American Journal of Kidney Diseases1997;30(4):495‐500. [MEDLINE: 9328363] LissKA , GaughanWJ , DunnSR , MichaelB , GoldmanJM , ArmentiVT , et al. A six month study of low‐dose recombinant human erythropoietin alone and in combination with androgen for the treatment of anemia in chronic hemodialysis patients [abstract no: A1206]. Journal of the American Society of Nephrology1996;7(9):1490. [CENTRAL: CN‐00626123] ">Gaughan 1997</a>; <a href="./references#CD006881-bbs2-0004" title="KimHY , EarmJH , SeoJC . Effects of low‐dose nandrolone decanoate on anemia and nutritional parameters in chronic hemodialysis patients with low‐dose subcutaneous erythropoietin [abstract no: A1452]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):287A. ">Kim 1999a</a>; <a href="./references#CD006881-bbs2-0005" title="KoronisC , MakrisF , StavroulakiE , LambropoulouA , OrthopoulosV . Combination of low‐dose recombinant human erythropoietin with androgens for the treatment of anaemia in hemodialysis patients [abstract]. 37th Congress European Renal Association. European Dialysis and Transplantation Association; 2000 Sept 17‐20; Nice, France. 2000:235. [CENTRAL: CN‐00461096] ">Koronis 2000</a>; <a href="./references#CD006881-bbs2-0007" title="SheashaaH , Abdel‐RazekW , El‐HusseiniA , SelimA , HassanN , AbbasT , et al. Use of nandrolone decanoate as an adjuvant for erythropoietin dose reduction in treating anemia in patients on hemodialysis. Nephron2005;99(4):c102–6. [MEDLINE: 15703460] ">Sheashaa 2005a</a>); one study investigated nandrolone decanoate versus rHuEPO alone as the control drug (<a href="./references#CD006881-bbs2-0006" title="NavarroJF , MoraC , MaciaM , ChahinJ , GallegoE , MendezML , et al. Effects of androgen therapy on hematologic and nutritional parameters in elderly peritoneal dialysis patients [abstract]. International Urology &amp; Nephrology2001;33(4):715‐6. [CENTRAL: CN‐00615848] NavarroJF , MoraC , MaciaML , GallegoE , ChahinJ , MendezML , et al. Prospective comparison between rHuEPO and androgens in CAPD patients: impact on hematologic and nutritional parameters [abstract]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):436A. [CENTRAL: CN‐00644231] NavarroJF , MoraF , MaciaM , GarciaJ . Randomized prospective comparison between erythropoietin and androgens in CAPD patients. Kidney International2002;61(4):1537‐44. [MEDLINE: 11918762] ">Navarro 2002</a>); two studies investigated no therapy as the control (<a href="./references#CD006881-bbs2-0002" title="CattranDC , FentonSS , WilsonDR , OreopoulosD , ShimizuA , RichardsonRM . A controlled trial of nandrolone decanoate in the treatment of uremic anemia. Kidney International1977;12(6):430‐7. [MEDLINE: 609193] ">Cattran 1977</a>; <a href="./references#CD006881-bbs2-0008" title="HendlerED , SolomonLR . Prospective controlled study of androgen effects on red cell oxygen transport and work capacity in chronic hemodialysis patients. Acta Haematologica1990;83(1):1‐8. [MEDLINE: 2105563] SolomonLR , HendlerED . Prospective controlled study of androgen therapy in the anemia of chronic renal disease: effects on iron kinetics. Acta Haematologica1988;79(1):12‐9. [MEDLINE: 3124456] ">Solomon 1988b</a>); one study investigated oxymetholone plus rHuEPO versus placebo plus rHuEPO as the control drug (<a href="./references#CD006881-bbs2-0001" title="AramwitP , PalapinyoS , WiwatniwongS , SupasyndhO . The efficacy of oxymetholone in combination with erythropoietin on hematologic parameters and muscle mass in CAPD patients. International Journal of Clinical Pharmacology &amp; Therapeutics2010;48(12):803‐13. [MEDLINE: 21084036] SupasyndhO , WiwatniwongS , AramwitP , RuangkanchanasetrP , ChoovichianP . Short course oral androgenic steroid improved lean body mass in continuous ambulatory peritoneal dialysis patients [abstract no: F‐PO580]. Journal of the American Society of Nephrology2005;16:461A. WiwatniwongS , SupasyndhO , AramwitP , RuangkanchanasetrP , LuesuthiviboonL . Oral androgenic steroid therapy for anemia in continuous ambulatory peritoneal dialysis patients [abstract no: F‐PO599]. Journal of the American Society of Nephrology2005;16:465A. ">Aramwit 2010</a>). </p> <p>Four studies (<a href="./references#CD006881-bbs2-0001" title="AramwitP , PalapinyoS , WiwatniwongS , SupasyndhO . The efficacy of oxymetholone in combination with erythropoietin on hematologic parameters and muscle mass in CAPD patients. International Journal of Clinical Pharmacology &amp; Therapeutics2010;48(12):803‐13. [MEDLINE: 21084036] SupasyndhO , WiwatniwongS , AramwitP , RuangkanchanasetrP , ChoovichianP . Short course oral androgenic steroid improved lean body mass in continuous ambulatory peritoneal dialysis patients [abstract no: F‐PO580]. Journal of the American Society of Nephrology2005;16:461A. WiwatniwongS , SupasyndhO , AramwitP , RuangkanchanasetrP , LuesuthiviboonL . Oral androgenic steroid therapy for anemia in continuous ambulatory peritoneal dialysis patients [abstract no: F‐PO599]. Journal of the American Society of Nephrology2005;16:465A. ">Aramwit 2010</a>; <a href="./references#CD006881-bbs2-0006" title="NavarroJF , MoraC , MaciaM , ChahinJ , GallegoE , MendezML , et al. Effects of androgen therapy on hematologic and nutritional parameters in elderly peritoneal dialysis patients [abstract]. International Urology &amp; Nephrology2001;33(4):715‐6. [CENTRAL: CN‐00615848] NavarroJF , MoraC , MaciaML , GallegoE , ChahinJ , MendezML , et al. Prospective comparison between rHuEPO and androgens in CAPD patients: impact on hematologic and nutritional parameters [abstract]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):436A. [CENTRAL: CN‐00644231] NavarroJF , MoraF , MaciaM , GarciaJ . Randomized prospective comparison between erythropoietin and androgens in CAPD patients. Kidney International2002;61(4):1537‐44. [MEDLINE: 11918762] ">Navarro 2002</a>; <a href="./references#CD006881-bbs2-0007" title="SheashaaH , Abdel‐RazekW , El‐HusseiniA , SelimA , HassanN , AbbasT , et al. Use of nandrolone decanoate as an adjuvant for erythropoietin dose reduction in treating anemia in patients on hemodialysis. Nephron2005;99(4):c102–6. [MEDLINE: 15703460] ">Sheashaa 2005a</a>; <a href="./references#CD006881-bbs2-0002" title="CattranDC , FentonSS , WilsonDR , OreopoulosD , ShimizuA , RichardsonRM . A controlled trial of nandrolone decanoate in the treatment of uremic anemia. Kidney International1977;12(6):430‐7. [MEDLINE: 609193] ">Cattran 1977</a>) reported Hb and HCT levels as indicators of anaemia correction; <a href="./references#CD006881-bbs2-0004" title="KimHY , EarmJH , SeoJC . Effects of low‐dose nandrolone decanoate on anemia and nutritional parameters in chronic hemodialysis patients with low‐dose subcutaneous erythropoietin [abstract no: A1452]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):287A. ">Kim 1999a</a> and <a href="./references#CD006881-bbs2-0005" title="KoronisC , MakrisF , StavroulakiE , LambropoulouA , OrthopoulosV . Combination of low‐dose recombinant human erythropoietin with androgens for the treatment of anaemia in hemodialysis patients [abstract]. 37th Congress European Renal Association. European Dialysis and Transplantation Association; 2000 Sept 17‐20; Nice, France. 2000:235. [CENTRAL: CN‐00461096] ">Koronis 2000</a> reported HCT levels only; <a href="./references#CD006881-bbs2-0008" title="HendlerED , SolomonLR . Prospective controlled study of androgen effects on red cell oxygen transport and work capacity in chronic hemodialysis patients. Acta Haematologica1990;83(1):1‐8. [MEDLINE: 2105563] SolomonLR , HendlerED . Prospective controlled study of androgen therapy in the anemia of chronic renal disease: effects on iron kinetics. Acta Haematologica1988;79(1):12‐9. [MEDLINE: 3124456] ">Solomon 1988b</a> reported Hb levels only. </p> <p><a href="./references#CD006881-bbs2-0001" title="AramwitP , PalapinyoS , WiwatniwongS , SupasyndhO . The efficacy of oxymetholone in combination with erythropoietin on hematologic parameters and muscle mass in CAPD patients. International Journal of Clinical Pharmacology &amp; Therapeutics2010;48(12):803‐13. [MEDLINE: 21084036] SupasyndhO , WiwatniwongS , AramwitP , RuangkanchanasetrP , ChoovichianP . Short course oral androgenic steroid improved lean body mass in continuous ambulatory peritoneal dialysis patients [abstract no: F‐PO580]. Journal of the American Society of Nephrology2005;16:461A. WiwatniwongS , SupasyndhO , AramwitP , RuangkanchanasetrP , LuesuthiviboonL . Oral androgenic steroid therapy for anemia in continuous ambulatory peritoneal dialysis patients [abstract no: F‐PO599]. Journal of the American Society of Nephrology2005;16:465A. ">Aramwit 2010</a> and <a href="./references#CD006881-bbs2-0006" title="NavarroJF , MoraC , MaciaM , ChahinJ , GallegoE , MendezML , et al. Effects of androgen therapy on hematologic and nutritional parameters in elderly peritoneal dialysis patients [abstract]. International Urology &amp; Nephrology2001;33(4):715‐6. [CENTRAL: CN‐00615848] NavarroJF , MoraC , MaciaML , GallegoE , ChahinJ , MendezML , et al. Prospective comparison between rHuEPO and androgens in CAPD patients: impact on hematologic and nutritional parameters [abstract]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):436A. [CENTRAL: CN‐00644231] NavarroJF , MoraF , MaciaM , GarciaJ . Randomized prospective comparison between erythropoietin and androgens in CAPD patients. Kidney International2002;61(4):1537‐44. [MEDLINE: 11918762] ">Navarro 2002</a> reported kidney function (BUN and SCr values). <a href="./references#CD006881-bbs2-0001" title="AramwitP , PalapinyoS , WiwatniwongS , SupasyndhO . The efficacy of oxymetholone in combination with erythropoietin on hematologic parameters and muscle mass in CAPD patients. International Journal of Clinical Pharmacology &amp; Therapeutics2010;48(12):803‐13. [MEDLINE: 21084036] SupasyndhO , WiwatniwongS , AramwitP , RuangkanchanasetrP , ChoovichianP . Short course oral androgenic steroid improved lean body mass in continuous ambulatory peritoneal dialysis patients [abstract no: F‐PO580]. Journal of the American Society of Nephrology2005;16:461A. WiwatniwongS , SupasyndhO , AramwitP , RuangkanchanasetrP , LuesuthiviboonL . Oral androgenic steroid therapy for anemia in continuous ambulatory peritoneal dialysis patients [abstract no: F‐PO599]. Journal of the American Society of Nephrology2005;16:465A. ">Aramwit 2010</a> also reported liver function measures (AST and ALT values) and lipid profile indicators (TG, HDL, LDL values); and <a href="./references#CD006881-bbs2-0003" title="GaughanWJ , LissKA , DunnSR , MangoldAM , BuhsmerJP , MichaelB , et al. A 6‐month study of low‐dose recombinant human erythropoietin alone and in combination with androgens for the treatment of anemia in chronic hemodialysis patients. American Journal of Kidney Diseases1997;30(4):495‐500. [MEDLINE: 9328363] LissKA , GaughanWJ , DunnSR , MichaelB , GoldmanJM , ArmentiVT , et al. A six month study of low‐dose recombinant human erythropoietin alone and in combination with androgen for the treatment of anemia in chronic hemodialysis patients [abstract no: A1206]. Journal of the American Society of Nephrology1996;7(9):1490. [CENTRAL: CN‐00626123] ">Gaughan 1997</a> reported TG only. </p> <p>Four studies (<a href="./references#CD006881-bbs2-0001" title="AramwitP , PalapinyoS , WiwatniwongS , SupasyndhO . The efficacy of oxymetholone in combination with erythropoietin on hematologic parameters and muscle mass in CAPD patients. International Journal of Clinical Pharmacology &amp; Therapeutics2010;48(12):803‐13. [MEDLINE: 21084036] SupasyndhO , WiwatniwongS , AramwitP , RuangkanchanasetrP , ChoovichianP . Short course oral androgenic steroid improved lean body mass in continuous ambulatory peritoneal dialysis patients [abstract no: F‐PO580]. Journal of the American Society of Nephrology2005;16:461A. WiwatniwongS , SupasyndhO , AramwitP , RuangkanchanasetrP , LuesuthiviboonL . Oral androgenic steroid therapy for anemia in continuous ambulatory peritoneal dialysis patients [abstract no: F‐PO599]. Journal of the American Society of Nephrology2005;16:465A. ">Aramwit 2010</a>; <a href="./references#CD006881-bbs2-0003" title="GaughanWJ , LissKA , DunnSR , MangoldAM , BuhsmerJP , MichaelB , et al. A 6‐month study of low‐dose recombinant human erythropoietin alone and in combination with androgens for the treatment of anemia in chronic hemodialysis patients. American Journal of Kidney Diseases1997;30(4):495‐500. [MEDLINE: 9328363] LissKA , GaughanWJ , DunnSR , MichaelB , GoldmanJM , ArmentiVT , et al. A six month study of low‐dose recombinant human erythropoietin alone and in combination with androgen for the treatment of anemia in chronic hemodialysis patients [abstract no: A1206]. Journal of the American Society of Nephrology1996;7(9):1490. [CENTRAL: CN‐00626123] ">Gaughan 1997</a>; <a href="./references#CD006881-bbs2-0006" title="NavarroJF , MoraC , MaciaM , ChahinJ , GallegoE , MendezML , et al. Effects of androgen therapy on hematologic and nutritional parameters in elderly peritoneal dialysis patients [abstract]. International Urology &amp; Nephrology2001;33(4):715‐6. [CENTRAL: CN‐00615848] NavarroJF , MoraC , MaciaML , GallegoE , ChahinJ , MendezML , et al. Prospective comparison between rHuEPO and androgens in CAPD patients: impact on hematologic and nutritional parameters [abstract]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):436A. [CENTRAL: CN‐00644231] NavarroJF , MoraF , MaciaM , GarciaJ . Randomized prospective comparison between erythropoietin and androgens in CAPD patients. Kidney International2002;61(4):1537‐44. [MEDLINE: 11918762] ">Navarro 2002</a>; <a href="./references#CD006881-bbs2-0007" title="SheashaaH , Abdel‐RazekW , El‐HusseiniA , SelimA , HassanN , AbbasT , et al. Use of nandrolone decanoate as an adjuvant for erythropoietin dose reduction in treating anemia in patients on hemodialysis. Nephron2005;99(4):c102–6. [MEDLINE: 15703460] ">Sheashaa 2005a</a>) reported serum albumin. <a href="./references#CD006881-bbs2-0001" title="AramwitP , PalapinyoS , WiwatniwongS , SupasyndhO . The efficacy of oxymetholone in combination with erythropoietin on hematologic parameters and muscle mass in CAPD patients. International Journal of Clinical Pharmacology &amp; Therapeutics2010;48(12):803‐13. [MEDLINE: 21084036] SupasyndhO , WiwatniwongS , AramwitP , RuangkanchanasetrP , ChoovichianP . Short course oral androgenic steroid improved lean body mass in continuous ambulatory peritoneal dialysis patients [abstract no: F‐PO580]. Journal of the American Society of Nephrology2005;16:461A. WiwatniwongS , SupasyndhO , AramwitP , RuangkanchanasetrP , LuesuthiviboonL . Oral androgenic steroid therapy for anemia in continuous ambulatory peritoneal dialysis patients [abstract no: F‐PO599]. Journal of the American Society of Nephrology2005;16:465A. ">Aramwit 2010</a> and <a href="./references#CD006881-bbs2-0006" title="NavarroJF , MoraC , MaciaM , ChahinJ , GallegoE , MendezML , et al. Effects of androgen therapy on hematologic and nutritional parameters in elderly peritoneal dialysis patients [abstract]. International Urology &amp; Nephrology2001;33(4):715‐6. [CENTRAL: CN‐00615848] NavarroJF , MoraC , MaciaML , GallegoE , ChahinJ , MendezML , et al. Prospective comparison between rHuEPO and androgens in CAPD patients: impact on hematologic and nutritional parameters [abstract]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):436A. [CENTRAL: CN‐00644231] NavarroJF , MoraF , MaciaM , GarciaJ . Randomized prospective comparison between erythropoietin and androgens in CAPD patients. Kidney International2002;61(4):1537‐44. [MEDLINE: 11918762] ">Navarro 2002</a> reported total protein; and <a href="./references#CD006881-bbs2-0006" title="NavarroJF , MoraC , MaciaM , ChahinJ , GallegoE , MendezML , et al. Effects of androgen therapy on hematologic and nutritional parameters in elderly peritoneal dialysis patients [abstract]. International Urology &amp; Nephrology2001;33(4):715‐6. [CENTRAL: CN‐00615848] NavarroJF , MoraC , MaciaML , GallegoE , ChahinJ , MendezML , et al. Prospective comparison between rHuEPO and androgens in CAPD patients: impact on hematologic and nutritional parameters [abstract]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):436A. [CENTRAL: CN‐00644231] NavarroJF , MoraF , MaciaM , GarciaJ . Randomized prospective comparison between erythropoietin and androgens in CAPD patients. Kidney International2002;61(4):1537‐44. [MEDLINE: 11918762] ">Navarro 2002</a> reported prealbumin and transferrin levels. </p> <p>Four studies reported adverse events, including: gastrointestinal bleeding (<a href="./references#CD006881-bbs2-0001" title="AramwitP , PalapinyoS , WiwatniwongS , SupasyndhO . The efficacy of oxymetholone in combination with erythropoietin on hematologic parameters and muscle mass in CAPD patients. International Journal of Clinical Pharmacology &amp; Therapeutics2010;48(12):803‐13. [MEDLINE: 21084036] SupasyndhO , WiwatniwongS , AramwitP , RuangkanchanasetrP , ChoovichianP . Short course oral androgenic steroid improved lean body mass in continuous ambulatory peritoneal dialysis patients [abstract no: F‐PO580]. Journal of the American Society of Nephrology2005;16:461A. WiwatniwongS , SupasyndhO , AramwitP , RuangkanchanasetrP , LuesuthiviboonL . Oral androgenic steroid therapy for anemia in continuous ambulatory peritoneal dialysis patients [abstract no: F‐PO599]. Journal of the American Society of Nephrology2005;16:465A. ">Aramwit 2010</a>); hydrothorax (<a href="./references#CD006881-bbs2-0006" title="NavarroJF , MoraC , MaciaM , ChahinJ , GallegoE , MendezML , et al. Effects of androgen therapy on hematologic and nutritional parameters in elderly peritoneal dialysis patients [abstract]. International Urology &amp; Nephrology2001;33(4):715‐6. [CENTRAL: CN‐00615848] NavarroJF , MoraC , MaciaML , GallegoE , ChahinJ , MendezML , et al. Prospective comparison between rHuEPO and androgens in CAPD patients: impact on hematologic and nutritional parameters [abstract]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):436A. [CENTRAL: CN‐00644231] NavarroJF , MoraF , MaciaM , GarciaJ . Randomized prospective comparison between erythropoietin and androgens in CAPD patients. Kidney International2002;61(4):1537‐44. [MEDLINE: 11918762] ">Navarro 2002</a>); acne (<a href="./references#CD006881-bbs2-0003" title="GaughanWJ , LissKA , DunnSR , MangoldAM , BuhsmerJP , MichaelB , et al. A 6‐month study of low‐dose recombinant human erythropoietin alone and in combination with androgens for the treatment of anemia in chronic hemodialysis patients. American Journal of Kidney Diseases1997;30(4):495‐500. [MEDLINE: 9328363] LissKA , GaughanWJ , DunnSR , MichaelB , GoldmanJM , ArmentiVT , et al. A six month study of low‐dose recombinant human erythropoietin alone and in combination with androgen for the treatment of anemia in chronic hemodialysis patients [abstract no: A1206]. Journal of the American Society of Nephrology1996;7(9):1490. [CENTRAL: CN‐00626123] ">Gaughan 1997</a>); menstrual disorders and excess body hair (<a href="./references#CD006881-bbs2-0007" title="SheashaaH , Abdel‐RazekW , El‐HusseiniA , SelimA , HassanN , AbbasT , et al. Use of nandrolone decanoate as an adjuvant for erythropoietin dose reduction in treating anemia in patients on hemodialysis. Nephron2005;99(4):c102–6. [MEDLINE: 15703460] ">Sheashaa 2005a</a>). </p> <p>Four studies reported no drop‐outs, withdrawals or losses to follow‐up (<a href="./references#CD006881-bbs2-0004" title="KimHY , EarmJH , SeoJC . Effects of low‐dose nandrolone decanoate on anemia and nutritional parameters in chronic hemodialysis patients with low‐dose subcutaneous erythropoietin [abstract no: A1452]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):287A. ">Kim 1999a</a>; <a href="./references#CD006881-bbs2-0005" title="KoronisC , MakrisF , StavroulakiE , LambropoulouA , OrthopoulosV . Combination of low‐dose recombinant human erythropoietin with androgens for the treatment of anaemia in hemodialysis patients [abstract]. 37th Congress European Renal Association. European Dialysis and Transplantation Association; 2000 Sept 17‐20; Nice, France. 2000:235. [CENTRAL: CN‐00461096] ">Koronis 2000</a>; <a href="./references#CD006881-bbs2-0007" title="SheashaaH , Abdel‐RazekW , El‐HusseiniA , SelimA , HassanN , AbbasT , et al. Use of nandrolone decanoate as an adjuvant for erythropoietin dose reduction in treating anemia in patients on hemodialysis. Nephron2005;99(4):c102–6. [MEDLINE: 15703460] ">Sheashaa 2005a</a>; <a href="./references#CD006881-bbs2-0008" title="HendlerED , SolomonLR . Prospective controlled study of androgen effects on red cell oxygen transport and work capacity in chronic hemodialysis patients. Acta Haematologica1990;83(1):1‐8. [MEDLINE: 2105563] SolomonLR , HendlerED . Prospective controlled study of androgen therapy in the anemia of chronic renal disease: effects on iron kinetics. Acta Haematologica1988;79(1):12‐9. [MEDLINE: 3124456] ">Solomon 1988b</a>). <a href="./references#CD006881-bbs2-0003" title="GaughanWJ , LissKA , DunnSR , MangoldAM , BuhsmerJP , MichaelB , et al. A 6‐month study of low‐dose recombinant human erythropoietin alone and in combination with androgens for the treatment of anemia in chronic hemodialysis patients. American Journal of Kidney Diseases1997;30(4):495‐500. [MEDLINE: 9328363] LissKA , GaughanWJ , DunnSR , MichaelB , GoldmanJM , ArmentiVT , et al. A six month study of low‐dose recombinant human erythropoietin alone and in combination with androgen for the treatment of anemia in chronic hemodialysis patients [abstract no: A1206]. Journal of the American Society of Nephrology1996;7(9):1490. [CENTRAL: CN‐00626123] ">Gaughan 1997</a> reported that one participant withdrew after developing an active mycobacterium tuberculosis infection; <a href="./references#CD006881-bbs2-0001" title="AramwitP , PalapinyoS , WiwatniwongS , SupasyndhO . The efficacy of oxymetholone in combination with erythropoietin on hematologic parameters and muscle mass in CAPD patients. International Journal of Clinical Pharmacology &amp; Therapeutics2010;48(12):803‐13. [MEDLINE: 21084036] SupasyndhO , WiwatniwongS , AramwitP , RuangkanchanasetrP , ChoovichianP . Short course oral androgenic steroid improved lean body mass in continuous ambulatory peritoneal dialysis patients [abstract no: F‐PO580]. Journal of the American Society of Nephrology2005;16:461A. WiwatniwongS , SupasyndhO , AramwitP , RuangkanchanasetrP , LuesuthiviboonL . Oral androgenic steroid therapy for anemia in continuous ambulatory peritoneal dialysis patients [abstract no: F‐PO599]. Journal of the American Society of Nephrology2005;16:465A. ">Aramwit 2010</a> and <a href="./references#CD006881-bbs2-0006" title="NavarroJF , MoraC , MaciaM , ChahinJ , GallegoE , MendezML , et al. Effects of androgen therapy on hematologic and nutritional parameters in elderly peritoneal dialysis patients [abstract]. International Urology &amp; Nephrology2001;33(4):715‐6. [CENTRAL: CN‐00615848] NavarroJF , MoraC , MaciaML , GallegoE , ChahinJ , MendezML , et al. Prospective comparison between rHuEPO and androgens in CAPD patients: impact on hematologic and nutritional parameters [abstract]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):436A. [CENTRAL: CN‐00644231] NavarroJF , MoraF , MaciaM , GarciaJ . Randomized prospective comparison between erythropoietin and androgens in CAPD patients. Kidney International2002;61(4):1537‐44. [MEDLINE: 11918762] ">Navarro 2002</a> both reported two participants discontinued treatment. <a href="./references#CD006881-bbs2-0002" title="CattranDC , FentonSS , WilsonDR , OreopoulosD , ShimizuA , RichardsonRM . A controlled trial of nandrolone decanoate in the treatment of uremic anemia. Kidney International1977;12(6):430‐7. [MEDLINE: 609193] ">Cattran 1977</a> reported that eight participants did not complete the study (21.6%). </p> </section> <section id="CD006881-sec-0057"> <h4 class="title">Excluded studies</h4> <p>We excluded 20 studies; of these eight were not RCTs (<a href="./references#CD006881-bbs2-0014" title="BuchwaldD , ArgyresS , EasterlingRE , OelshlegelFJ , BrewerGJ , SchoomakerEB , et al. Effect of nandrolone decanoate on the anemia of chronic hemodialysis patients. Nephron1977;18(4):232‐8. [MEDLINE: 323739] ">Buchwald 1977</a>; <a href="./references#CD006881-bbs2-0015" title="DiezJJ , IglesiasP , BajoMA , deAlvaroFD , SelgasR . Effects of erythropoietin on gonadotropin responses to gonadotropin‐releasing hormone in uremic patients. Nephron1997;77(2):169‐75. [MEDLINE: 9346383] ">Diez 1997</a>; <a href="./references#CD006881-bbs2-0017" title="GasconA , BelvisJJ , BerisaF , IglesiasE , EstopinanV , TeruelJL . Nandrolone decanoate is a good alternative for the treatment of anemia in elderly male patients on hemodialysis. Geriatric Nephrology &amp; Urology1999;9(2):67‐72. [MEDLINE: 10518249] ">Gascon 1999</a>; <a href="./references#CD006881-bbs2-0019" title="LeeMS , AhnSH , SongJH . Effects of adjuvant androgen on anemia and nutritional parameters in chronic hemodialysis patients using low‐dose recombinant human erythropoietin. Korean Journal of Internal Medicine2002;17(3):167‐73. [MEDLINE: 12298427] ">Lee 2002</a>; <a href="./references#CD006881-bbs2-0020" title="LoganJL , LienYH , SilvaS , DeLongM , YongK . Six months of testosterone replacement improves musculoskeletal health but not mental health or anemia management in men on hemodialysis [abstract no: F‐PO690]. Journal of the American Society of Nephrology2005;16:485A. ">Logan 2005</a>; <a href="./references#CD006881-bbs2-0022" title="MoraC , MacíaML , GarcíaJ , NavarroJF . Effect of nandrolone decanoate on the lipid profile of male peritoneal dialysis patients. Peritoneal Dialysis International2001;21(6):611‐14. [MEDLINE: 11783772] ">Mora 2001</a>; <a href="./references#CD006881-bbs2-0026" title="SolomonLR , HendlerED . Androgen therapy in haemodialysis patients. II. Effects on red cell metabolism. British Journal of Haematology1987;65(2):223‐30. [MEDLINE: 3828230] SolomonLR , HendlerED . Androgen therapy in haemodialysis patients: further observations on erythropoiesis and ferrokinetics. British Journal of Haematology1988;69(3):426‐7. [MEDLINE: 3408679] SolomonLR , HendlerED . Androgen therapy in hemodialysis patients: effects on red cell metabolism and exercise tolerance [abstract: 10]. Blood1986;68(5 Suppl 1):58a. [CENTRAL: CN‐00485953] ">Solomon 1987</a>; <a href="./references#CD006881-bbs2-0027" title="vonHartitzschB , KerrDN . Response to parenteral iron with and without androgen therapy in patients undergoing regular haemodialysis. Nephron1976;17(6):430‐8. [MEDLINE: 796740] ">von Hartitzsch 1976</a>); nine were fewer than six months duration (<a href="./references#CD006881-bbs2-0009" title="AggarwalHK , SehgalR , SinghS , NandN , BhartiK , ChakrabartiD . Evaluation of efficacy of low dose recombinant human erythropoietin in combination with androgen therapy in anaemia of chronic renal failure. Journal, Indian Academy of Clinical Medicine2005;6(3):208‐15. [EMBASE: 2005526349] ">Aggarwal 2005</a>; <a href="./references#CD006881-bbs2-0010" title="AslanhanI , ErsoyA , SarandolE , DemirayM , UstaM , DalkilicE , et al. The comparison of the effects of rHuEPO and testosterone ester compounds on lipid peroxidation in male hemodialysis patients [abstract]. 38th Congress. European Renal Association. European Dialysis and Transplantation Association; 2001 Jun 24‐27; Vienna, Austria. 2001:212. [CENTRAL: CN‐00636137] AslanhanI , ErsoyA , UstaM , ErsoyC , YavuzM , GulluluM , et al. The comparison of the effects of erythropoietin and testosterone ester compounds on lipid and lipoprotein profile in the male hemodialysis patients [abstract]. Nephrology Dialysis Transplantation2001;16(6):A138. [CENTRAL: CN‐00444248] ">Aslanhan 2001</a>; <a href="./references#CD006881-bbs2-0011" title="BallalSH , DomotoDT , PolackDC , MarciulonisP , MartinKJ . Androgens potentiate the effects of erythropoietin in the treatment of anemia of end‐stage renal disease. American Journal of Kidney Diseases1991;17(1):29‐33. [MEDLINE: 1986567] ">Ballal 1991</a>; <a href="./references#CD006881-bbs2-0012" title="BernsJS , RudnickMR , CohenRM . A controlled trial of recombinant human erythropoietin and nandrolone decanoate in the treatment of anemia in patients on chronic hemodialysis. Clinical Nephrology1992;37(5):264‐7. [MEDLINE: 1606777] ">Berns 1992</a>; <a href="./references#CD006881-bbs2-0016" title="Eiam‐OngS , BuranaosotS , Eiam‐OngS , WathanavahaA , PansinP . Nutritional effect of nandrolone decanoate in predialysis patients with chronic kidney disease. Journal of Renal Nutrition2007;17(3):173‐8. [MEDLINE: 17462549] ">Eiam‐Ong 2007</a>; <a href="./references#CD006881-bbs2-0018" title="HendlerED , GoffinetJA , RossS , LongneckerRE , BakovicV . Controlled study of androgen therapy in anemia of patients on maintenance hemodialysis. New England Journal of Medicine1974;291(20):1046‐51. [MEDLINE: 4606387] ">Hendler 1974</a>; <a href="./references#CD006881-bbs2-0021" title="MirahmadiMK , VaziriND , GormanJT . Controlled evaluation of hemodialysis patients on nandrolone decanoate (ND) vs testosterone enanthate (TE) (Androgens and dialysis patient). Transactions ‐ American Society for Artificial Internal Organs1979;25:449‐54. [MEDLINE: 524621] ">Mirahmadi 1979</a>; <a href="./references#CD006881-bbs2-0025" title="SaxenaS , DashSC , TiwariSC , AgarwalSK , JainPK , AslamJ . Effect of nandrolone decanoate on response to low dose erythropoietin (EPO) in anemia of end stage renal disease (ESRD) patients on maintenance hemodialysis (MHD) [abstract]. Nephrology1997;3(Suppl 1):S310. [CENTRAL: CN‐00461666] ">Saxena 1997</a>; <a href="./references#CD006881-bbs2-0028" title="WilliamsJS , SteinJH , FerrisTF . Nandrolone decanoate therapy for patients receiving hemodialysis. A controlled study. Archives of Internal Medicine1974;134(2):289‐92. [MEDLINE: 4602048] ">Williams 1974</a>); treatment and control group data were indistinct in <a href="./references#CD006881-bbs2-0023" title="NaikRB , GibbonsAR , GydeOH , HarrisBR , RobinsonBH . Androgen trial in renal anaemia. Proceedings of the European Dialysis &amp; Transplant Association1978;15:136‐43. [MEDLINE: 368770] ">Naik 1978</a>; it was unclear if androgen therapy had been administered to participants during the six months preceding the study (<a href="./references#CD006881-bbs2-0024" title="NeffMS , GoldbergJ , SlifkinRF , EiserAR , CalamiaV , KaplanM , et al. A comparison of androgens for anemia in patients on hemodialysis. New England Journal of Medicine1981;304(15):871‐5. [MEDLINE: 7010161] ">Neff 1981</a>); reported withdrawals/losses were internally inconsistent in <a href="./references#CD006881-bbs2-0013" title="BrockenbroughAT , DittrichMO , PageST , SmithT , StivelmanJC , BremnerWJ . Transdermal androgen therapy to augment EPO in the treatment of anemia of chronic renal disease. American Journal of Kidney Diseases2006;47(2):251‐62. [MEDLINE: 16431254] ">Brockenbrough 2006</a>; and <a href="./references#CD006881-bbs2-0008" title="HendlerED , SolomonLR . Prospective controlled study of androgen effects on red cell oxygen transport and work capacity in chronic hemodialysis patients. Acta Haematologica1990;83(1):1‐8. [MEDLINE: 2105563] SolomonLR , HendlerED . Prospective controlled study of androgen therapy in the anemia of chronic renal disease: effects on iron kinetics. Acta Haematologica1988;79(1):12‐9. [MEDLINE: 3124456] ">Solomon 1988b</a> investigated an intervention outside the scope of this review. See <a href="./references#CD006881-sec-0104" title="">Characteristics of excluded studies</a>. </p> </section> </section> <section id="CD006881-sec-0058"> <h3 class="title">Risk of bias in included studies</h3> <p><a href="./references#CD006881-bbs2-0001" title="AramwitP , PalapinyoS , WiwatniwongS , SupasyndhO . The efficacy of oxymetholone in combination with erythropoietin on hematologic parameters and muscle mass in CAPD patients. International Journal of Clinical Pharmacology &amp; Therapeutics2010;48(12):803‐13. [MEDLINE: 21084036] SupasyndhO , WiwatniwongS , AramwitP , RuangkanchanasetrP , ChoovichianP . Short course oral androgenic steroid improved lean body mass in continuous ambulatory peritoneal dialysis patients [abstract no: F‐PO580]. Journal of the American Society of Nephrology2005;16:461A. WiwatniwongS , SupasyndhO , AramwitP , RuangkanchanasetrP , LuesuthiviboonL . Oral androgenic steroid therapy for anemia in continuous ambulatory peritoneal dialysis patients [abstract no: F‐PO599]. Journal of the American Society of Nephrology2005;16:465A. ">Aramwit 2010</a> was assessed as a high quality study; six were judged to be of moderate quality (<a href="./references#CD006881-bbs2-0003" title="GaughanWJ , LissKA , DunnSR , MangoldAM , BuhsmerJP , MichaelB , et al. A 6‐month study of low‐dose recombinant human erythropoietin alone and in combination with androgens for the treatment of anemia in chronic hemodialysis patients. American Journal of Kidney Diseases1997;30(4):495‐500. [MEDLINE: 9328363] LissKA , GaughanWJ , DunnSR , MichaelB , GoldmanJM , ArmentiVT , et al. A six month study of low‐dose recombinant human erythropoietin alone and in combination with androgen for the treatment of anemia in chronic hemodialysis patients [abstract no: A1206]. Journal of the American Society of Nephrology1996;7(9):1490. [CENTRAL: CN‐00626123] ">Gaughan 1997</a>; <a href="./references#CD006881-bbs2-0004" title="KimHY , EarmJH , SeoJC . Effects of low‐dose nandrolone decanoate on anemia and nutritional parameters in chronic hemodialysis patients with low‐dose subcutaneous erythropoietin [abstract no: A1452]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):287A. ">Kim 1999a</a>; <a href="./references#CD006881-bbs2-0005" title="KoronisC , MakrisF , StavroulakiE , LambropoulouA , OrthopoulosV . Combination of low‐dose recombinant human erythropoietin with androgens for the treatment of anaemia in hemodialysis patients [abstract]. 37th Congress European Renal Association. European Dialysis and Transplantation Association; 2000 Sept 17‐20; Nice, France. 2000:235. [CENTRAL: CN‐00461096] ">Koronis 2000</a>; <a href="./references#CD006881-bbs2-0006" title="NavarroJF , MoraC , MaciaM , ChahinJ , GallegoE , MendezML , et al. Effects of androgen therapy on hematologic and nutritional parameters in elderly peritoneal dialysis patients [abstract]. International Urology &amp; Nephrology2001;33(4):715‐6. [CENTRAL: CN‐00615848] NavarroJF , MoraC , MaciaML , GallegoE , ChahinJ , MendezML , et al. Prospective comparison between rHuEPO and androgens in CAPD patients: impact on hematologic and nutritional parameters [abstract]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):436A. [CENTRAL: CN‐00644231] NavarroJF , MoraF , MaciaM , GarciaJ . Randomized prospective comparison between erythropoietin and androgens in CAPD patients. Kidney International2002;61(4):1537‐44. [MEDLINE: 11918762] ">Navarro 2002</a>; <a href="./references#CD006881-bbs2-0007" title="SheashaaH , Abdel‐RazekW , El‐HusseiniA , SelimA , HassanN , AbbasT , et al. Use of nandrolone decanoate as an adjuvant for erythropoietin dose reduction in treating anemia in patients on hemodialysis. Nephron2005;99(4):c102–6. [MEDLINE: 15703460] ">Sheashaa 2005a</a>; <a href="./references#CD006881-bbs2-0008" title="HendlerED , SolomonLR . Prospective controlled study of androgen effects on red cell oxygen transport and work capacity in chronic hemodialysis patients. Acta Haematologica1990;83(1):1‐8. [MEDLINE: 2105563] SolomonLR , HendlerED . Prospective controlled study of androgen therapy in the anemia of chronic renal disease: effects on iron kinetics. Acta Haematologica1988;79(1):12‐9. [MEDLINE: 3124456] ">Solomon 1988b</a>); and <a href="./references#CD006881-bbs2-0002" title="CattranDC , FentonSS , WilsonDR , OreopoulosD , ShimizuA , RichardsonRM . A controlled trial of nandrolone decanoate in the treatment of uremic anemia. Kidney International1977;12(6):430‐7. [MEDLINE: 609193] ">Cattran 1977</a> was low quality. Summaries of quality assessments are presented in <a href="#CD006881-fig-0002">Figure 2</a> and <a href="#CD006881-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD006881-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies" data-id="CD006881-fig-0002" src="/cdsr/doi/10.1002/14651858.CD006881.pub2/media/CDSR/CD006881/image_n/nCD006881-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies </p> </div> </div> </div> <div class="figure" id="CD006881-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study" data-id="CD006881-fig-0003" src="/cdsr/doi/10.1002/14651858.CD006881.pub2/media/CDSR/CD006881/image_n/nCD006881-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study </p> </div> </div> </div> <section id="CD006881-sec-0059"> <h4 class="title">Allocation</h4> <p>Although all studies reported that participants were randomised, six did not provide sequencing details (<a href="./references#CD006881-bbs2-0002" title="CattranDC , FentonSS , WilsonDR , OreopoulosD , ShimizuA , RichardsonRM . A controlled trial of nandrolone decanoate in the treatment of uremic anemia. Kidney International1977;12(6):430‐7. [MEDLINE: 609193] ">Cattran 1977</a>; <a href="./references#CD006881-bbs2-0003" title="GaughanWJ , LissKA , DunnSR , MangoldAM , BuhsmerJP , MichaelB , et al. A 6‐month study of low‐dose recombinant human erythropoietin alone and in combination with androgens for the treatment of anemia in chronic hemodialysis patients. American Journal of Kidney Diseases1997;30(4):495‐500. [MEDLINE: 9328363] LissKA , GaughanWJ , DunnSR , MichaelB , GoldmanJM , ArmentiVT , et al. A six month study of low‐dose recombinant human erythropoietin alone and in combination with androgen for the treatment of anemia in chronic hemodialysis patients [abstract no: A1206]. Journal of the American Society of Nephrology1996;7(9):1490. [CENTRAL: CN‐00626123] ">Gaughan 1997</a>; <a href="./references#CD006881-bbs2-0004" title="KimHY , EarmJH , SeoJC . Effects of low‐dose nandrolone decanoate on anemia and nutritional parameters in chronic hemodialysis patients with low‐dose subcutaneous erythropoietin [abstract no: A1452]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):287A. ">Kim 1999a</a>; <a href="./references#CD006881-bbs2-0005" title="KoronisC , MakrisF , StavroulakiE , LambropoulouA , OrthopoulosV . Combination of low‐dose recombinant human erythropoietin with androgens for the treatment of anaemia in hemodialysis patients [abstract]. 37th Congress European Renal Association. European Dialysis and Transplantation Association; 2000 Sept 17‐20; Nice, France. 2000:235. [CENTRAL: CN‐00461096] ">Koronis 2000</a>; <a href="./references#CD006881-bbs2-0007" title="SheashaaH , Abdel‐RazekW , El‐HusseiniA , SelimA , HassanN , AbbasT , et al. Use of nandrolone decanoate as an adjuvant for erythropoietin dose reduction in treating anemia in patients on hemodialysis. Nephron2005;99(4):c102–6. [MEDLINE: 15703460] ">Sheashaa 2005a</a>; <a href="./references#CD006881-bbs2-0008" title="HendlerED , SolomonLR . Prospective controlled study of androgen effects on red cell oxygen transport and work capacity in chronic hemodialysis patients. Acta Haematologica1990;83(1):1‐8. [MEDLINE: 2105563] SolomonLR , HendlerED . Prospective controlled study of androgen therapy in the anemia of chronic renal disease: effects on iron kinetics. Acta Haematologica1988;79(1):12‐9. [MEDLINE: 3124456] ">Solomon 1988b</a>). <a href="./references#CD006881-bbs2-0001" title="AramwitP , PalapinyoS , WiwatniwongS , SupasyndhO . The efficacy of oxymetholone in combination with erythropoietin on hematologic parameters and muscle mass in CAPD patients. International Journal of Clinical Pharmacology &amp; Therapeutics2010;48(12):803‐13. [MEDLINE: 21084036] SupasyndhO , WiwatniwongS , AramwitP , RuangkanchanasetrP , ChoovichianP . Short course oral androgenic steroid improved lean body mass in continuous ambulatory peritoneal dialysis patients [abstract no: F‐PO580]. Journal of the American Society of Nephrology2005;16:461A. WiwatniwongS , SupasyndhO , AramwitP , RuangkanchanasetrP , LuesuthiviboonL . Oral androgenic steroid therapy for anemia in continuous ambulatory peritoneal dialysis patients [abstract no: F‐PO599]. Journal of the American Society of Nephrology2005;16:465A. ">Aramwit 2010</a> and <a href="./references#CD006881-bbs2-0006" title="NavarroJF , MoraC , MaciaM , ChahinJ , GallegoE , MendezML , et al. Effects of androgen therapy on hematologic and nutritional parameters in elderly peritoneal dialysis patients [abstract]. International Urology &amp; Nephrology2001;33(4):715‐6. [CENTRAL: CN‐00615848] NavarroJF , MoraC , MaciaML , GallegoE , ChahinJ , MendezML , et al. Prospective comparison between rHuEPO and androgens in CAPD patients: impact on hematologic and nutritional parameters [abstract]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):436A. [CENTRAL: CN‐00644231] NavarroJF , MoraF , MaciaM , GarciaJ . Randomized prospective comparison between erythropoietin and androgens in CAPD patients. Kidney International2002;61(4):1537‐44. [MEDLINE: 11918762] ">Navarro 2002</a> used computer‐generated random number tables, and although <a href="./references#CD006881-bbs2-0001" title="AramwitP , PalapinyoS , WiwatniwongS , SupasyndhO . The efficacy of oxymetholone in combination with erythropoietin on hematologic parameters and muscle mass in CAPD patients. International Journal of Clinical Pharmacology &amp; Therapeutics2010;48(12):803‐13. [MEDLINE: 21084036] SupasyndhO , WiwatniwongS , AramwitP , RuangkanchanasetrP , ChoovichianP . Short course oral androgenic steroid improved lean body mass in continuous ambulatory peritoneal dialysis patients [abstract no: F‐PO580]. Journal of the American Society of Nephrology2005;16:461A. WiwatniwongS , SupasyndhO , AramwitP , RuangkanchanasetrP , LuesuthiviboonL . Oral androgenic steroid therapy for anemia in continuous ambulatory peritoneal dialysis patients [abstract no: F‐PO599]. Journal of the American Society of Nephrology2005;16:465A. ">Aramwit 2010</a> did not report allocation concealment methods, it was likely that concealment was adequate; investigators were not actively involved in treatment, and physicians involved in participants' care were unaware of study outcome parameters. Allocation concealment was not adequately reported by the remaining seven studies (<a href="./references#CD006881-bbs2-0002" title="CattranDC , FentonSS , WilsonDR , OreopoulosD , ShimizuA , RichardsonRM . A controlled trial of nandrolone decanoate in the treatment of uremic anemia. Kidney International1977;12(6):430‐7. [MEDLINE: 609193] ">Cattran 1977</a>; <a href="./references#CD006881-bbs2-0003" title="GaughanWJ , LissKA , DunnSR , MangoldAM , BuhsmerJP , MichaelB , et al. A 6‐month study of low‐dose recombinant human erythropoietin alone and in combination with androgens for the treatment of anemia in chronic hemodialysis patients. American Journal of Kidney Diseases1997;30(4):495‐500. [MEDLINE: 9328363] LissKA , GaughanWJ , DunnSR , MichaelB , GoldmanJM , ArmentiVT , et al. A six month study of low‐dose recombinant human erythropoietin alone and in combination with androgen for the treatment of anemia in chronic hemodialysis patients [abstract no: A1206]. Journal of the American Society of Nephrology1996;7(9):1490. [CENTRAL: CN‐00626123] ">Gaughan 1997</a>; <a href="./references#CD006881-bbs2-0004" title="KimHY , EarmJH , SeoJC . Effects of low‐dose nandrolone decanoate on anemia and nutritional parameters in chronic hemodialysis patients with low‐dose subcutaneous erythropoietin [abstract no: A1452]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):287A. ">Kim 1999a</a>; <a href="./references#CD006881-bbs2-0005" title="KoronisC , MakrisF , StavroulakiE , LambropoulouA , OrthopoulosV . Combination of low‐dose recombinant human erythropoietin with androgens for the treatment of anaemia in hemodialysis patients [abstract]. 37th Congress European Renal Association. European Dialysis and Transplantation Association; 2000 Sept 17‐20; Nice, France. 2000:235. [CENTRAL: CN‐00461096] ">Koronis 2000</a>; <a href="./references#CD006881-bbs2-0006" title="NavarroJF , MoraC , MaciaM , ChahinJ , GallegoE , MendezML , et al. Effects of androgen therapy on hematologic and nutritional parameters in elderly peritoneal dialysis patients [abstract]. International Urology &amp; Nephrology2001;33(4):715‐6. [CENTRAL: CN‐00615848] NavarroJF , MoraC , MaciaML , GallegoE , ChahinJ , MendezML , et al. Prospective comparison between rHuEPO and androgens in CAPD patients: impact on hematologic and nutritional parameters [abstract]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):436A. [CENTRAL: CN‐00644231] NavarroJF , MoraF , MaciaM , GarciaJ . Randomized prospective comparison between erythropoietin and androgens in CAPD patients. Kidney International2002;61(4):1537‐44. [MEDLINE: 11918762] ">Navarro 2002</a>; <a href="./references#CD006881-bbs2-0007" title="SheashaaH , Abdel‐RazekW , El‐HusseiniA , SelimA , HassanN , AbbasT , et al. Use of nandrolone decanoate as an adjuvant for erythropoietin dose reduction in treating anemia in patients on hemodialysis. Nephron2005;99(4):c102–6. [MEDLINE: 15703460] ">Sheashaa 2005a</a><a href="./references#CD006881-bbs2-0008" title="HendlerED , SolomonLR . Prospective controlled study of androgen effects on red cell oxygen transport and work capacity in chronic hemodialysis patients. Acta Haematologica1990;83(1):1‐8. [MEDLINE: 2105563] SolomonLR , HendlerED . Prospective controlled study of androgen therapy in the anemia of chronic renal disease: effects on iron kinetics. Acta Haematologica1988;79(1):12‐9. [MEDLINE: 3124456] ">Solomon 1988b</a>). </p> </section> <section id="CD006881-sec-0060"> <h4 class="title">Blinding</h4> <p><a href="./references#CD006881-bbs2-0001" title="AramwitP , PalapinyoS , WiwatniwongS , SupasyndhO . The efficacy of oxymetholone in combination with erythropoietin on hematologic parameters and muscle mass in CAPD patients. International Journal of Clinical Pharmacology &amp; Therapeutics2010;48(12):803‐13. [MEDLINE: 21084036] SupasyndhO , WiwatniwongS , AramwitP , RuangkanchanasetrP , ChoovichianP . Short course oral androgenic steroid improved lean body mass in continuous ambulatory peritoneal dialysis patients [abstract no: F‐PO580]. Journal of the American Society of Nephrology2005;16:461A. WiwatniwongS , SupasyndhO , AramwitP , RuangkanchanasetrP , LuesuthiviboonL . Oral androgenic steroid therapy for anemia in continuous ambulatory peritoneal dialysis patients [abstract no: F‐PO599]. Journal of the American Society of Nephrology2005;16:465A. ">Aramwit 2010</a> and <a href="./references#CD006881-bbs2-0002" title="CattranDC , FentonSS , WilsonDR , OreopoulosD , ShimizuA , RichardsonRM . A controlled trial of nandrolone decanoate in the treatment of uremic anemia. Kidney International1977;12(6):430‐7. [MEDLINE: 609193] ">Cattran 1977</a> were double‐blinded, placebo‐controlled studies; <a href="./references#CD006881-bbs2-0003" title="GaughanWJ , LissKA , DunnSR , MangoldAM , BuhsmerJP , MichaelB , et al. A 6‐month study of low‐dose recombinant human erythropoietin alone and in combination with androgens for the treatment of anemia in chronic hemodialysis patients. American Journal of Kidney Diseases1997;30(4):495‐500. [MEDLINE: 9328363] LissKA , GaughanWJ , DunnSR , MichaelB , GoldmanJM , ArmentiVT , et al. A six month study of low‐dose recombinant human erythropoietin alone and in combination with androgen for the treatment of anemia in chronic hemodialysis patients [abstract no: A1206]. Journal of the American Society of Nephrology1996;7(9):1490. [CENTRAL: CN‐00626123] ">Gaughan 1997</a> was an open‐label study. Blinding was not reported in the remaining five studies (<a href="./references#CD006881-bbs2-0004" title="KimHY , EarmJH , SeoJC . Effects of low‐dose nandrolone decanoate on anemia and nutritional parameters in chronic hemodialysis patients with low‐dose subcutaneous erythropoietin [abstract no: A1452]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):287A. ">Kim 1999a</a>; <a href="./references#CD006881-bbs2-0005" title="KoronisC , MakrisF , StavroulakiE , LambropoulouA , OrthopoulosV . Combination of low‐dose recombinant human erythropoietin with androgens for the treatment of anaemia in hemodialysis patients [abstract]. 37th Congress European Renal Association. European Dialysis and Transplantation Association; 2000 Sept 17‐20; Nice, France. 2000:235. [CENTRAL: CN‐00461096] ">Koronis 2000</a>; <a href="./references#CD006881-bbs2-0006" title="NavarroJF , MoraC , MaciaM , ChahinJ , GallegoE , MendezML , et al. Effects of androgen therapy on hematologic and nutritional parameters in elderly peritoneal dialysis patients [abstract]. International Urology &amp; Nephrology2001;33(4):715‐6. [CENTRAL: CN‐00615848] NavarroJF , MoraC , MaciaML , GallegoE , ChahinJ , MendezML , et al. Prospective comparison between rHuEPO and androgens in CAPD patients: impact on hematologic and nutritional parameters [abstract]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):436A. [CENTRAL: CN‐00644231] NavarroJF , MoraF , MaciaM , GarciaJ . Randomized prospective comparison between erythropoietin and androgens in CAPD patients. Kidney International2002;61(4):1537‐44. [MEDLINE: 11918762] ">Navarro 2002</a>; <a href="./references#CD006881-bbs2-0007" title="SheashaaH , Abdel‐RazekW , El‐HusseiniA , SelimA , HassanN , AbbasT , et al. Use of nandrolone decanoate as an adjuvant for erythropoietin dose reduction in treating anemia in patients on hemodialysis. Nephron2005;99(4):c102–6. [MEDLINE: 15703460] ">Sheashaa 2005a</a>; <a href="./references#CD006881-bbs2-0008" title="HendlerED , SolomonLR . Prospective controlled study of androgen effects on red cell oxygen transport and work capacity in chronic hemodialysis patients. Acta Haematologica1990;83(1):1‐8. [MEDLINE: 2105563] SolomonLR , HendlerED . Prospective controlled study of androgen therapy in the anemia of chronic renal disease: effects on iron kinetics. Acta Haematologica1988;79(1):12‐9. [MEDLINE: 3124456] ">Solomon 1988b</a>). </p> </section> <section id="CD006881-sec-0061"> <h4 class="title">Incomplete outcome data</h4> <p>Outcome data were reported clearly in seven studies (<a href="./references#CD006881-bbs2-0001" title="AramwitP , PalapinyoS , WiwatniwongS , SupasyndhO . The efficacy of oxymetholone in combination with erythropoietin on hematologic parameters and muscle mass in CAPD patients. International Journal of Clinical Pharmacology &amp; Therapeutics2010;48(12):803‐13. [MEDLINE: 21084036] SupasyndhO , WiwatniwongS , AramwitP , RuangkanchanasetrP , ChoovichianP . Short course oral androgenic steroid improved lean body mass in continuous ambulatory peritoneal dialysis patients [abstract no: F‐PO580]. Journal of the American Society of Nephrology2005;16:461A. WiwatniwongS , SupasyndhO , AramwitP , RuangkanchanasetrP , LuesuthiviboonL . Oral androgenic steroid therapy for anemia in continuous ambulatory peritoneal dialysis patients [abstract no: F‐PO599]. Journal of the American Society of Nephrology2005;16:465A. ">Aramwit 2010</a>; <a href="./references#CD006881-bbs2-0003" title="GaughanWJ , LissKA , DunnSR , MangoldAM , BuhsmerJP , MichaelB , et al. A 6‐month study of low‐dose recombinant human erythropoietin alone and in combination with androgens for the treatment of anemia in chronic hemodialysis patients. American Journal of Kidney Diseases1997;30(4):495‐500. [MEDLINE: 9328363] LissKA , GaughanWJ , DunnSR , MichaelB , GoldmanJM , ArmentiVT , et al. A six month study of low‐dose recombinant human erythropoietin alone and in combination with androgen for the treatment of anemia in chronic hemodialysis patients [abstract no: A1206]. Journal of the American Society of Nephrology1996;7(9):1490. [CENTRAL: CN‐00626123] ">Gaughan 1997</a>; <a href="./references#CD006881-bbs2-0004" title="KimHY , EarmJH , SeoJC . Effects of low‐dose nandrolone decanoate on anemia and nutritional parameters in chronic hemodialysis patients with low‐dose subcutaneous erythropoietin [abstract no: A1452]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):287A. ">Kim 1999a</a>; <a href="./references#CD006881-bbs2-0005" title="KoronisC , MakrisF , StavroulakiE , LambropoulouA , OrthopoulosV . Combination of low‐dose recombinant human erythropoietin with androgens for the treatment of anaemia in hemodialysis patients [abstract]. 37th Congress European Renal Association. European Dialysis and Transplantation Association; 2000 Sept 17‐20; Nice, France. 2000:235. [CENTRAL: CN‐00461096] ">Koronis 2000</a>; <a href="./references#CD006881-bbs2-0006" title="NavarroJF , MoraC , MaciaM , ChahinJ , GallegoE , MendezML , et al. Effects of androgen therapy on hematologic and nutritional parameters in elderly peritoneal dialysis patients [abstract]. International Urology &amp; Nephrology2001;33(4):715‐6. [CENTRAL: CN‐00615848] NavarroJF , MoraC , MaciaML , GallegoE , ChahinJ , MendezML , et al. Prospective comparison between rHuEPO and androgens in CAPD patients: impact on hematologic and nutritional parameters [abstract]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):436A. [CENTRAL: CN‐00644231] NavarroJF , MoraF , MaciaM , GarciaJ . Randomized prospective comparison between erythropoietin and androgens in CAPD patients. Kidney International2002;61(4):1537‐44. [MEDLINE: 11918762] ">Navarro 2002</a>; <a href="./references#CD006881-bbs2-0008" title="HendlerED , SolomonLR . Prospective controlled study of androgen effects on red cell oxygen transport and work capacity in chronic hemodialysis patients. Acta Haematologica1990;83(1):1‐8. [MEDLINE: 2105563] SolomonLR , HendlerED . Prospective controlled study of androgen therapy in the anemia of chronic renal disease: effects on iron kinetics. Acta Haematologica1988;79(1):12‐9. [MEDLINE: 3124456] ">Solomon 1988b</a>; <a href="./references#CD006881-bbs2-0007" title="SheashaaH , Abdel‐RazekW , El‐HusseiniA , SelimA , HassanN , AbbasT , et al. Use of nandrolone decanoate as an adjuvant for erythropoietin dose reduction in treating anemia in patients on hemodialysis. Nephron2005;99(4):c102–6. [MEDLINE: 15703460] ">Sheashaa 2005a</a>), among which drop‐out rates and losses to follow‐up were lower than 10%; and hence, risk of attrition bias was assessed as low. <a href="./references#CD006881-bbs2-0002" title="CattranDC , FentonSS , WilsonDR , OreopoulosD , ShimizuA , RichardsonRM . A controlled trial of nandrolone decanoate in the treatment of uremic anemia. Kidney International1977;12(6):430‐7. [MEDLINE: 609193] ">Cattran 1977</a> reported a drop‐out and loss to follow‐up rate of 21.6% (8/37 participants), and was assessed at high risk of attrition bias. </p> </section> <section id="CD006881-sec-0062"> <h4 class="title">Selective reporting</h4> <p>Investigators involved in two studies were contacted to obtain study protocols (<a href="./references#CD006881-bbs2-0001" title="AramwitP , PalapinyoS , WiwatniwongS , SupasyndhO . The efficacy of oxymetholone in combination with erythropoietin on hematologic parameters and muscle mass in CAPD patients. International Journal of Clinical Pharmacology &amp; Therapeutics2010;48(12):803‐13. [MEDLINE: 21084036] SupasyndhO , WiwatniwongS , AramwitP , RuangkanchanasetrP , ChoovichianP . Short course oral androgenic steroid improved lean body mass in continuous ambulatory peritoneal dialysis patients [abstract no: F‐PO580]. Journal of the American Society of Nephrology2005;16:461A. WiwatniwongS , SupasyndhO , AramwitP , RuangkanchanasetrP , LuesuthiviboonL . Oral androgenic steroid therapy for anemia in continuous ambulatory peritoneal dialysis patients [abstract no: F‐PO599]. Journal of the American Society of Nephrology2005;16:465A. ">Aramwit 2010</a>; <a href="./references#CD006881-bbs2-0003" title="GaughanWJ , LissKA , DunnSR , MangoldAM , BuhsmerJP , MichaelB , et al. A 6‐month study of low‐dose recombinant human erythropoietin alone and in combination with androgens for the treatment of anemia in chronic hemodialysis patients. American Journal of Kidney Diseases1997;30(4):495‐500. [MEDLINE: 9328363] LissKA , GaughanWJ , DunnSR , MichaelB , GoldmanJM , ArmentiVT , et al. A six month study of low‐dose recombinant human erythropoietin alone and in combination with androgen for the treatment of anemia in chronic hemodialysis patients [abstract no: A1206]. Journal of the American Society of Nephrology1996;7(9):1490. [CENTRAL: CN‐00626123] ">Gaughan 1997</a>). Although protocols were not provided, it was clear that the published reports included all expected outcomes, and were assessed at low risk of reporting bias. </p> <p>Reporting was insufficient in six studies and was assessed as unclear risk of selective reporting (<a href="./references#CD006881-bbs2-0002" title="CattranDC , FentonSS , WilsonDR , OreopoulosD , ShimizuA , RichardsonRM . A controlled trial of nandrolone decanoate in the treatment of uremic anemia. Kidney International1977;12(6):430‐7. [MEDLINE: 609193] ">Cattran 1977</a>; <a href="./references#CD006881-bbs2-0004" title="KimHY , EarmJH , SeoJC . Effects of low‐dose nandrolone decanoate on anemia and nutritional parameters in chronic hemodialysis patients with low‐dose subcutaneous erythropoietin [abstract no: A1452]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):287A. ">Kim 1999a</a>; <a href="./references#CD006881-bbs2-0005" title="KoronisC , MakrisF , StavroulakiE , LambropoulouA , OrthopoulosV . Combination of low‐dose recombinant human erythropoietin with androgens for the treatment of anaemia in hemodialysis patients [abstract]. 37th Congress European Renal Association. European Dialysis and Transplantation Association; 2000 Sept 17‐20; Nice, France. 2000:235. [CENTRAL: CN‐00461096] ">Koronis 2000</a>; <a href="./references#CD006881-bbs2-0006" title="NavarroJF , MoraC , MaciaM , ChahinJ , GallegoE , MendezML , et al. Effects of androgen therapy on hematologic and nutritional parameters in elderly peritoneal dialysis patients [abstract]. International Urology &amp; Nephrology2001;33(4):715‐6. [CENTRAL: CN‐00615848] NavarroJF , MoraC , MaciaML , GallegoE , ChahinJ , MendezML , et al. Prospective comparison between rHuEPO and androgens in CAPD patients: impact on hematologic and nutritional parameters [abstract]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):436A. [CENTRAL: CN‐00644231] NavarroJF , MoraF , MaciaM , GarciaJ . Randomized prospective comparison between erythropoietin and androgens in CAPD patients. Kidney International2002;61(4):1537‐44. [MEDLINE: 11918762] ">Navarro 2002</a>; <a href="./references#CD006881-bbs2-0007" title="SheashaaH , Abdel‐RazekW , El‐HusseiniA , SelimA , HassanN , AbbasT , et al. Use of nandrolone decanoate as an adjuvant for erythropoietin dose reduction in treating anemia in patients on hemodialysis. Nephron2005;99(4):c102–6. [MEDLINE: 15703460] ">Sheashaa 2005a</a>; <a href="./references#CD006881-bbs2-0008" title="HendlerED , SolomonLR . Prospective controlled study of androgen effects on red cell oxygen transport and work capacity in chronic hemodialysis patients. Acta Haematologica1990;83(1):1‐8. [MEDLINE: 2105563] SolomonLR , HendlerED . Prospective controlled study of androgen therapy in the anemia of chronic renal disease: effects on iron kinetics. Acta Haematologica1988;79(1):12‐9. [MEDLINE: 3124456] ">Solomon 1988b</a>). </p> </section> <section id="CD006881-sec-0063"> <h4 class="title">Other potential sources of bias</h4> <p>Participant demographic data were comparable and protocols were approved by relevant ethics committees in two studies (<a href="./references#CD006881-bbs2-0001" title="AramwitP , PalapinyoS , WiwatniwongS , SupasyndhO . The efficacy of oxymetholone in combination with erythropoietin on hematologic parameters and muscle mass in CAPD patients. International Journal of Clinical Pharmacology &amp; Therapeutics2010;48(12):803‐13. [MEDLINE: 21084036] SupasyndhO , WiwatniwongS , AramwitP , RuangkanchanasetrP , ChoovichianP . Short course oral androgenic steroid improved lean body mass in continuous ambulatory peritoneal dialysis patients [abstract no: F‐PO580]. Journal of the American Society of Nephrology2005;16:461A. WiwatniwongS , SupasyndhO , AramwitP , RuangkanchanasetrP , LuesuthiviboonL . Oral androgenic steroid therapy for anemia in continuous ambulatory peritoneal dialysis patients [abstract no: F‐PO599]. Journal of the American Society of Nephrology2005;16:465A. ">Aramwit 2010</a>; <a href="./references#CD006881-bbs2-0003" title="GaughanWJ , LissKA , DunnSR , MangoldAM , BuhsmerJP , MichaelB , et al. A 6‐month study of low‐dose recombinant human erythropoietin alone and in combination with androgens for the treatment of anemia in chronic hemodialysis patients. American Journal of Kidney Diseases1997;30(4):495‐500. [MEDLINE: 9328363] LissKA , GaughanWJ , DunnSR , MichaelB , GoldmanJM , ArmentiVT , et al. A six month study of low‐dose recombinant human erythropoietin alone and in combination with androgen for the treatment of anemia in chronic hemodialysis patients [abstract no: A1206]. Journal of the American Society of Nephrology1996;7(9):1490. [CENTRAL: CN‐00626123] ">Gaughan 1997</a>). It was unclear if a protocol was completed for the study by <a href="./references#CD006881-bbs2-0006" title="NavarroJF , MoraC , MaciaM , ChahinJ , GallegoE , MendezML , et al. Effects of androgen therapy on hematologic and nutritional parameters in elderly peritoneal dialysis patients [abstract]. International Urology &amp; Nephrology2001;33(4):715‐6. [CENTRAL: CN‐00615848] NavarroJF , MoraC , MaciaML , GallegoE , ChahinJ , MendezML , et al. Prospective comparison between rHuEPO and androgens in CAPD patients: impact on hematologic and nutritional parameters [abstract]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):436A. [CENTRAL: CN‐00644231] NavarroJF , MoraF , MaciaM , GarciaJ . Randomized prospective comparison between erythropoietin and androgens in CAPD patients. Kidney International2002;61(4):1537‐44. [MEDLINE: 11918762] ">Navarro 2002</a>, and ethics approval was not reported. <a href="./references#CD006881-bbs2-0002" title="CattranDC , FentonSS , WilsonDR , OreopoulosD , ShimizuA , RichardsonRM . A controlled trial of nandrolone decanoate in the treatment of uremic anemia. Kidney International1977;12(6):430‐7. [MEDLINE: 609193] ">Cattran 1977</a> secured participants' informed consent but neither demographic data nor ethics approval were reported, and was determined to be at high risk of bias. </p> <p>Participant demographic data were similar between arms in three studies (<a href="./references#CD006881-bbs2-0004" title="KimHY , EarmJH , SeoJC . Effects of low‐dose nandrolone decanoate on anemia and nutritional parameters in chronic hemodialysis patients with low‐dose subcutaneous erythropoietin [abstract no: A1452]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):287A. ">Kim 1999a</a>; <a href="./references#CD006881-bbs2-0005" title="KoronisC , MakrisF , StavroulakiE , LambropoulouA , OrthopoulosV . Combination of low‐dose recombinant human erythropoietin with androgens for the treatment of anaemia in hemodialysis patients [abstract]. 37th Congress European Renal Association. European Dialysis and Transplantation Association; 2000 Sept 17‐20; Nice, France. 2000:235. [CENTRAL: CN‐00461096] ">Koronis 2000</a>; <a href="./references#CD006881-bbs2-0007" title="SheashaaH , Abdel‐RazekW , El‐HusseiniA , SelimA , HassanN , AbbasT , et al. Use of nandrolone decanoate as an adjuvant for erythropoietin dose reduction in treating anemia in patients on hemodialysis. Nephron2005;99(4):c102–6. [MEDLINE: 15703460] ">Sheashaa 2005a</a>), but informed consent, protocols and ethics approval were not reported. Signed informed consent and demographic data were not reported in <a href="./references#CD006881-bbs2-0008" title="HendlerED , SolomonLR . Prospective controlled study of androgen effects on red cell oxygen transport and work capacity in chronic hemodialysis patients. Acta Haematologica1990;83(1):1‐8. [MEDLINE: 2105563] SolomonLR , HendlerED . Prospective controlled study of androgen therapy in the anemia of chronic renal disease: effects on iron kinetics. Acta Haematologica1988;79(1):12‐9. [MEDLINE: 3124456] ">Solomon 1988b</a>. </p> </section> </section> <section id="CD006881-sec-0064"> <h3 class="title" id="CD006881-sec-0064">Effects of interventions</h3> <p>See: <a href="./full#CD006881-tbl-0001"><b>Summary of findings for the main comparison</b> </a> </p> <p>We analysed reported data on androgens plus routine therapy versus routine therapy alone, androgens plus routine therapy versus placebo plus routine therapy, androgens versus routine therapy, and androgens versus no drug. Androgens assessed were nandrolone decanoate and oxymetholone. </p> <p>Baseline participant characteristics were clearly reported in six studies (<a href="./references#CD006881-bbs2-0001" title="AramwitP , PalapinyoS , WiwatniwongS , SupasyndhO . The efficacy of oxymetholone in combination with erythropoietin on hematologic parameters and muscle mass in CAPD patients. International Journal of Clinical Pharmacology &amp; Therapeutics2010;48(12):803‐13. [MEDLINE: 21084036] SupasyndhO , WiwatniwongS , AramwitP , RuangkanchanasetrP , ChoovichianP . Short course oral androgenic steroid improved lean body mass in continuous ambulatory peritoneal dialysis patients [abstract no: F‐PO580]. Journal of the American Society of Nephrology2005;16:461A. WiwatniwongS , SupasyndhO , AramwitP , RuangkanchanasetrP , LuesuthiviboonL . Oral androgenic steroid therapy for anemia in continuous ambulatory peritoneal dialysis patients [abstract no: F‐PO599]. Journal of the American Society of Nephrology2005;16:465A. ">Aramwit 2010</a>; <a href="./references#CD006881-bbs2-0003" title="GaughanWJ , LissKA , DunnSR , MangoldAM , BuhsmerJP , MichaelB , et al. A 6‐month study of low‐dose recombinant human erythropoietin alone and in combination with androgens for the treatment of anemia in chronic hemodialysis patients. American Journal of Kidney Diseases1997;30(4):495‐500. [MEDLINE: 9328363] LissKA , GaughanWJ , DunnSR , MichaelB , GoldmanJM , ArmentiVT , et al. A six month study of low‐dose recombinant human erythropoietin alone and in combination with androgen for the treatment of anemia in chronic hemodialysis patients [abstract no: A1206]. Journal of the American Society of Nephrology1996;7(9):1490. [CENTRAL: CN‐00626123] ">Gaughan 1997</a>; <a href="./references#CD006881-bbs2-0004" title="KimHY , EarmJH , SeoJC . Effects of low‐dose nandrolone decanoate on anemia and nutritional parameters in chronic hemodialysis patients with low‐dose subcutaneous erythropoietin [abstract no: A1452]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):287A. ">Kim 1999a</a>; <a href="./references#CD006881-bbs2-0005" title="KoronisC , MakrisF , StavroulakiE , LambropoulouA , OrthopoulosV . Combination of low‐dose recombinant human erythropoietin with androgens for the treatment of anaemia in hemodialysis patients [abstract]. 37th Congress European Renal Association. European Dialysis and Transplantation Association; 2000 Sept 17‐20; Nice, France. 2000:235. [CENTRAL: CN‐00461096] ">Koronis 2000</a>; <a href="./references#CD006881-bbs2-0006" title="NavarroJF , MoraC , MaciaM , ChahinJ , GallegoE , MendezML , et al. Effects of androgen therapy on hematologic and nutritional parameters in elderly peritoneal dialysis patients [abstract]. International Urology &amp; Nephrology2001;33(4):715‐6. [CENTRAL: CN‐00615848] NavarroJF , MoraC , MaciaML , GallegoE , ChahinJ , MendezML , et al. Prospective comparison between rHuEPO and androgens in CAPD patients: impact on hematologic and nutritional parameters [abstract]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):436A. [CENTRAL: CN‐00644231] NavarroJF , MoraF , MaciaM , GarciaJ . Randomized prospective comparison between erythropoietin and androgens in CAPD patients. Kidney International2002;61(4):1537‐44. [MEDLINE: 11918762] ">Navarro 2002</a>; <a href="./references#CD006881-bbs2-0007" title="SheashaaH , Abdel‐RazekW , El‐HusseiniA , SelimA , HassanN , AbbasT , et al. Use of nandrolone decanoate as an adjuvant for erythropoietin dose reduction in treating anemia in patients on hemodialysis. Nephron2005;99(4):c102–6. [MEDLINE: 15703460] ">Sheashaa 2005a</a>). </p> <p>None of the included studies reported on death or quality of life.</p> <section id="CD006881-sec-0065"> <h4 class="title">Nandrolone decanoate plus rHuEPO versus rHuEPO alone</h4> <p>Four studies investigated nandrolone decanoate plus rHuEPO versus rHuEPO alone (<a href="./references#CD006881-bbs2-0003" title="GaughanWJ , LissKA , DunnSR , MangoldAM , BuhsmerJP , MichaelB , et al. A 6‐month study of low‐dose recombinant human erythropoietin alone and in combination with androgens for the treatment of anemia in chronic hemodialysis patients. American Journal of Kidney Diseases1997;30(4):495‐500. [MEDLINE: 9328363] LissKA , GaughanWJ , DunnSR , MichaelB , GoldmanJM , ArmentiVT , et al. A six month study of low‐dose recombinant human erythropoietin alone and in combination with androgen for the treatment of anemia in chronic hemodialysis patients [abstract no: A1206]. Journal of the American Society of Nephrology1996;7(9):1490. [CENTRAL: CN‐00626123] ">Gaughan 1997</a>; <a href="./references#CD006881-bbs2-0004" title="KimHY , EarmJH , SeoJC . Effects of low‐dose nandrolone decanoate on anemia and nutritional parameters in chronic hemodialysis patients with low‐dose subcutaneous erythropoietin [abstract no: A1452]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):287A. ">Kim 1999a</a>; <a href="./references#CD006881-bbs2-0005" title="KoronisC , MakrisF , StavroulakiE , LambropoulouA , OrthopoulosV . Combination of low‐dose recombinant human erythropoietin with androgens for the treatment of anaemia in hemodialysis patients [abstract]. 37th Congress European Renal Association. European Dialysis and Transplantation Association; 2000 Sept 17‐20; Nice, France. 2000:235. [CENTRAL: CN‐00461096] ">Koronis 2000</a>; <a href="./references#CD006881-bbs2-0007" title="SheashaaH , Abdel‐RazekW , El‐HusseiniA , SelimA , HassanN , AbbasT , et al. Use of nandrolone decanoate as an adjuvant for erythropoietin dose reduction in treating anemia in patients on hemodialysis. Nephron2005;99(4):c102–6. [MEDLINE: 15703460] ">Sheashaa 2005a</a>). </p> <section id="CD006881-sec-0066"> <h5 class="title">Haemoglobin and haematocrit</h5> <p><a href="./references#CD006881-bbs2-0007" title="SheashaaH , Abdel‐RazekW , El‐HusseiniA , SelimA , HassanN , AbbasT , et al. Use of nandrolone decanoate as an adjuvant for erythropoietin dose reduction in treating anemia in patients on hemodialysis. Nephron2005;99(4):c102–6. [MEDLINE: 15703460] ">Sheashaa 2005a</a> reported no significant difference in Hb (<a href="./references#CD006881-fig-0004" title="">Analysis 1.1</a> (1 study, 32 participants): MD 0.44 g/dL, 95% CI ‐0.17 to 1.05). </p> <p>Compared to rHuEPO alone nandrolone decanoate plus rHuEPO significantly increased HCT (<a href="./references#CD006881-fig-0005" title="">Analysis 1.2</a> (3 studies, 73 participants): MD 2.54%, 95% CI 0.96 to 4.12); I² = 17%) </p> </section> <section id="CD006881-sec-0067"> <h5 class="title">Albumin and triglycerides</h5> <p>There was no significant difference in serum albumin at the end of treatment (<a href="./references#CD006881-fig-0006" title="">Analysis 1.3</a> (2 studies, 51 participants): MD ‐0.09 g/dL, 95% CI ‐0.24 to 0.06; I² = 0%). </p> <p><a href="./references#CD006881-bbs2-0003" title="GaughanWJ , LissKA , DunnSR , MangoldAM , BuhsmerJP , MichaelB , et al. A 6‐month study of low‐dose recombinant human erythropoietin alone and in combination with androgens for the treatment of anemia in chronic hemodialysis patients. American Journal of Kidney Diseases1997;30(4):495‐500. [MEDLINE: 9328363] LissKA , GaughanWJ , DunnSR , MichaelB , GoldmanJM , ArmentiVT , et al. A six month study of low‐dose recombinant human erythropoietin alone and in combination with androgen for the treatment of anemia in chronic hemodialysis patients [abstract no: A1206]. Journal of the American Society of Nephrology1996;7(9):1490. [CENTRAL: CN‐00626123] ">Gaughan 1997</a> reported no significant difference in serum triglycerides at the end of treatment (<a href="./references#CD006881-fig-0007" title="">Analysis 1.4</a> (1 study, 19 participants): MD 34.00 mg/dL, 95% CI ‐74.70 to 42.70). </p> </section> <section id="CD006881-sec-0068"> <h5 class="title">Adverse events</h5> <p><a href="./references#CD006881-bbs2-0003" title="GaughanWJ , LissKA , DunnSR , MangoldAM , BuhsmerJP , MichaelB , et al. A 6‐month study of low‐dose recombinant human erythropoietin alone and in combination with androgens for the treatment of anemia in chronic hemodialysis patients. American Journal of Kidney Diseases1997;30(4):495‐500. [MEDLINE: 9328363] LissKA , GaughanWJ , DunnSR , MichaelB , GoldmanJM , ArmentiVT , et al. A six month study of low‐dose recombinant human erythropoietin alone and in combination with androgen for the treatment of anemia in chronic hemodialysis patients [abstract no: A1206]. Journal of the American Society of Nephrology1996;7(9):1490. [CENTRAL: CN‐00626123] ">Gaughan 1997</a> reported no differences in acne between the groups (<a href="./references#CD006881-fig-0008" title="">Analysis 1.5</a>.1 (1 study, 19 participants): RR 3.30, 95% CI 0.15 to 72.08). <a href="./references#CD006881-bbs2-0007" title="SheashaaH , Abdel‐RazekW , El‐HusseiniA , SelimA , HassanN , AbbasT , et al. Use of nandrolone decanoate as an adjuvant for erythropoietin dose reduction in treating anemia in patients on hemodialysis. Nephron2005;99(4):c102–6. [MEDLINE: 15703460] ">Sheashaa 2005a</a> reported no differences in menstrual disorders (<a href="./references#CD006881-fig-0008" title="">Analysis 1.5</a>.2 (1 study, 32 participants): RR 11.0, 95% CI 0.66 to 183.79) or excess body hair (<a href="./references#CD006881-fig-0008" title="">Analysis 1.5</a>.3 (1 study, 32 participants): RR 11.0, 95% CI 0.66 to 183.79) between the groups. </p> </section> </section> <section id="CD006881-sec-0069"> <h4 class="title">Oxymetholone plus alpha rHuEPO versus placebo plus alpha rHuEPO</h4> <p><a href="./references#CD006881-bbs2-0001" title="AramwitP , PalapinyoS , WiwatniwongS , SupasyndhO . The efficacy of oxymetholone in combination with erythropoietin on hematologic parameters and muscle mass in CAPD patients. International Journal of Clinical Pharmacology &amp; Therapeutics2010;48(12):803‐13. [MEDLINE: 21084036] SupasyndhO , WiwatniwongS , AramwitP , RuangkanchanasetrP , ChoovichianP . Short course oral androgenic steroid improved lean body mass in continuous ambulatory peritoneal dialysis patients [abstract no: F‐PO580]. Journal of the American Society of Nephrology2005;16:461A. WiwatniwongS , SupasyndhO , AramwitP , RuangkanchanasetrP , LuesuthiviboonL . Oral androgenic steroid therapy for anemia in continuous ambulatory peritoneal dialysis patients [abstract no: F‐PO599]. Journal of the American Society of Nephrology2005;16:465A. ">Aramwit 2010</a> investigated oxymetholone plus alpha rHuEPO versus placebo plus alpha rHuEPO. </p> <section id="CD006881-sec-0070"> <h5 class="title">Haemoglobin and haematocrit</h5> <p><a href="./references#CD006881-bbs2-0001" title="AramwitP , PalapinyoS , WiwatniwongS , SupasyndhO . The efficacy of oxymetholone in combination with erythropoietin on hematologic parameters and muscle mass in CAPD patients. International Journal of Clinical Pharmacology &amp; Therapeutics2010;48(12):803‐13. [MEDLINE: 21084036] SupasyndhO , WiwatniwongS , AramwitP , RuangkanchanasetrP , ChoovichianP . Short course oral androgenic steroid improved lean body mass in continuous ambulatory peritoneal dialysis patients [abstract no: F‐PO580]. Journal of the American Society of Nephrology2005;16:461A. WiwatniwongS , SupasyndhO , AramwitP , RuangkanchanasetrP , LuesuthiviboonL . Oral androgenic steroid therapy for anemia in continuous ambulatory peritoneal dialysis patients [abstract no: F‐PO599]. Journal of the American Society of Nephrology2005;16:465A. ">Aramwit 2010</a> reported oxymetholone plus rHuEPO significantly increased Hb when compared to rHuEPO alone (<a href="./references#CD006881-fig-0009" title="">Analysis 2.1</a> (1 study, 24 participants): MD 1.90 g/dL, 95% CI 1.66 to 2.14) and HCT (<a href="./references#CD006881-fig-0010" title="">Analysis 2.2</a> (1 study, 24 participants): MD 27.10%, 95% CI 26.49 to 27.71). </p> </section> <section id="CD006881-sec-0071"> <h5 class="title">Liver and kidney function</h5> <p><a href="./references#CD006881-bbs2-0001" title="AramwitP , PalapinyoS , WiwatniwongS , SupasyndhO . The efficacy of oxymetholone in combination with erythropoietin on hematologic parameters and muscle mass in CAPD patients. International Journal of Clinical Pharmacology &amp; Therapeutics2010;48(12):803‐13. [MEDLINE: 21084036] SupasyndhO , WiwatniwongS , AramwitP , RuangkanchanasetrP , ChoovichianP . Short course oral androgenic steroid improved lean body mass in continuous ambulatory peritoneal dialysis patients [abstract no: F‐PO580]. Journal of the American Society of Nephrology2005;16:461A. WiwatniwongS , SupasyndhO , AramwitP , RuangkanchanasetrP , LuesuthiviboonL . Oral androgenic steroid therapy for anemia in continuous ambulatory peritoneal dialysis patients [abstract no: F‐PO599]. Journal of the American Society of Nephrology2005;16:465A. ">Aramwit 2010</a> reported oxymetholone plus rHuEPO significantly decreased ALT (<a href="./references#CD006881-fig-0011" title="">Analysis 2.3</a>.1 (1 study, 24 participants): MD 54.50 U/L, 95% CI 43.94 to 65.06 and AST levels (<a href="./references#CD006881-fig-0011" title="">Analysis 2.3</a>.2 (1 study, 24 participants): MD 47.33 U/L, 95% CI 37.69 to 56.97). No improvement in kidney function was apparent with either intervention measured in terms of BUN (<a href="./references#CD006881-fig-0012" title="">Analysis 2.4</a>.1 (1 study, 24 participants): MD ‐0.94 mmol/L, 95% CI ‐4.02 to 2.14) or SCr (<a href="./references#CD006881-fig-0012" title="">Analysis 2.4</a>.2 (1 study, 24 participants): MD 261.60 µmol/L, 95% CI ‐37.76 to 560.96). </p> </section> <section id="CD006881-sec-0072"> <h5 class="title">Lipid profile and albumin</h5> <p><a href="./references#CD006881-bbs2-0001" title="AramwitP , PalapinyoS , WiwatniwongS , SupasyndhO . The efficacy of oxymetholone in combination with erythropoietin on hematologic parameters and muscle mass in CAPD patients. International Journal of Clinical Pharmacology &amp; Therapeutics2010;48(12):803‐13. [MEDLINE: 21084036] SupasyndhO , WiwatniwongS , AramwitP , RuangkanchanasetrP , ChoovichianP . Short course oral androgenic steroid improved lean body mass in continuous ambulatory peritoneal dialysis patients [abstract no: F‐PO580]. Journal of the American Society of Nephrology2005;16:461A. WiwatniwongS , SupasyndhO , AramwitP , RuangkanchanasetrP , LuesuthiviboonL . Oral androgenic steroid therapy for anemia in continuous ambulatory peritoneal dialysis patients [abstract no: F‐PO599]. Journal of the American Society of Nephrology2005;16:465A. ">Aramwit 2010</a> reported no significant differences in total cholesterol (<a href="./references#CD006881-fig-0013" title="">Analysis 2.5</a>.1 (1 study, 24 participants): MD ‐26.16 mg/dL, 95% CI ‐63.86 to 11.54), TG (<a href="./references#CD006881-fig-0013" title="">Analysis 2.5</a>.2 (1 study, 24 participants): MD ‐47.80 mg/dL, 95% CI ‐117.41 to 21.81) or LDL (<a href="./references#CD006881-fig-0013" title="">Analysis 2.5</a>.4 (1 study, 24 participants): MD ‐1.11 mg/dL, 95% CI ‐31.80 to 29.58), but a significant decrease was reported for HDL (<a href="./references#CD006881-fig-0013" title="">Analysis 2.5</a>.3 (1 study, 24 participants): MD ‐15.66 mg/dL, 95% CI ‐24.84 to ‐6.48) </p> <p>A significant increase in change in serum albumin was reported for oxymetholone plus rHuEPO (<a href="./references#CD006881-fig-0014" title="">Analysis 2.6</a> (1 study, 24 participants): MD 4.91 g/L, 95% CI 3.69 to 6.13) </p> </section> <section id="CD006881-sec-0073"> <h5 class="title">Adverse events</h5> <p><a href="./references#CD006881-bbs2-0001" title="AramwitP , PalapinyoS , WiwatniwongS , SupasyndhO . The efficacy of oxymetholone in combination with erythropoietin on hematologic parameters and muscle mass in CAPD patients. International Journal of Clinical Pharmacology &amp; Therapeutics2010;48(12):803‐13. [MEDLINE: 21084036] SupasyndhO , WiwatniwongS , AramwitP , RuangkanchanasetrP , ChoovichianP . Short course oral androgenic steroid improved lean body mass in continuous ambulatory peritoneal dialysis patients [abstract no: F‐PO580]. Journal of the American Society of Nephrology2005;16:461A. WiwatniwongS , SupasyndhO , AramwitP , RuangkanchanasetrP , LuesuthiviboonL . Oral androgenic steroid therapy for anemia in continuous ambulatory peritoneal dialysis patients [abstract no: F‐PO599]. Journal of the American Society of Nephrology2005;16:465A. ">Aramwit 2010</a> reported no significant differences in adverse effects (<a href="./references#CD006881-fig-0015" title="">Analysis 2.7</a> (1 study, 24 participants): RR 1.18, 95% CI 0.08 to 16.78). </p> </section> </section> <section id="CD006881-sec-0074"> <h4 class="title">Nandrolone decanoate versus rHuEPO</h4> <p><a href="./references#CD006881-bbs2-0006" title="NavarroJF , MoraC , MaciaM , ChahinJ , GallegoE , MendezML , et al. Effects of androgen therapy on hematologic and nutritional parameters in elderly peritoneal dialysis patients [abstract]. International Urology &amp; Nephrology2001;33(4):715‐6. [CENTRAL: CN‐00615848] NavarroJF , MoraC , MaciaML , GallegoE , ChahinJ , MendezML , et al. Prospective comparison between rHuEPO and androgens in CAPD patients: impact on hematologic and nutritional parameters [abstract]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):436A. [CENTRAL: CN‐00644231] NavarroJF , MoraF , MaciaM , GarciaJ . Randomized prospective comparison between erythropoietin and androgens in CAPD patients. Kidney International2002;61(4):1537‐44. [MEDLINE: 11918762] ">Navarro 2002</a> investigated nandrolone decanoate versus rHuEPO. </p> <section id="CD006881-sec-0075"> <h5 class="title">Haemoglobin and haematocrit</h5> <p><a href="./references#CD006881-bbs2-0006" title="NavarroJF , MoraC , MaciaM , ChahinJ , GallegoE , MendezML , et al. Effects of androgen therapy on hematologic and nutritional parameters in elderly peritoneal dialysis patients [abstract]. International Urology &amp; Nephrology2001;33(4):715‐6. [CENTRAL: CN‐00615848] NavarroJF , MoraC , MaciaML , GallegoE , ChahinJ , MendezML , et al. Prospective comparison between rHuEPO and androgens in CAPD patients: impact on hematologic and nutritional parameters [abstract]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):436A. [CENTRAL: CN‐00644231] NavarroJF , MoraF , MaciaM , GarciaJ . Randomized prospective comparison between erythropoietin and androgens in CAPD patients. Kidney International2002;61(4):1537‐44. [MEDLINE: 11918762] ">Navarro 2002</a> reported no significant change in Hb (<a href="./references#CD006881-fig-0016" title="">Analysis 3.1</a> (1 study, 27 participants): MD 0.10 g/dL, 95% CI ‐0.28 to 0.48) or HCT (<a href="./references#CD006881-fig-0017" title="">Analysis 3.2</a> (1 study, 27 participants): MD 0.40%, 95% CI ‐0.77 to 1.57). </p> </section> <section id="CD006881-sec-0076"> <h5 class="title">Total protein, pre‐albumin, transferrin and albumin</h5> <p><a href="./references#CD006881-bbs2-0006" title="NavarroJF , MoraC , MaciaM , ChahinJ , GallegoE , MendezML , et al. Effects of androgen therapy on hematologic and nutritional parameters in elderly peritoneal dialysis patients [abstract]. International Urology &amp; Nephrology2001;33(4):715‐6. [CENTRAL: CN‐00615848] NavarroJF , MoraC , MaciaML , GallegoE , ChahinJ , MendezML , et al. Prospective comparison between rHuEPO and androgens in CAPD patients: impact on hematologic and nutritional parameters [abstract]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):436A. [CENTRAL: CN‐00644231] NavarroJF , MoraF , MaciaM , GarciaJ . Randomized prospective comparison between erythropoietin and androgens in CAPD patients. Kidney International2002;61(4):1537‐44. [MEDLINE: 11918762] ">Navarro 2002</a> reported nandrolone decanoate significantly increased total protein (<a href="./references#CD006881-fig-0018" title="">Analysis 3.3</a> (1 study, 27 participants): MD 0.40 g/L, 95% CI 0.13 to 0.67), transferrin (<a href="./references#CD006881-fig-0020" title="">Analysis 3.5</a> (1 study, 27 participants): MD 45.00 mg/dL, 95% CI 12.61 to 77.39) and albumin (<a href="./references#CD006881-fig-0021" title="">Analysis 3.6</a> (1 study, 27 participants): MD 0.20/L, 95% CI 0.01 to 0.39); but not prealbumin (<a href="./references#CD006881-fig-0019" title="">Analysis 3.4</a> (1 study, 27 participants): MD 1.00 mg/dL, 95% CI ‐3.53 to 5.53). </p> </section> <section id="CD006881-sec-0077"> <h5 class="title">Kidney function</h5> <p><a href="./references#CD006881-bbs2-0006" title="NavarroJF , MoraC , MaciaM , ChahinJ , GallegoE , MendezML , et al. Effects of androgen therapy on hematologic and nutritional parameters in elderly peritoneal dialysis patients [abstract]. International Urology &amp; Nephrology2001;33(4):715‐6. [CENTRAL: CN‐00615848] NavarroJF , MoraC , MaciaML , GallegoE , ChahinJ , MendezML , et al. Prospective comparison between rHuEPO and androgens in CAPD patients: impact on hematologic and nutritional parameters [abstract]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):436A. [CENTRAL: CN‐00644231] NavarroJF , MoraF , MaciaM , GarciaJ . Randomized prospective comparison between erythropoietin and androgens in CAPD patients. Kidney International2002;61(4):1537‐44. [MEDLINE: 11918762] ">Navarro 2002</a> reported nandrolone decanoate did not significantly decrease BUN (<a href="./references#CD006881-fig-0022" title="">Analysis 3.7</a>.1 (1 study, 27 participants): MD ‐9.00 mg/dL, 95% Cl ‐18.13 to 0.13) or SCr (<a href="./references#CD006881-fig-0022" title="">Analysis 3.7</a>.2 (1 study, 27 participants): MD 0.80 mg/dL, 95% Cl ‐0.88 to 2.48). </p> </section> <section id="CD006881-sec-0078"> <h5 class="title">Adverse events</h5> <p><a href="./references#CD006881-bbs2-0006" title="NavarroJF , MoraC , MaciaM , ChahinJ , GallegoE , MendezML , et al. Effects of androgen therapy on hematologic and nutritional parameters in elderly peritoneal dialysis patients [abstract]. International Urology &amp; Nephrology2001;33(4):715‐6. [CENTRAL: CN‐00615848] NavarroJF , MoraC , MaciaML , GallegoE , ChahinJ , MendezML , et al. Prospective comparison between rHuEPO and androgens in CAPD patients: impact on hematologic and nutritional parameters [abstract]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):436A. [CENTRAL: CN‐00644231] NavarroJF , MoraF , MaciaM , GarciaJ . Randomized prospective comparison between erythropoietin and androgens in CAPD patients. Kidney International2002;61(4):1537‐44. [MEDLINE: 11918762] ">Navarro 2002</a> reported that one participant in the nandrolone decanoate group developed peritonitis, and one participant in the rHuEPO group experienced exacerbation of CKD‐related anaemia. There was no statistical difference in adverse effects between groups (<a href="./references#CD006881-fig-0023" title="">Analysis 3.8</a> (1 study, 27 participants): RR 1.08, 95% CI 0.07 to 15.50). </p> </section> </section> <section id="CD006881-sec-0079"> <h4 class="title">Nandrolone decanoate versus no therapy</h4> <p><a href="./references#CD006881-bbs2-0002" title="CattranDC , FentonSS , WilsonDR , OreopoulosD , ShimizuA , RichardsonRM . A controlled trial of nandrolone decanoate in the treatment of uremic anemia. Kidney International1977;12(6):430‐7. [MEDLINE: 609193] ">Cattran 1977</a> and <a href="./references#CD006881-bbs2-0008" title="HendlerED , SolomonLR . Prospective controlled study of androgen effects on red cell oxygen transport and work capacity in chronic hemodialysis patients. Acta Haematologica1990;83(1):1‐8. [MEDLINE: 2105563] SolomonLR , HendlerED . Prospective controlled study of androgen therapy in the anemia of chronic renal disease: effects on iron kinetics. Acta Haematologica1988;79(1):12‐9. [MEDLINE: 3124456] ">Solomon 1988b</a> investigated nandrolone decanoate versus no drug. <a href="./references#CD006881-bbs2-0002" title="CattranDC , FentonSS , WilsonDR , OreopoulosD , ShimizuA , RichardsonRM . A controlled trial of nandrolone decanoate in the treatment of uremic anemia. Kidney International1977;12(6):430‐7. [MEDLINE: 609193] ">Cattran 1977</a> investigated the effects of nandrolone decanoate versus no drug therapy among remnant kidney patients (15/9 intervention/control) and anephric participants (3/2 intervention/control). </p> <section id="CD006881-sec-0080"> <h5 class="title">Haemoglobin and haematocrit</h5> <p>Nandrolone decanoate significantly increased Hb (<a href="./references#CD006881-fig-0024" title="">Analysis 4.1</a> (2 studies, 33 participants): MD 1.04 g/dL, 95% CI 0.66 to 1.41; I² = 0%). <a href="./references#CD006881-bbs2-0002" title="CattranDC , FentonSS , WilsonDR , OreopoulosD , ShimizuA , RichardsonRM . A controlled trial of nandrolone decanoate in the treatment of uremic anemia. Kidney International1977;12(6):430‐7. [MEDLINE: 609193] ">Cattran 1977</a> reported nandrolone decanoate significantly increased HCT (<a href="./references#CD006881-fig-0025" title="">Analysis 4.2</a> (1 study, 24 participants): MD 3.70%, 95% CI 0.68 to 6.72). <a href="./references#CD006881-bbs2-0002" title="CattranDC , FentonSS , WilsonDR , OreopoulosD , ShimizuA , RichardsonRM . A controlled trial of nandrolone decanoate in the treatment of uremic anemia. Kidney International1977;12(6):430‐7. [MEDLINE: 609193] ">Cattran 1977</a> also reported the effects in anephric participants and reported a statistically significant increase in Hb with nandrolone decanoate (<a href="./references#CD006881-fig-0026" title="">Analysis 5.1</a> (1 study, 5 participants): MD 1.30 g/dL, 95% CI 0.57 to 2.03), but no significant difference in HCT (<a href="./references#CD006881-fig-0027" title="">Analysis 5.2</a> (1 study, 5 participants): MD 2.00%, 95% CI ‐0.85 to 4.85). </p> <p>Mortality, quality of life and adverse events were not reported.</p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD006881-sec-0081" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD006881-sec-0081"></div> <section id="CD006881-sec-0082"> <h3 class="title" id="CD006881-sec-0082">Summary of main results</h3> <p>We found limited evidence to suggest that androgens may confer positive effects to increase Hb, HCT and serum albumin. </p> <p>Studies by <a href="./references#CD006881-bbs2-0004" title="KimHY , EarmJH , SeoJC . Effects of low‐dose nandrolone decanoate on anemia and nutritional parameters in chronic hemodialysis patients with low‐dose subcutaneous erythropoietin [abstract no: A1452]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):287A. ">Kim 1999a</a>, <a href="./references#CD006881-bbs2-0005" title="KoronisC , MakrisF , StavroulakiE , LambropoulouA , OrthopoulosV . Combination of low‐dose recombinant human erythropoietin with androgens for the treatment of anaemia in hemodialysis patients [abstract]. 37th Congress European Renal Association. European Dialysis and Transplantation Association; 2000 Sept 17‐20; Nice, France. 2000:235. [CENTRAL: CN‐00461096] ">Koronis 2000</a> and <a href="./references#CD006881-bbs2-0007" title="SheashaaH , Abdel‐RazekW , El‐HusseiniA , SelimA , HassanN , AbbasT , et al. Use of nandrolone decanoate as an adjuvant for erythropoietin dose reduction in treating anemia in patients on hemodialysis. Nephron2005;99(4):c102–6. [MEDLINE: 15703460] ">Sheashaa 2005a</a> comparing nandrolone decanoate plus rHuEPO with rHuEPO alone reported increased HCT levels. <a href="./references#CD006881-bbs2-0007" title="SheashaaH , Abdel‐RazekW , El‐HusseiniA , SelimA , HassanN , AbbasT , et al. Use of nandrolone decanoate as an adjuvant for erythropoietin dose reduction in treating anemia in patients on hemodialysis. Nephron2005;99(4):c102–6. [MEDLINE: 15703460] ">Sheashaa 2005a</a> reported no significant increase in Hb. There was insufficient evidence to discern if nandrolone decanoate plus rHuEPO increased serum albumin and decreased rates of adverse events. </p> <p>Findings reported by <a href="./references#CD006881-bbs2-0001" title="AramwitP , PalapinyoS , WiwatniwongS , SupasyndhO . The efficacy of oxymetholone in combination with erythropoietin on hematologic parameters and muscle mass in CAPD patients. International Journal of Clinical Pharmacology &amp; Therapeutics2010;48(12):803‐13. [MEDLINE: 21084036] SupasyndhO , WiwatniwongS , AramwitP , RuangkanchanasetrP , ChoovichianP . Short course oral androgenic steroid improved lean body mass in continuous ambulatory peritoneal dialysis patients [abstract no: F‐PO580]. Journal of the American Society of Nephrology2005;16:461A. WiwatniwongS , SupasyndhO , AramwitP , RuangkanchanasetrP , LuesuthiviboonL . Oral androgenic steroid therapy for anemia in continuous ambulatory peritoneal dialysis patients [abstract no: F‐PO599]. Journal of the American Society of Nephrology2005;16:465A. ">Aramwit 2010</a> in a comparison of oxymetholone plus rHuEPO with placebo plus rHuEPO indicated significant increases in Hb, HCT, serum albumin, AST and ALT; and a significant decrease in HDL. There was insufficient evidence to discern if oxymetholone plus rHuEPO decreased BUN, SCr, cholesterol, TG, LDL and adverse events. </p> <p>In a comparative analysis of nandrolone decanoate with rHuEPO, <a href="./references#CD006881-bbs2-0006" title="NavarroJF , MoraC , MaciaM , ChahinJ , GallegoE , MendezML , et al. Effects of androgen therapy on hematologic and nutritional parameters in elderly peritoneal dialysis patients [abstract]. International Urology &amp; Nephrology2001;33(4):715‐6. [CENTRAL: CN‐00615848] NavarroJF , MoraC , MaciaML , GallegoE , ChahinJ , MendezML , et al. Prospective comparison between rHuEPO and androgens in CAPD patients: impact on hematologic and nutritional parameters [abstract]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):436A. [CENTRAL: CN‐00644231] NavarroJF , MoraF , MaciaM , GarciaJ . Randomized prospective comparison between erythropoietin and androgens in CAPD patients. Kidney International2002;61(4):1537‐44. [MEDLINE: 11918762] ">Navarro 2002</a> reported a statistically significant increase in total protein, transferrin, and serum albumin. BUN was decreased but not significantly. There was insufficient evidence to assess if nandrolone decanoate had an effect in increasing Hb, HCT, prealbumin, and decreasing SCr and adverse events. </p> <p><a href="./references#CD006881-bbs2-0002" title="CattranDC , FentonSS , WilsonDR , OreopoulosD , ShimizuA , RichardsonRM . A controlled trial of nandrolone decanoate in the treatment of uremic anemia. Kidney International1977;12(6):430‐7. [MEDLINE: 609193] ">Cattran 1977</a> and <a href="./references#CD006881-bbs2-0008" title="HendlerED , SolomonLR . Prospective controlled study of androgen effects on red cell oxygen transport and work capacity in chronic hemodialysis patients. Acta Haematologica1990;83(1):1‐8. [MEDLINE: 2105563] SolomonLR , HendlerED . Prospective controlled study of androgen therapy in the anemia of chronic renal disease: effects on iron kinetics. Acta Haematologica1988;79(1):12‐9. [MEDLINE: 3124456] ">Solomon 1988b</a>, comparing nandrolone decanoate with no therapy, reported increased Hb levels. In a subgroup analysis of participants with remnant kidney status. <a href="./references#CD006881-bbs2-0002" title="CattranDC , FentonSS , WilsonDR , OreopoulosD , ShimizuA , RichardsonRM . A controlled trial of nandrolone decanoate in the treatment of uremic anemia. Kidney International1977;12(6):430‐7. [MEDLINE: 609193] ">Cattran 1977</a> reported that compared with no therapy, nandrolone decanoate significantly increased HCT levels. In a further subgroup analysis in anephric participants, a significant increase in Hb was reported, but there was no change in HCT. Evidence was insufficient to demonstrate if nandrolone decanoate increased HCT in anephric patients. </p> <p>There was limited evidence to indicate that oxymetholone may increase Hb, HCT, plasma albumin, AST, and ALT; and decrease HDL, cholesterol, triglyceride, and LDL. Evidence was insufficient to determine if oxymetholone had an effect in decreasing BUN, SCr, and LDL or in increasing plasma total protein, prealbumin, and transferrin. There was no evidence to demonstrate that androgens decreased BUN or SCr. </p> <p>Nandrolone decanoate may have an effect in increasing Hb, HCT, plasma total protein, plasma albumin, and transferrin, but there was is insufficient evidence to demonstrate increases prealbumin or decrease in BUN, SCr, AST, ALT, cholesterol, triglyceride, HDL, or to decrease LDL. Reporting was suboptimal, and it remains unclear whether oxymetholone and nandrolone decanoate conferred significant adverse effects among adults with CKD‐related anaemia. </p> <p>We were unable to determine if:</p> <p> <ol id="CD006881-list-0011"> <li> <p>dose‐effect relationships exist in relation to androgens and CKD‐related anaemia in adults; </p> </li> <li> <p>time‐effect relationships exist in relation to androgens and CKD‐related anaemia in adults; </p> </li> <li> <p>androgens‐erythropoietin relationships exist in relation to androgens and CKD‐related anaemia in adults. </p> </li> </ol> </p> </section> <section id="CD006881-sec-0083"> <h3 class="title" id="CD006881-sec-0083">Overall completeness and applicability of evidence</h3> <p>Based on the eight small included studies, scant evidence was identified in relation to the efficacy or safety of androgens for adults with CKD‐related anaemia. Evidence was flawed by sparseness, methodological and reporting quality in most studies. More adequately powered and robust study designs would help to clearly determine the role of androgens for adults with CKD‐related anaemia compared with other therapies. There was a marked absence of reporting of mortality and quality of life, and although there was some reporting of adverse effects, the small study cohorts may have meant that studies were underpowered to capture rates accurately. Our findings of adverse events reporting did not equate with those cited in the KDOQI guidelines (<a href="./references#CD006881-bbs2-0054" title="National Kidney Foundation. Clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. http://www.kidney.org/Professionals/kdoqi/guidelines_anemia/index.htm (accessed 23 August 2014). ">NKF 2006</a>). </p> </section> <section id="CD006881-sec-0084"> <h3 class="title" id="CD006881-sec-0084">Quality of the evidence</h3> <p>Evidence quality and reporting were suboptimal (<a href="./full#CD006881-tbl-0001">summary of findings Table for the main comparison</a>). Results were not robust, studies inadequately powered, and methodological processes were absent or flawed in many instances. Randomisation was claimed, but methods not reported in six included studies (<a href="./references#CD006881-bbs2-0002" title="CattranDC , FentonSS , WilsonDR , OreopoulosD , ShimizuA , RichardsonRM . A controlled trial of nandrolone decanoate in the treatment of uremic anemia. Kidney International1977;12(6):430‐7. [MEDLINE: 609193] ">Cattran 1977</a>; <a href="./references#CD006881-bbs2-0003" title="GaughanWJ , LissKA , DunnSR , MangoldAM , BuhsmerJP , MichaelB , et al. A 6‐month study of low‐dose recombinant human erythropoietin alone and in combination with androgens for the treatment of anemia in chronic hemodialysis patients. American Journal of Kidney Diseases1997;30(4):495‐500. [MEDLINE: 9328363] LissKA , GaughanWJ , DunnSR , MichaelB , GoldmanJM , ArmentiVT , et al. A six month study of low‐dose recombinant human erythropoietin alone and in combination with androgen for the treatment of anemia in chronic hemodialysis patients [abstract no: A1206]. Journal of the American Society of Nephrology1996;7(9):1490. [CENTRAL: CN‐00626123] ">Gaughan 1997</a>; <a href="./references#CD006881-bbs2-0004" title="KimHY , EarmJH , SeoJC . Effects of low‐dose nandrolone decanoate on anemia and nutritional parameters in chronic hemodialysis patients with low‐dose subcutaneous erythropoietin [abstract no: A1452]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):287A. ">Kim 1999a</a>; <a href="./references#CD006881-bbs2-0005" title="KoronisC , MakrisF , StavroulakiE , LambropoulouA , OrthopoulosV . Combination of low‐dose recombinant human erythropoietin with androgens for the treatment of anaemia in hemodialysis patients [abstract]. 37th Congress European Renal Association. European Dialysis and Transplantation Association; 2000 Sept 17‐20; Nice, France. 2000:235. [CENTRAL: CN‐00461096] ">Koronis 2000</a>; <a href="./references#CD006881-bbs2-0007" title="SheashaaH , Abdel‐RazekW , El‐HusseiniA , SelimA , HassanN , AbbasT , et al. Use of nandrolone decanoate as an adjuvant for erythropoietin dose reduction in treating anemia in patients on hemodialysis. Nephron2005;99(4):c102–6. [MEDLINE: 15703460] ">Sheashaa 2005a</a>; <a href="./references#CD006881-bbs2-0008" title="HendlerED , SolomonLR . Prospective controlled study of androgen effects on red cell oxygen transport and work capacity in chronic hemodialysis patients. Acta Haematologica1990;83(1):1‐8. [MEDLINE: 2105563] SolomonLR , HendlerED . Prospective controlled study of androgen therapy in the anemia of chronic renal disease: effects on iron kinetics. Acta Haematologica1988;79(1):12‐9. [MEDLINE: 3124456] ">Solomon 1988b</a>). Similarly, allocation concealment was mentioned, but detailed description was not included in those six studies. </p> <p>Blinding procedures were unclear in five studies (<a href="./references#CD006881-bbs2-0004" title="KimHY , EarmJH , SeoJC . Effects of low‐dose nandrolone decanoate on anemia and nutritional parameters in chronic hemodialysis patients with low‐dose subcutaneous erythropoietin [abstract no: A1452]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):287A. ">Kim 1999a</a>; <a href="./references#CD006881-bbs2-0005" title="KoronisC , MakrisF , StavroulakiE , LambropoulouA , OrthopoulosV . Combination of low‐dose recombinant human erythropoietin with androgens for the treatment of anaemia in hemodialysis patients [abstract]. 37th Congress European Renal Association. European Dialysis and Transplantation Association; 2000 Sept 17‐20; Nice, France. 2000:235. [CENTRAL: CN‐00461096] ">Koronis 2000</a>; <a href="./references#CD006881-bbs2-0006" title="NavarroJF , MoraC , MaciaM , ChahinJ , GallegoE , MendezML , et al. Effects of androgen therapy on hematologic and nutritional parameters in elderly peritoneal dialysis patients [abstract]. International Urology &amp; Nephrology2001;33(4):715‐6. [CENTRAL: CN‐00615848] NavarroJF , MoraC , MaciaML , GallegoE , ChahinJ , MendezML , et al. Prospective comparison between rHuEPO and androgens in CAPD patients: impact on hematologic and nutritional parameters [abstract]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):436A. [CENTRAL: CN‐00644231] NavarroJF , MoraF , MaciaM , GarciaJ . Randomized prospective comparison between erythropoietin and androgens in CAPD patients. Kidney International2002;61(4):1537‐44. [MEDLINE: 11918762] ">Navarro 2002</a>; <a href="./references#CD006881-bbs2-0007" title="SheashaaH , Abdel‐RazekW , El‐HusseiniA , SelimA , HassanN , AbbasT , et al. Use of nandrolone decanoate as an adjuvant for erythropoietin dose reduction in treating anemia in patients on hemodialysis. Nephron2005;99(4):c102–6. [MEDLINE: 15703460] ">Sheashaa 2005a</a>; <a href="./references#CD006881-bbs2-0008" title="HendlerED , SolomonLR . Prospective controlled study of androgen effects on red cell oxygen transport and work capacity in chronic hemodialysis patients. Acta Haematologica1990;83(1):1‐8. [MEDLINE: 2105563] SolomonLR , HendlerED . Prospective controlled study of androgen therapy in the anemia of chronic renal disease: effects on iron kinetics. Acta Haematologica1988;79(1):12‐9. [MEDLINE: 3124456] ">Solomon 1988b</a>) and reported as open‐label in <a href="./references#CD006881-bbs2-0003" title="GaughanWJ , LissKA , DunnSR , MangoldAM , BuhsmerJP , MichaelB , et al. A 6‐month study of low‐dose recombinant human erythropoietin alone and in combination with androgens for the treatment of anemia in chronic hemodialysis patients. American Journal of Kidney Diseases1997;30(4):495‐500. [MEDLINE: 9328363] LissKA , GaughanWJ , DunnSR , MichaelB , GoldmanJM , ArmentiVT , et al. A six month study of low‐dose recombinant human erythropoietin alone and in combination with androgen for the treatment of anemia in chronic hemodialysis patients [abstract no: A1206]. Journal of the American Society of Nephrology1996;7(9):1490. [CENTRAL: CN‐00626123] ">Gaughan 1997</a>. </p> <p>Consequently, there was a high risk of selection, performance and detection biases. Our efforts to clarify and expand on reported data by contacting study authors did not obtain significant or sufficient additional data to enhance our assessments. </p> </section> <section id="CD006881-sec-0085"> <h3 class="title" id="CD006881-sec-0085">Potential biases in the review process</h3> <p>We assessed that six of the eight included studies were of suboptimal methodological quality, although it is possible that these deficits may relate wholly or partly to lack of adequate reporting. Nevertheless, there was significant likelihood of presence of selection, performance, and detection biases in the evidence. </p> </section> <section id="CD006881-sec-0086"> <h3 class="title" id="CD006881-sec-0086">Agreements and disagreements with other studies or reviews</h3> <p><a href="./references#CD006881-bbs2-0032" title="AdamuB , Ma'ajiSM , ErwinPJ , TleyjehIM . Meta‐analysis of randomized controlled trials on androgens versus erythropoietin for anaemia of chronic kidney disease: Implications for developing countries. International Journal of Nephrology, 2012. http://www.hindawi.com/journals/ijn/2012/580437/ (accessed 23 August 2014). [DOI: 10.1155/2012/580437] ">Adamu 2012</a> conducted a review that compared androgen therapy and EPO use for the treatment of people with CKD‐related anaemia while focusing on implications for developing countries. Similar methodological approaches were applied in both reviews, and both looked at nandrolone decanoate versus rHuEPO and measures of anaemia correction such as haemoglobin, total protein and liver function. </p> <p>There were differences in study inclusion criteria: we excluded reviews fewer than six months duration, which were eligible for inclusion by <a href="./references#CD006881-bbs2-0032" title="AdamuB , Ma'ajiSM , ErwinPJ , TleyjehIM . Meta‐analysis of randomized controlled trials on androgens versus erythropoietin for anaemia of chronic kidney disease: Implications for developing countries. International Journal of Nephrology, 2012. http://www.hindawi.com/journals/ijn/2012/580437/ (accessed 23 August 2014). [DOI: 10.1155/2012/580437] ">Adamu 2012</a>; we included eight studies (181 participants) and <a href="./references#CD006881-bbs2-0032" title="AdamuB , Ma'ajiSM , ErwinPJ , TleyjehIM . Meta‐analysis of randomized controlled trials on androgens versus erythropoietin for anaemia of chronic kidney disease: Implications for developing countries. International Journal of Nephrology, 2012. http://www.hindawi.com/journals/ijn/2012/580437/ (accessed 23 August 2014). [DOI: 10.1155/2012/580437] ">Adamu 2012</a> included four studies (114 participants). Only one study was common to both reviews (<a href="./references#CD006881-bbs2-0006" title="NavarroJF , MoraC , MaciaM , ChahinJ , GallegoE , MendezML , et al. Effects of androgen therapy on hematologic and nutritional parameters in elderly peritoneal dialysis patients [abstract]. International Urology &amp; Nephrology2001;33(4):715‐6. [CENTRAL: CN‐00615848] NavarroJF , MoraC , MaciaML , GallegoE , ChahinJ , MendezML , et al. Prospective comparison between rHuEPO and androgens in CAPD patients: impact on hematologic and nutritional parameters [abstract]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):436A. [CENTRAL: CN‐00644231] NavarroJF , MoraF , MaciaM , GarciaJ . Randomized prospective comparison between erythropoietin and androgens in CAPD patients. Kidney International2002;61(4):1537‐44. [MEDLINE: 11918762] ">Navarro 2002</a>). Interventions investigated also differed: we investigated androgens versus EPO; androgens versus no drug or placebo alone; androgens plus EPO versus EPO; androgens plus EPO versus placebo plus EPO. <a href="./references#CD006881-bbs2-0032" title="AdamuB , Ma'ajiSM , ErwinPJ , TleyjehIM . Meta‐analysis of randomized controlled trials on androgens versus erythropoietin for anaemia of chronic kidney disease: Implications for developing countries. International Journal of Nephrology, 2012. http://www.hindawi.com/journals/ijn/2012/580437/ (accessed 23 August 2014). [DOI: 10.1155/2012/580437] ">Adamu 2012</a> considered nandrolone versus EPO and nandrolone plus EPO versus EPO. There were also differences in outcome measures. We sought kidney function measures (BUN and SCr values), lipid profiles (TG, HDL, LDL values), albumin, prealbumin, and transferrin values; while <a href="./references#CD006881-bbs2-0032" title="AdamuB , Ma'ajiSM , ErwinPJ , TleyjehIM . Meta‐analysis of randomized controlled trials on androgens versus erythropoietin for anaemia of chronic kidney disease: Implications for developing countries. International Journal of Nephrology, 2012. http://www.hindawi.com/journals/ijn/2012/580437/ (accessed 23 August 2014). [DOI: 10.1155/2012/580437] ">Adamu 2012</a> sought only blood pressure as an outcome measure. </p> <p>Although there were some similarities in reported results, there were also differences. Our finding based on limited evidence suggesting that nandrolone decanoate may increase Hb and HCT was not reported by <a href="./references#CD006881-bbs2-0032" title="AdamuB , Ma'ajiSM , ErwinPJ , TleyjehIM . Meta‐analysis of randomized controlled trials on androgens versus erythropoietin for anaemia of chronic kidney disease: Implications for developing countries. International Journal of Nephrology, 2012. http://www.hindawi.com/journals/ijn/2012/580437/ (accessed 23 August 2014). [DOI: 10.1155/2012/580437] ">Adamu 2012</a>, who found that total protein and blood pressure were increased. However, both reviews found that there was significant change in total protein increase associated with nandrolone decanoate versus rHuEPO; there was no change in liver function. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD006881-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006881.pub2/media/CDSR/CD006881/urn:x-wiley:14651858:media:CD006881:CD006881-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006881.pub2/media/CDSR/CD006881/image_t/tCD006881-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Flow diagram showing study selection" data-id="CD006881-fig-0001" src="/cdsr/doi/10.1002/14651858.CD006881.pub2/media/CDSR/CD006881/image_n/nCD006881-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Flow diagram showing study selection</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006881.pub2/full#CD006881-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006881.pub2/media/CDSR/CD006881/image_n/nCD006881-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006881-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006881.pub2/media/CDSR/CD006881/urn:x-wiley:14651858:media:CD006881:CD006881-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006881.pub2/media/CDSR/CD006881/image_t/tCD006881-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies" data-id="CD006881-fig-0002" src="/cdsr/doi/10.1002/14651858.CD006881.pub2/media/CDSR/CD006881/image_n/nCD006881-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006881.pub2/full#CD006881-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006881.pub2/media/CDSR/CD006881/image_n/nCD006881-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006881-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006881.pub2/media/CDSR/CD006881/urn:x-wiley:14651858:media:CD006881:CD006881-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006881.pub2/media/CDSR/CD006881/image_t/tCD006881-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study" data-id="CD006881-fig-0003" src="/cdsr/doi/10.1002/14651858.CD006881.pub2/media/CDSR/CD006881/image_n/nCD006881-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006881.pub2/full#CD006881-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006881.pub2/media/CDSR/CD006881/image_n/nCD006881-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006881-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006881.pub2/media/CDSR/CD006881/urn:x-wiley:14651858:media:CD006881:CD006881-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006881.pub2/media/CDSR/CD006881/image_t/tCD006881-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Nandrolone decanoate + rHuEPO versus rHuEPO, Outcome 1 Haemoglobin." data-id="CD006881-fig-0004" src="/cdsr/doi/10.1002/14651858.CD006881.pub2/media/CDSR/CD006881/image_n/nCD006881-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Nandrolone decanoate + rHuEPO versus rHuEPO, Outcome 1 Haemoglobin.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006881.pub2/references#CD006881-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006881.pub2/media/CDSR/CD006881/image_n/nCD006881-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006881-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006881.pub2/media/CDSR/CD006881/urn:x-wiley:14651858:media:CD006881:CD006881-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006881.pub2/media/CDSR/CD006881/image_t/tCD006881-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Nandrolone decanoate + rHuEPO versus rHuEPO, Outcome 2 Haematocrit." data-id="CD006881-fig-0005" src="/cdsr/doi/10.1002/14651858.CD006881.pub2/media/CDSR/CD006881/image_n/nCD006881-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Nandrolone decanoate + rHuEPO versus rHuEPO, Outcome 2 Haematocrit.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006881.pub2/references#CD006881-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006881.pub2/media/CDSR/CD006881/image_n/nCD006881-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006881-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006881.pub2/media/CDSR/CD006881/urn:x-wiley:14651858:media:CD006881:CD006881-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006881.pub2/media/CDSR/CD006881/image_t/tCD006881-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Nandrolone decanoate + rHuEPO versus rHuEPO, Outcome 3 Serum albumin." data-id="CD006881-fig-0006" src="/cdsr/doi/10.1002/14651858.CD006881.pub2/media/CDSR/CD006881/image_n/nCD006881-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Nandrolone decanoate + rHuEPO versus rHuEPO, Outcome 3 Serum albumin.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006881.pub2/references#CD006881-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006881.pub2/media/CDSR/CD006881/image_n/nCD006881-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006881-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006881.pub2/media/CDSR/CD006881/urn:x-wiley:14651858:media:CD006881:CD006881-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006881.pub2/media/CDSR/CD006881/image_t/tCD006881-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Nandrolone decanoate + rHuEPO versus rHuEPO, Outcome 4 Triglycerides." data-id="CD006881-fig-0007" src="/cdsr/doi/10.1002/14651858.CD006881.pub2/media/CDSR/CD006881/image_n/nCD006881-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Nandrolone decanoate + rHuEPO versus rHuEPO, Outcome 4 Triglycerides.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006881.pub2/references#CD006881-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006881.pub2/media/CDSR/CD006881/image_n/nCD006881-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006881-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006881.pub2/media/CDSR/CD006881/urn:x-wiley:14651858:media:CD006881:CD006881-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006881.pub2/media/CDSR/CD006881/image_t/tCD006881-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Nandrolone decanoate + rHuEPO versus rHuEPO, Outcome 5 Adverse events." data-id="CD006881-fig-0008" src="/cdsr/doi/10.1002/14651858.CD006881.pub2/media/CDSR/CD006881/image_n/nCD006881-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Nandrolone decanoate + rHuEPO versus rHuEPO, Outcome 5 Adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006881.pub2/references#CD006881-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006881.pub2/media/CDSR/CD006881/image_n/nCD006881-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006881-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006881.pub2/media/CDSR/CD006881/urn:x-wiley:14651858:media:CD006881:CD006881-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006881.pub2/media/CDSR/CD006881/image_t/tCD006881-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Oxymetholone + rHuEPO versus placebo + rHuEPO, Outcome 1 Haemoglobin g/dL." data-id="CD006881-fig-0009" src="/cdsr/doi/10.1002/14651858.CD006881.pub2/media/CDSR/CD006881/image_n/nCD006881-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Oxymetholone + rHuEPO versus placebo + rHuEPO, Outcome 1 Haemoglobin g/dL. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006881.pub2/references#CD006881-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006881.pub2/media/CDSR/CD006881/image_n/nCD006881-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006881-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006881.pub2/media/CDSR/CD006881/urn:x-wiley:14651858:media:CD006881:CD006881-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006881.pub2/media/CDSR/CD006881/image_t/tCD006881-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Oxymetholone + rHuEPO versus placebo + rHuEPO, Outcome 2 Haematocrit." data-id="CD006881-fig-0010" src="/cdsr/doi/10.1002/14651858.CD006881.pub2/media/CDSR/CD006881/image_n/nCD006881-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Oxymetholone + rHuEPO versus placebo + rHuEPO, Outcome 2 Haematocrit.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006881.pub2/references#CD006881-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006881.pub2/media/CDSR/CD006881/image_n/nCD006881-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006881-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006881.pub2/media/CDSR/CD006881/urn:x-wiley:14651858:media:CD006881:CD006881-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006881.pub2/media/CDSR/CD006881/image_t/tCD006881-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Oxymetholone + rHuEPO versus placebo + rHuEPO, Outcome 3 Liver function." data-id="CD006881-fig-0011" src="/cdsr/doi/10.1002/14651858.CD006881.pub2/media/CDSR/CD006881/image_n/nCD006881-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Oxymetholone + rHuEPO versus placebo + rHuEPO, Outcome 3 Liver function.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006881.pub2/references#CD006881-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006881.pub2/media/CDSR/CD006881/image_n/nCD006881-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006881-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006881.pub2/media/CDSR/CD006881/urn:x-wiley:14651858:media:CD006881:CD006881-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006881.pub2/media/CDSR/CD006881/image_t/tCD006881-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Oxymetholone + rHuEPO versus placebo + rHuEPO, Outcome 4 Kidney function." data-id="CD006881-fig-0012" src="/cdsr/doi/10.1002/14651858.CD006881.pub2/media/CDSR/CD006881/image_n/nCD006881-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Oxymetholone + rHuEPO versus placebo + rHuEPO, Outcome 4 Kidney function.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006881.pub2/references#CD006881-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006881.pub2/media/CDSR/CD006881/image_n/nCD006881-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006881-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006881.pub2/media/CDSR/CD006881/urn:x-wiley:14651858:media:CD006881:CD006881-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006881.pub2/media/CDSR/CD006881/image_t/tCD006881-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Oxymetholone + rHuEPO versus placebo + rHuEPO, Outcome 5 Lipid profile." data-id="CD006881-fig-0013" src="/cdsr/doi/10.1002/14651858.CD006881.pub2/media/CDSR/CD006881/image_n/nCD006881-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Oxymetholone + rHuEPO versus placebo + rHuEPO, Outcome 5 Lipid profile.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006881.pub2/references#CD006881-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006881.pub2/media/CDSR/CD006881/image_n/nCD006881-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006881-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006881.pub2/media/CDSR/CD006881/urn:x-wiley:14651858:media:CD006881:CD006881-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006881.pub2/media/CDSR/CD006881/image_t/tCD006881-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Oxymetholone + rHuEPO versus placebo + rHuEPO, Outcome 6 Change in serum albumin." data-id="CD006881-fig-0014" src="/cdsr/doi/10.1002/14651858.CD006881.pub2/media/CDSR/CD006881/image_n/nCD006881-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 Oxymetholone + rHuEPO versus placebo + rHuEPO, Outcome 6 Change in serum albumin. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006881.pub2/references#CD006881-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006881.pub2/media/CDSR/CD006881/image_n/nCD006881-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006881-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006881.pub2/media/CDSR/CD006881/urn:x-wiley:14651858:media:CD006881:CD006881-CMP-002-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006881.pub2/media/CDSR/CD006881/image_t/tCD006881-CMP-002-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Oxymetholone + rHuEPO versus placebo + rHuEPO, Outcome 7 Adverse effects." data-id="CD006881-fig-0015" src="/cdsr/doi/10.1002/14651858.CD006881.pub2/media/CDSR/CD006881/image_n/nCD006881-CMP-002-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2 Oxymetholone + rHuEPO versus placebo + rHuEPO, Outcome 7 Adverse effects.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006881.pub2/references#CD006881-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006881.pub2/media/CDSR/CD006881/image_n/nCD006881-CMP-002-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006881-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006881.pub2/media/CDSR/CD006881/urn:x-wiley:14651858:media:CD006881:CD006881-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006881.pub2/media/CDSR/CD006881/image_t/tCD006881-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Nandrolone decanoate versus EPO, Outcome 1 Haemoglobin." data-id="CD006881-fig-0016" src="/cdsr/doi/10.1002/14651858.CD006881.pub2/media/CDSR/CD006881/image_n/nCD006881-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Nandrolone decanoate versus EPO, Outcome 1 Haemoglobin.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006881.pub2/references#CD006881-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006881.pub2/media/CDSR/CD006881/image_n/nCD006881-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006881-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006881.pub2/media/CDSR/CD006881/urn:x-wiley:14651858:media:CD006881:CD006881-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006881.pub2/media/CDSR/CD006881/image_t/tCD006881-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Nandrolone decanoate versus EPO, Outcome 2 Haematocrit." data-id="CD006881-fig-0017" src="/cdsr/doi/10.1002/14651858.CD006881.pub2/media/CDSR/CD006881/image_n/nCD006881-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Nandrolone decanoate versus EPO, Outcome 2 Haematocrit.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006881.pub2/references#CD006881-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006881.pub2/media/CDSR/CD006881/image_n/nCD006881-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006881-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006881.pub2/media/CDSR/CD006881/urn:x-wiley:14651858:media:CD006881:CD006881-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006881.pub2/media/CDSR/CD006881/image_t/tCD006881-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Nandrolone decanoate versus EPO, Outcome 3 Plasma total protein." data-id="CD006881-fig-0018" src="/cdsr/doi/10.1002/14651858.CD006881.pub2/media/CDSR/CD006881/image_n/nCD006881-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Nandrolone decanoate versus EPO, Outcome 3 Plasma total protein.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006881.pub2/references#CD006881-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006881.pub2/media/CDSR/CD006881/image_n/nCD006881-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006881-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006881.pub2/media/CDSR/CD006881/urn:x-wiley:14651858:media:CD006881:CD006881-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006881.pub2/media/CDSR/CD006881/image_t/tCD006881-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Nandrolone decanoate versus EPO, Outcome 4 Prealbumin." data-id="CD006881-fig-0019" src="/cdsr/doi/10.1002/14651858.CD006881.pub2/media/CDSR/CD006881/image_n/nCD006881-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 Nandrolone decanoate versus EPO, Outcome 4 Prealbumin.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006881.pub2/references#CD006881-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006881.pub2/media/CDSR/CD006881/image_n/nCD006881-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006881-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006881.pub2/media/CDSR/CD006881/urn:x-wiley:14651858:media:CD006881:CD006881-CMP-003-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006881.pub2/media/CDSR/CD006881/image_t/tCD006881-CMP-003-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Nandrolone decanoate versus EPO, Outcome 5 Transferrin." data-id="CD006881-fig-0020" src="/cdsr/doi/10.1002/14651858.CD006881.pub2/media/CDSR/CD006881/image_n/nCD006881-CMP-003-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3 Nandrolone decanoate versus EPO, Outcome 5 Transferrin.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006881.pub2/references#CD006881-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006881.pub2/media/CDSR/CD006881/image_n/nCD006881-CMP-003-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006881-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006881.pub2/media/CDSR/CD006881/urn:x-wiley:14651858:media:CD006881:CD006881-CMP-003-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006881.pub2/media/CDSR/CD006881/image_t/tCD006881-CMP-003-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Nandrolone decanoate versus EPO, Outcome 6 Serum albumin." data-id="CD006881-fig-0021" src="/cdsr/doi/10.1002/14651858.CD006881.pub2/media/CDSR/CD006881/image_n/nCD006881-CMP-003-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3 Nandrolone decanoate versus EPO, Outcome 6 Serum albumin.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006881.pub2/references#CD006881-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006881.pub2/media/CDSR/CD006881/image_n/nCD006881-CMP-003-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006881-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006881.pub2/media/CDSR/CD006881/urn:x-wiley:14651858:media:CD006881:CD006881-CMP-003-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006881.pub2/media/CDSR/CD006881/image_t/tCD006881-CMP-003-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Nandrolone decanoate versus EPO, Outcome 7 Kidney function." data-id="CD006881-fig-0022" src="/cdsr/doi/10.1002/14651858.CD006881.pub2/media/CDSR/CD006881/image_n/nCD006881-CMP-003-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3 Nandrolone decanoate versus EPO, Outcome 7 Kidney function.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006881.pub2/references#CD006881-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006881.pub2/media/CDSR/CD006881/image_n/nCD006881-CMP-003-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006881-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006881.pub2/media/CDSR/CD006881/urn:x-wiley:14651858:media:CD006881:CD006881-CMP-003-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006881.pub2/media/CDSR/CD006881/image_t/tCD006881-CMP-003-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Nandrolone decanoate versus EPO, Outcome 8 Adverse effects." data-id="CD006881-fig-0023" src="/cdsr/doi/10.1002/14651858.CD006881.pub2/media/CDSR/CD006881/image_n/nCD006881-CMP-003-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.8</div> <div class="figure-caption"> <p>Comparison 3 Nandrolone decanoate versus EPO, Outcome 8 Adverse effects.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006881.pub2/references#CD006881-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006881.pub2/media/CDSR/CD006881/image_n/nCD006881-CMP-003-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006881-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006881.pub2/media/CDSR/CD006881/urn:x-wiley:14651858:media:CD006881:CD006881-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006881.pub2/media/CDSR/CD006881/image_t/tCD006881-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Nandrolone decanoate versus no therapy (remnant kidney patients), Outcome 1 Haemoglobin." data-id="CD006881-fig-0024" src="/cdsr/doi/10.1002/14651858.CD006881.pub2/media/CDSR/CD006881/image_n/nCD006881-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Nandrolone decanoate versus no therapy (remnant kidney patients), Outcome 1 Haemoglobin. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006881.pub2/references#CD006881-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006881.pub2/media/CDSR/CD006881/image_n/nCD006881-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006881-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006881.pub2/media/CDSR/CD006881/urn:x-wiley:14651858:media:CD006881:CD006881-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006881.pub2/media/CDSR/CD006881/image_t/tCD006881-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Nandrolone decanoate versus no therapy (remnant kidney patients), Outcome 2 Haematocrit." data-id="CD006881-fig-0025" src="/cdsr/doi/10.1002/14651858.CD006881.pub2/media/CDSR/CD006881/image_n/nCD006881-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 Nandrolone decanoate versus no therapy (remnant kidney patients), Outcome 2 Haematocrit. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006881.pub2/references#CD006881-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006881.pub2/media/CDSR/CD006881/image_n/nCD006881-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006881-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006881.pub2/media/CDSR/CD006881/urn:x-wiley:14651858:media:CD006881:CD006881-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006881.pub2/media/CDSR/CD006881/image_t/tCD006881-CMP-005-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Nandrolone decanoate versus no therapy (anephric patients), Outcome 1 Haemoglobin." data-id="CD006881-fig-0026" src="/cdsr/doi/10.1002/14651858.CD006881.pub2/media/CDSR/CD006881/image_n/nCD006881-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 Nandrolone decanoate versus no therapy (anephric patients), Outcome 1 Haemoglobin. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006881.pub2/references#CD006881-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006881.pub2/media/CDSR/CD006881/image_n/nCD006881-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006881-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006881.pub2/media/CDSR/CD006881/urn:x-wiley:14651858:media:CD006881:CD006881-CMP-005-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006881.pub2/media/CDSR/CD006881/image_t/tCD006881-CMP-005-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Nandrolone decanoate versus no therapy (anephric patients), Outcome 2 Haematocrit." data-id="CD006881-fig-0027" src="/cdsr/doi/10.1002/14651858.CD006881.pub2/media/CDSR/CD006881/image_n/nCD006881-CMP-005-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5 Nandrolone decanoate versus no therapy (anephric patients), Outcome 2 Haematocrit. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006881.pub2/references#CD006881-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006881.pub2/media/CDSR/CD006881/image_n/nCD006881-CMP-005-02.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD006881-tbl-0001"> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Nandrolone decanoate plus erythropoietin (rHuEPO) versus erythropoietin (rHuEPO) for the anaemia of chronic kidney disease in adults</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with the anaemia of chronic kidney disease </p> <p><b>Intervention:</b> nandrolone decanoate plus rHuEPO versus rHuEPO </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>rHuEPO</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Nandrolone decanoate plus rHuEPO</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Haematocrit (%)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean haematocrit in the intervention group was <b>2.4 higher</b> (1.04 to 3.77 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b>¹ </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Haemoglobin (g/dL)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean haemoglobin in the intervention group was <b>0.44 higher</b> (0.17 lower to 1.05 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b>² </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serum albumin (g/L)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Mean serum albumin in the intervention group was <b>0.09 lower</b> (0.24 lower to 0.06 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b>² </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 7.72</b> <br/> (1.45 to 41.12) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>83 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>very low</b>³ </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate </p> <p><b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate </p> <p><b>Very low quality:</b> We are very uncertain about the estimate </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Reduce the evidence quality factors:</b> methodology defect, included in the research results of the inconsistency, indirect evidence, inexactness, publication bias.   </p> <p><b>Increase the level of evidence factor:</b> large effect quantity, confounding factors cannot change effect quantity, or the existing concentration–response relationship. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>¹ Few studies included<br/> ² One study included<br/> ³ High risk of performance bias<br/> Two studies included </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-title"></span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006881.pub2/full#CD006881-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006881-tbl-0002"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Nandrolone decanoate + rHuEPO versus rHuEPO</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Haemoglobin <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Haematocrit <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.54 [0.96, 4.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Serum albumin <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.09 [‐0.24, 0.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Triglycerides <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Acne</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Menstrual disorders</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 Hirsutism</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Nandrolone decanoate + rHuEPO versus rHuEPO</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006881.pub2/references#CD006881-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006881-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Oxymetholone + rHuEPO versus placebo + rHuEPO</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Haemoglobin g/dL <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Haematocrit <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Liver function <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 AST</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 ALT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Kidney function <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 BUN [mmol/L]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 SCr [µmol/L]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Lipid profile <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Total cholesterol [mg/dL]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Triglycerides [mg/dL]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 HDL [mg/dL]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4 LDL [mg/dL]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Change in serum albumin <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Oxymetholone + rHuEPO versus placebo + rHuEPO</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006881.pub2/references#CD006881-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006881-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Nandrolone decanoate versus EPO</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Haemoglobin <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Haematocrit <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Plasma total protein <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Prealbumin <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Transferrin <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Serum albumin <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Kidney function <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 BUN [mg/dL]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 SCr [mg/dL]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Nandrolone decanoate versus EPO</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006881.pub2/references#CD006881-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006881-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Nandrolone decanoate versus no therapy (remnant kidney patients)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Haemoglobin <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.66, 1.41]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Haematocrit <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Nandrolone decanoate versus no therapy (remnant kidney patients)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006881.pub2/references#CD006881-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006881-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Nandrolone decanoate versus no therapy (anephric patients)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Haemoglobin <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Haematocrit <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Nandrolone decanoate versus no therapy (anephric patients)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006881.pub2/references#CD006881-tbl-0006">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD006881.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD006881-note-0003">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD006881-note-0006">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD006881-note-0002">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD006881-note-0001">Hrvatski</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006881\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006881\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006881\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006881\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006881\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006881\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006881\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006881\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006881\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006881\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006881\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006881\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006881\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006881\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006881\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006881\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006881\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006881\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=xNbeAU8n&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006881.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD006881.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD006881.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD006881.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006881.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740716831103"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD006881.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740716831106"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD006881.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918da912dbd61be3',t:'MTc0MDcxNjgzMS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 